UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED ~~September 30, 2021~~March 31, 2022

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

COMMISSION FILE NUMBER: 814-01074

NexPoint Capital, Inc.

(Exact name of registrant as specified in its charter)


Delaware		38-3926499
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

300 Crescent Court, Suite 700 Dallas, Texas		75201
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (972) 628-4100

Securities registered pursuant to Section 12(b) of the Act:

None

~~Title of each class~~

~~Trading~~

~~Symbol(s)~~

~~Name of each exchange~~

~~on which registered~~

~~N/A~~

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, par value $0.001 per share

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~September 30, 2021,~~March 31, 2022, the Registrant had ~~10,037,423~~9,918,671 shares of common stock, $0.001 par value, outstanding.

NexPoint Capital, Inc.

Statements of Assets and Liabilities


		September 30, 2021 (Unaudited)			December 31, 2020				March 31, 2022 (Unaudited)			December 31, 2021
Assets	Assets							Assets
Unaffiliated investments, at fair value (cost of $44,664,349 and $54,444,617, respectively)		$	50,636,097		$	54,031,676
Affiliated investments, at fair value (cost of $12,422,738 and $12,020,643, respectively)⁽¹⁾			12,351,057			10,636,939
Unaffiliated investments, at fair value (cost of $44,078,289 and $42,376,505, respectively)									$	47,821,381		$	47,457,661
Affiliated investments, at fair value (cost of $12,328,392 and $12,394,189, respectively)⁽¹⁾										14,537,708			12,778,650
Cash and cash equivalents			2,159,475			729,467				1,279,391			2,811,171
Receivable for investments sold			8,765			—				—			990,537
Dividends and interest receivable			405,872			285,212				621,615			440,404
Receivable from Adviser⁽²⁾			61,306			101,542				58,376			95,458
Prepaid expenses			2,488			—				10,664			13,222

Total assets			65,625,060			65,784,836				64,329,135			64,587,103


Liabilities	Liabilities							Liabilities
Payable for investments purchased										—			301,369
Payable to Adviser⁽²⁾			354,231			423,537				359,236			378,587
Accrued expenses and other liabilities			149,209			228,062				129,942			72,178
Distributions payable			903,368			942,765				892,680			896,061

Total liabilities			1,406,808			1,594,364				1,381,858			1,648,195


Commitments and contingencies⁽³⁾	Commitments and contingencies⁽³⁾							Commitments and contingencies⁽³⁾

Net assets	Net assets							Net assets
Preferred stock, $0.001 par value (25,000,000 shares authorized, 0 shares issued and outstanding)			—			—				—			—
Common stock, $0.001 par value (200,000,000 shares authorized, 10,037,423 and 10,475,168 shares issued and outstanding, respectively)			10,037			10,475
Common stock, $0.001 par value (200,000,000 shares authorized, 9,918,671 and 9,956,228 shares issued and outstanding, respectively)										9,919			9,956
Paid-in capital in excess of par			89,545,093			92,354,786				90,891,788			91,135,719
Distributable earnings (accumulated loss)			(25,336,878	)		(28,174,789	)			(27,954,430	)		(28,206,767	)

Total net assets		$	64,218,252		$	64,190,472			$	62,947,277		$	62,938,908

Net asset value per share of common stock		$	6.40		$	6.13			$	6.35		$	6.32

⁽¹⁾	See Note 109 for a discussion of affiliated investments.

⁽²⁾	See Note 4 for a discussion of related party transactions and arrangements.

⁽³⁾	See Note 4 and Note 87 for a discussion of the commitments and contingencies of the Company (as defined in Note 1).

See Notes to Financial Statements

NexPoint Capital, Inc.

Statements of Operations

(Unaudited)


		Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
		2021			2020			2021			2020			2022			2021
Investment income:	Investment income:
Interest		$	699,991		$	879,499		$	2,304,380		$	2,440,684		$	562,607		$	836,896
Interest paid-in-kind			25,985			22,425			74,634			377,440			106,711			23,684
Dividend income from unaffiliated investments			199,617			84,493			213,271			503,857			95,633			1,254
Dividend income from affiliated investments ⁽¹⁾			442,367			133,221			930,928			502,709			249,659			245,644
Other fee income			6,181			1			6,181			108,555

Total investment income			1,374,141			1,119,639			3,529,394			3,933,245			1,014,610			1,107,478


Expenses:	Expenses:
Investment advisory fees ⁽³⁾⁽²⁾			291,857			201,136			900,559			829,100			299,270			303,707
Custodian and accounting service fees			77,329			81,522			229,575			234,657			76,747			75,821
Administration fees ⁽³⁾⁽²⁾			61,568			59,839			183,308			185,433			59,601			62,539
Stock transfer fee			53,383			59,005			154,869			175,227			50,183			49,333
Audit and tax fees			36,403			46,114			132,743			140,397			39,474			54,641
Other expenses			22,134			23,980			92,888			41,375			20,230			61,493
Legal fees			19,185			27,538			50,825			52,854			18,218			12,756
Reports to stockholders			28,798			14,173			46,034			43,517			17,795			2,024
Directors’ fees ⁽³⁾⁽²⁾			4,695			6,238			13,460			16,127			3,731			4,057
Interest expense and commitment fees ⁽²⁾			—			—			—			176,707

Total expenses			595,352			519,545			1,804,261			1,895,394			585,249			626,371
Expenses (waived) or recouped by the Adviser ⁽³⁾			(68,134	)		(94,039	)		(200,499	)		(247,947	)
Expenses (waived) or recouped by the Adviser⁽²⁾															(61,761	)		(63,446	)

Net expenses			527,218			425,506			1,603,762			1,647,447			523,488			562,925

Net investment income			846,923			694,133			1,925,632			2,285,798			491,122			544,553


Net realized and unrealized gains (losses) on investments:	Net realized and unrealized gains (losses) on investments:
Net realized gain (loss) on:	Net realized gain (loss) on:
Unaffiliated investments			(4,198,825	)		(2,737,698	)		(4,047,315	)		(19,220,443	)		241,708			(91,660	)
Affiliated investments ⁽¹⁾			—			—			—			(1,452,337	)		(74,604	)		—
Total return swaps ⁽⁴⁾			—			—			—			(6,929,996	)
Net change in unrealized appreciation (depreciation) on:	Net change in unrealized appreciation (depreciation) on:
Unaffiliated investments			4,445,800			5,150,162			6,384,689			462,129			(1,338,064	)		722,628
Affiliated investments ⁽¹⁾			(1,112,351	)		(454,501	)		1,312,023			(1,454,802	)		1,824,855			1,098,536
Total return swaps ⁽⁴⁾			—			—			—			2,745,042

Net realized and unrealized gains (losses)			(865,376	)		1,957,963			3,649,397			(25,850,407	)		653,895			1,729,504

Net increase (decrease) in net assets resulting from operations		$	(18,453	)	$	2,652,096		$	5,575,029		$	(23,564,609	)	$	1,145,017		$	2,274,057

Per share information - basic and diluted per common share	Per share information - basic and diluted per common share
Net investment income:		$	0.08		$	0.07		$	0.19		$	0.22		$	0.05		$	0.05
Earnings (loss) per share:		$	—		$	0.25		$	0.54		$	(2.24	)	$	0.11		$	0.22
Weighted average shares outstanding:			10,141,588			10,528,658			10,316,029			10,520,781			9,990,797			10,508,636

⁽¹⁾	See Note 109 for a discussion of affiliated investments.

⁽²⁾	See Note ~~7 for a discussion of credit facility.~~

⁽³⁾	~~See Note~~ 4 for a discussion of related party transactions and arrangements.

⁽⁴⁾	~~See Note 7 for a discussion of total return swaps.~~

See Notes to Financial Statements

NexPoint Capital, Inc.

Statements of Changes in Net Assets

(Unaudited)

   Common Stock
   Shares Par Amount Paid in Capital
in
Excess of Par Distributable
Earnings Total
Net Assets
Balance at June 30, 2020
   10,545,693 $ 10,546 $ 94,418,250 $ (33,225,984 ) $ 61,202,812
Increase (decrease) in net assets resulting from operations

Net investment income
   —   —   —   694,133 694,133
Net realized gain (loss) on investments and securities sold short
   —   —   —   (2,737,698 ) (2,737,698 )
Net change in unrealized appreciation (depreciation) on investments and securities sold short
   —   —   —   4,695,661 4,695,661
Shareholder distributions:

Issuance of common stock
   —   —   —   —   —
Repurchase of common stock
   (51,384 ) (52 ) (312,876 ) —   (312,928 )
Reinvestment of common stock
   —   —   —   —   —
Distributions to stockholders
   —   —   —   (944,487 ) (944,487 )


Total increase (decrease) for the three months ended September 30, 2020
   (51,384 ) (52 ) (312,876 ) 1,707,609 1,394,681


Balance at September 30, 2020
   10,494,309 $ 10,494 $ 94,105,374 $ (31,518,375 ) $ 62,597,493


Distributions to stockholders per share
   —   $ —   $ —   $ 0.09 $ 0.09


Balance at December 31, 2019
   10,425,431 $ 10,425 $ 93,412,260 $ (4,487,132 ) $ 88,935,553
Increase (decrease) in net assets resulting from operations

Net investment income
   —   —   —   2,285,798 2,285,798
Net realized gain (loss) on investments and securities sold short
   —   —   —   (20,672,780 ) (20,672,780 )
Net realized gain (loss) on total return swaps⁽¹⁾
   —   —   —   (6,929,996 ) (6,929,996 )
Net change in unrealized appreciation (depreciation) on investments and securities sold short
   —   —   —   (992,673 ) (992,673 )
Net change in unrealized appreciation (depreciation) on total return swaps⁽¹⁾
   —   —   —   2,745,042 2,745,042
Shareholder distributions:

Issuance of common stock
   —   —   —   —   —
Repurchase of common stock
   (146,718 ) (147 ) (823,469 ) —   (823,616 )
Reinvestment of common stock
   215,596 216 1,516,583 —   1,516,799
Distributions to stockholders
   —   —   —   (3,466,634 ) (3,466,634 )


Total increase (decrease) for the nine months ended September 30, 2020
   68,878 69 693,114 (27,031,243 ) (26,338,060 )


Balance at September 30, 2020
   10,494,309 $ 10,494 $ 94,105,374 $ (31,518,375 ) $ 62,597,493


Distributions to stockholders per share
   —   $ —   $ —   $ 0.33 $ 0.33

⁽¹⁾	~~See Note 7 for a discussion on Total Return Swaps.~~


	Common Stock
	Shares			Par Amount			Paid in Capital in Excess of Par			Distributable Earnings (Accumulated Loss)			Total Net Assets
Balance at December 31, 2020		10,475,168		$	10,475		$	92,354,786		$	(28,174,789	)	$	64,190,472
Increase (decrease) in net assets resulting from operations
Net investment income		—			—			—			544,553			544,553
Net realized gain (loss) on investments		—			—			—			(91,660	)		(91,660	)
Net change in unrealized appreciation (depreciation) on investments		—			—			—			1,821,164			1,821,164
Shareholder distributions:
Issuance of common stock		—			—			—			—			—
Repurchase of common stock		(263,285	)		(263	)		(1,661,063	)		—			(1,661,326	)
Reinvestment of common stock		56,335			56			345,275			—			345,331
Distributions to stockholders		—			—			—			(924,140	)		(924,140	)

Total increase (decrease) for the three months ended March 31, 2021		(206,950	)		(207	)		(1,315,788	)		1,349,917			33,922

Balance at March 31, 2021		10,268,218		$	10,268		$	91,038,998		$	(26,824,872	)	$	64,224,394

Distributions to stockholders per share		—		$	—		$	—		$	0.09		$	0.09

See Notes to Financial Statements

NexPoint Capital, Inc.

Statements of Changes in Net Assets

(Unaudited)


		Common Stock																Common Stock
		Shares			Par Amount			Paid in Capital in Excess of Par			Distributable Earnings			Total Net Assets				Shares			Par Amount			Paid in Capital in Excess of Par			Distributable Earnings (Accumulated Loss)			Total Net Assets
Balance at June 30, 2021			10,106,783		$	10,107		$	90,002,309		$	(24,415,066	)	$	65,597,350
Balance at December 31, 2021																			9,956,228		$	9,956		$	91,135,719		$	(28,206,767	)	$	62,938,908
Increase (decrease) in net assets resulting from operations	Increase (decrease) in net assets resulting from operations																Increase (decrease) in net assets resulting from operations
Net investment income			—			—			—			846,923			846,923				—			—			—			491,122			491,122
Net realized gain (loss) on investments			—			—			—			(4,198,825	)		(4,198,825	)			—			—			—			167,104			167,104
Net change in unrealized appreciation (depreciation) on investments			—			—			—			3,333,449			3,333,449				—			—			—			486,791			486,791
Shareholder distributions:	Shareholder distributions:																Shareholder distributions:
Issuance of common stock			—			—			—			—			—				—			—			—			—			—
Repurchase of common stock			(119,018	)		(120	)		(779,452	)		—			(779,572	)			(85,999	)		(86	)		(550,034	)		—			(550,120	)
Reinvestment of common stock			49,658			50			322,236			—			322,286				48,442			49			306,103			—			306,152
Distributions to stockholders			—			—			—			(903,359	)		(903,359	)			—			—			—			(892,680	)		(892,680	)

Total increase (decrease) for the three months ended September 30, 2021			(69,360	)		(70	)		(457,216	)		(921,812	)		(1,379,098	)
Total increase (decrease) for the three months ended March 31, 2022																			(37,557	)		(37	)		(243,931	)		252,337			8,369

Balance at September 30, 2021			10,037,423		$	10,037		$	89,545,093		$	(25,336,878	)	$	64,218,252
Balance at March 31, 2022																			9,918,671		$	9,919		$	90,891,788		$	(27,954,430	)	$	62,947,277

Distributions to stockholders per share			—		$	—		$	—		$	0.18		$	0.18				—		$	—		$	—		$	0.09		$	0.09

Balance at December 31, 2020			10,475,168		$	10,475		$	92,354,786		$	(28,174,789	)	$	64,190,472
Increase (decrease) in net assets resulting from operations
Net investment income			—			—			—			1,925,632			1,925,632
Net realized gain (loss) on investments			—			—			—			(4,047,315	)		(4,047,315	)
Net change in unrealized appreciation (depreciation) on investments			—			—			—			7,696,712			7,696,712
Shareholder distributions:
Issuance of common stock			—			—			—			—			—
Repurchase of common stock			(596,763	)		(597	)		(3,808,557	)		—			(3,809,154	)
Reinvestment of common stock			159,018			159			998,864			—			999,023
Distributions to stockholders			—			—			—			(2,737,118	)		(2,737,118	)

Total increase (decrease) for the nine months ended September 30, 2021			(437,745	)		(438	)		(2,809,693	)		2,837,911			27,780

Balance at September 30, 2021			10,037,423		$	10,037		$	89,545,093		$	(25,336,878	)	$	64,218,252

Distributions to stockholders per share			—		$	—		$	—		$	0.27		$	0.27

See Notes to Financial Statements

NexPoint Capital, Inc.

Statements of Cash Flows

(Unaudited)


		Nine Months Ended September 30,							Three Months Ended March 31,
		2021			2020				2022			2021
Cash flows provided by (used in) operating activities	Cash flows provided by (used in) operating activities							Cash flows provided by (used in) operating activities
Net increase (decrease) in net assets resulting from operations		$	5,575,029		$	(23,564,609	)
Net increase in net assets resulting from operations									$	1,145,017		$	2,274,057

Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by (used in) operating activities:
Purchases of investment securities			(4,164,636	)		(48,565,179	)			(6,918,805	)		(7,726	)
Payment-in-kind investments			(74,634	)		(377,440	)			(106,711	)		(23,684	)
Proceeds from sales and principal repayments of investment securities			10,274,204			69,041,052				5,643,969			2,397,713
Net realized gain on investments			4,047,315			20,672,780
Net realized (gain)/loss on investments										(167,104	)		91,660
Net change in unrealized (appreciation) depreciation on investments			(7,696,712	)		992,673				(486,791	)		(1,821,164	)
Net change in unrealized (appreciation) depreciation on total return swaps			—			(2,745,042	)
Amortization of premium/discount, net			(704,076	)		(697,422	)			(87,336	)		(255,696	)
Change in operating assets and liabilities:
(Increase) decrease in receivable for investments sold			(8,765	)		—				990,537			(6,372	)
(Increase) decrease in dividends and interest receivable			(120,660	)		770,861				(181,211	)		(5,925	)
(Increase) decrease in receivable from Adviser			40,236			(43,909	)			37,082			38,096
(Increase) decrease in other receivables			—			(39,117	)
(Increase) decrease in prepaid expenses			(2,488	)		10,124				2,558			(8,477	)
(Increase) decrease in due from counterparty			—			21,400,000
Increase (decrease) in payable for investments purchased			—			(2,533,314	)			(301,369	)		—
Increase (decrease) in payable to Adviser			(69,306	)		(309,477	)			(19,351	)		(57,291	)
Increase (decrease) in interest expense and commitment fees payable			—			(80,207	)
Increase (decrease) in accrued expenses and other liabilities			(78,853	)		(145,027	)			57,764			(59,855	)
Increase (decrease) in payable on total return swap			—			(11,458	)

Net cash flows provided by (used in) operating activities			7,016,654			33,775,289				(391,751	)		2,555,336


Cash flows provided by used in financing activities
Cash flows provided by (used in) financing activities								Cash flows provided by (used in) financing activities
Repurchase of common stock, net of payable			(3,809,154	)		(1,926,021	)			(550,120	)		(1,661,326	)
Distributions paid in cash			(1,777,492	)		(1,630,874	)			(589,909	)		(597,435	)
(Decrease) in credit facilities payable			—			(40,971,068	)
Increase in credit facilities payable			—			7,256,204

Net cash flows (used in) financing activities			(5,586,646	)		(37,271,759	)			(1,140,029	)		(2,258,761	)

Net increase (decrease) in cash and cash equivalents			1,430,008			(3,496,470	)			(1,531,780	)		296,575


Cash and cash equivalents	Cash and cash equivalents							Cash and cash equivalents
Beginning of the period			729,467			7,764,892				2,811,171			729,467

End of the period		$	2,159,475		$	4,268,422			$	1,279,391		$	1,026,042


Supplemental disclosure and non-cash financing activities	Supplemental disclosure and non-cash financing activities							Supplemental disclosure and non-cash financing activities
Paid-in-kind interest income		$	74,634		$	377,440			$	106,711		$	23,684
Cash paid during the period for interest		$	—		$	256,914
Reinvestment of distributions paid		$	999,023		$	1,516,799			$	306,152		$	345,331
Local and excise taxes paid		$	114,609		$	47,000			$	30,187		$	35,000

See Notes to Financial Statements

NexPoint Capital, Inc.

Schedule of Investments

As of ~~September 30, 2021~~March 31, 2022

(Unaudited)

Portfolio Company⁽¹⁾⁽²⁾
   Interest
Rate    Base Rate
Floor Maturity
Date    Principal
Amount    Amortized
Cost⁽³⁾    Fair Value
Senior Secured Loans – 45.1%⁽⁴⁾

Healthcare – 43.7%

Air Methods Corp. (First Lien Term Loan)⁽⁵⁾
   L + 350    1.00 % 4/22/2024    $ 1,947,240    $ 1,609,256    $ 1,934,456
Auris Luxembourg III S.a.r.l. (First Lien Term
Loan)^{(6) (7)}
   L + 375    0.08 % 2/27/2026    2,521,561    2,512,760    2,503,443
BW NHHC Holdco, Inc. (First Lien Term Loan)⁽⁵⁾
   L + 500    0.12 % 5/15/2025    4,479,167    3,214,399    3,973,267
CNT Holdings I Corp (Second Lien Term Loan)⁽⁵⁾
   L + 675    0.75 % 10/16/2028    1,500,000    1,493,124    1,530,000
Covenant Surgical Partners, Inc. (First Lien Delayed Draw Term Loan)
   4% Fixed    7/1/2026    333,333    333,991    328,750
Covenant Surgical Partners, Inc. (First Lien Term Loan)⁽⁶⁾
   L + 400    0.09 % 7/1/2026    1,633,624    1,636,921    1,611,161
Envision Healthcare Corp. (First Lien Term Loan)⁽⁶⁾
   L + 375    0.08 % 10/10/2025    5,842,349    4,544,778    5,216,633
Global Medical Response, Inc. (First Lien Term Loan)⁽⁸⁾
   L + 425    1.00 % 3/14/2025    3,374,508    3,120,339    3,391,802
NMSC Holdings, Inc. (First Lien Term Loan)⁽⁶⁾
   L + 500    1.00 % 4/19/2023    1,010,661    1,008,287    1,011,672
RxBenefits, Inc. (First Lien Term Loan)⁽⁸⁾
   L + 525    0.75 % 12/17/2027    3,970,050    3,897,716    3,994,863
Sound Inpatient Physicians (Second Lien Term
Loan)⁽⁶⁾
   L + 675    0.08 % 6/26/2026    1,555,556    1,460,435    1,560,735
Wellpath Holdings, Inc. (First Lien Term Loan)”(First Lien Term Loan)(First Lien Term
Loan)⁽⁶⁾
   L + 550    0.08 % 10/1/2025    997,436    991,202    979,981


               28,036,763


Telecommunication Services – 1.4%

TerreStar Corp. (First Lien Term Loan F)^{(9) (10)}
   11% PIK    2/28/2022    168,100    168,100    168,100
TerreStar Corp. (First Lien Term Loan E)^{(9) (10)}
   11% PIK    2/27/2022    710,053    710,053    710,053
TerreStar Corp. (First Lien Term Loan G)^{(9) (10)}
   11% PIK    2/28/2022    30,032    30,032    30,032
TerreStar Corp. (First Lien Term Loan H)^{(9) (10)}
   11% PIK    2/28/2022    28,020    28,020    28,020


               936,205


Total Senior Secured Loans
            28,972,968


Asset-Backed Securities – 0.7%

Financials – 0.7%

Grayson Investor Corp. ^{(7) (9) (10) (11) (12) (13)}
      11/1/2021    800    456,000    352,500
PAMCO CLO 1997-1A B ^{(7) (9) (10) (11) (13) (14)}
         374,239    215,187    89,759


               442,259


Total Asset-Backed Securities
            442,259


Corporate Bonds – 10.7%

Healthcare – 10.2%

Hadrian Merger Sub, Inc. ⁽¹¹⁾
   8.500%    5/1/2026    2,728,000    2,384,080    2,830,314
Surgery Center Holdings, Inc. ^{(7) (11)}
   6.750%    7/1/2025    3,630,000    3,514,183    3,698,062


               6,528,376


Media/Telecommunications – 0.5%

iHeartCommunications, Inc. ⁽⁷⁾
   6.375%    5/1/2026    115,507    313,455    122,079
iHeartCommunications, Inc. ⁽⁷⁾
   8.375%    5/1/2027    214,073    584,792    229,058


               351,137


Total Corporate Bonds
            6,879,513


         Shares
Common Stocks – 26.7%

Chemicals – 0.1%

MPM Holdings, Inc. ^{(9) (10) (15)}
         8,500    17,000    42,500


Energy – 1.4%

Quarternorth Energy, Inc.
         8,841    701,357    917,254


Portfolio Company⁽¹⁾⁽²⁾	Interest Rate		Base Rate Floor			Maturity Date		Principal Amount		Amortized Cost⁽³⁾		Fair Value

Senior Secured Loans – 28.0%⁽⁴⁾
Healthcare – 26.4%
Auris Luxembourg III S.a.r.l. (First Lien Term Loan)⁽⁵⁾⁽⁶⁾		L + 375		0.21	%		2/27/2026	$	1,480,353	$	1,475,729	$	1,445,661
CCS Medical, Inc (First Lien Term Loan)⁽⁷⁾⁽⁸⁾		13% Fixed					4/7/2026		3,000,000		2,913,809		3,000,000
CNT Holdings I Corp (Second Lien Term Loan)⁽⁹⁾		L + 675		0.75	%		11/6/2028		1,500,000		1,493,503		1,503,128
Covenant Surgical Partners, Inc. (First Lien Delayed Draw Term Loan)		4% Fixed					7/1/2026		333,333		333,922		328,750
Covenant Surgical Partners, Inc. (First Lien Term Loan)⁽⁵⁾		L + 400		0.18	%		7/1/2026		1,629,539		1,632,510		1,607,133
Envision Healthcare Corp. (First Lien Term Loan)⁽⁵⁾		L + 375		0.21	%		10/10/2025		4,568,738		3,571,194		3,053,448
RxBenefits, Inc. (First Lien Term Loan)⁽⁹⁾		L + 450		0.75	%		12/17/2027		3,203,909		3,149,545		3,191,895
Sound Inpatient Physicians (Second Lien Term Loan)⁽⁵⁾		L + 675		0.21	%		6/26/2026		1,555,556		1,468,929		1,544,325
Wellpath Holdings, Inc. (First Lien Term Loan)⁽⁵⁾		L + 550		0.21	%		10/1/2025		992,308		986,772		974,327

													16,648,667


Telecommunication Services – 1.6%
TerreStar Corp. (First Lien Term Loan G)⁽⁷⁾⁽⁸⁾		11% PIK					2/28/2024		31,732		31,732		31,732
TerreStar Corp. (First Lien Term Loan H)⁽⁷⁾⁽⁸⁾		11% PIK					2/28/2024		29,606		29,606		29,606
TerreStar Corp. (First Lien Term Loan E)⁽⁷⁾⁽⁸⁾		11% PIK					2/28/2024		750,238		750,238		750,238
TerreStar Corp. (First Lien Term Loan F)⁽⁷⁾⁽⁸⁾		11% PIK					2/28/2024		177,613		177,613		177,613

													989,189


Total Senior Secured Loans													17,637,856


Asset-Backed Securities – 0.6%
Financials – 0.6%
Grayson Investor Corp.⁽⁶⁾^{(7) (8) (10) (11) (12)}							11/1/2021		800		218,665		312,000
PAMCO CLO 1997-1A B⁽⁶⁾^{(7) (8) (10) (12) (13)}									324,568		186,627		87,848

													399,848


Total Asset-Backed Securities													399,848


Corporate Bonds – 10.7%
Healthcare – 10.1%
Hadrian Merger Sub, Inc.⁽¹⁰⁾		8.500%					5/1/2026		2,728,000		2,413,294		2,749,265
Surgery Center Holdings, Inc.⁽⁶⁾⁽¹⁰⁾		6.750%					7/1/2025		3,630,000		3,527,748		3,620,689

													6,369,954

Media/Telecommunications – 0.6%
iHeartCommunications, Inc.⁽⁶⁾		6.375%					5/1/2026		116,808		313,455		120,414
iHeartCommunications, Inc.⁽⁶⁾		8.375%					5/1/2027		214,073		584,792		221,833

													342,247


Total Corporate Bonds													6,712,201


								Shares

Common Stocks – 36.8%
Chemicals – 0.1%
MPM Holdings, Inc.⁽¹⁴⁾									8,500		17,000		42,500

Energy – 2.5%
Quarternorth Energy, Inc.									11,534		981,428		1,585,925

Financials – 2.6%
American Banknote Corp.⁽⁷⁾^{(8) (14)}									750,000		2,062,500		1,605,300

Healthcare – 0.5%
Amryt Pharma, PLC⁽⁶⁾^{(14) (15)}									40,000		500,000		330,400

Real Estate – 20.4%
Nexpoint Real Estate Finance, Inc.⁽¹⁶⁾									481,670		9,960,591		10,885,734
IQHQ, Inc.⁽⁷⁾⁽⁸⁾									100,000		1,500,000		1,964,000

													12,849,734

See Notes to Financial Statements.

NexPoint Capital, Inc.

Schedule of Investments (continued)

As of ~~September 30, 2021~~March 31, 2022

(Unaudited)

Financials – 2.7%

American Banknote Corp. ^{(9) (10) (15)}
            750,000    $ 2,062,500    $ 1,717,500


Healthcare – 0.7%

Amryt Pharma, PLC ^{(7) (15) (16)}
            40,000    500,000    483,600


Real Estate – 12.2%

IQHQ, Inc. ^{(9) (10)}
            100,000    1,500,000    1,661,000
NexPoint Real Estate Finance, Inc. ⁽¹⁷⁾
            315,631    6,691,375    6,148,490


                  7,809,490


Real Estate Investment Trust (REIT) – 2.2%

NexPoint Residential Trust, Inc. ^{(7) (17)}
            23,068    731,363    1,427,448


Service – 0.0%

Wayne Services Legacy Inc. ^{(9) (10) (15)}
            237    253,404    17,196


Telecommunication Services – 7.4%

TerreStar Corp. ^{(9) (10) (15)}
            14,035    1,599,990    4,740,040


Total Common Stocks
                  17,155,028


LLC Interests – 11.9%


Consumer Products – 4.5%

US GAMING LLC ^{(9) (10) (15)}
            2,000    2,000,000    2,874,640


Real Estate – 7.4%

SFR WLIF II, LLC ^{(9) (10) (17)}
            3,348,888    3,348,888    3,234,434
SFR WLIF III, LLC ^{(9) (10) (17)}
            1,651,112    1,651,112    1,540,685


                  4,775,119


Total LLC Interests
                  7,649,759


   Preferred
Dividend
Rate
Preferred Stocks – 2.8%

Financials – 2.8%

777 PARTNERS LLC
   10.000%          750    750,000    750,000
United Fidelity Bank FSB
   7.000%          1,000    1,000,000    1,000,000


                  1,750,000


Total Preferred Stocks
                  1,750,000


Warrants – 0.2%

Energy – 0.1%

QUARTERNORTH TRANCHE 1 ⁽¹⁵⁾
         8/27/2029    3,051    —      30,510
QUARTERNORTH TRANCHE 2 ⁽¹⁵⁾
         8/27/2029    5,876    —      35,256


                  65,766


Healthcare – 0.0%

Gemphire Therapeutics, Inc. ^{(9) (10) (15)}
         3/15/2022    4,752    —      —


Media/Telecommunications – 0.1%

iHeartMedia, Inc. ^{(7) (15)}
         5/1/2039    2,875    52,988    71,861


Total Warrants
                  137,627


Total Investments – 98.1%
               $ 57,087,087    $ 62,987,154




Cash Equivalents – 3.2%⁽¹⁹⁾
                  $ 2,033,024
Other Assets & Liabilities, net – (1.2%)
                  $ (801,926 )


Net Assets – 100.0%
                  $ 64,218,252


Real Estate Investment Trust (REIT) – 3.4%
NexPoint Residential Trust, Inc.⁽⁶⁾⁽¹⁶⁾				23,268	$	716,689	$	2,101,333

Service – 0.0%
Wayne Services Legacy Inc.⁽⁷⁾^{(8) (14)}				237		253,404		5,172

Telecommunication Services – 7.3%
TerreStar Corp.⁽⁷⁾^{(8) (14)}				14,035		1,599,990		4,611,901


Total Common Stocks								23,132,265


LLC Interests – 7.2%
Consumer Products – 4.7%
US GAMING LLC⁽⁷⁾^{(8) (14)}				2,000		2,000,000		2,981,638

Real Estate – 2.5%
SFR WLIF III, LLC⁽⁷⁾^{(8) (16)}				1,651,112		1,651,112		1,550,641


Total LLC Interests								4,532,279


	Preferred Dividend Rate

Preferred Stocks – 15.5%
Financials – 2.6%
777 PARTNERS LLC		10.000%		750		750,000		750,000
United Fidelity Bank FSB		7.000%		1,000		1,000,000		900,000

								1,650,000

Healthcare – 12.9%
Sapience Therapeutics, Inc.⁽⁷⁾⁽⁸⁾				2,730,159		8,080,000		8,080,000


Total Preferred Stocks								9,730,000


Warrants – 0.3%
Energy – 0.2%
QUARTERNORTH TRANCHE 1⁽¹⁴⁾			8/27/2029	5,738		16,122		71,725
QUARTERNORTH TRANCHE 2⁽¹⁴⁾			8/27/2029	11,051		5,175		99,459

								171,184

Media/Telecommunications – 0.1%
iHeartMedia, Inc.⁽⁶⁾⁽¹⁴⁾			5/1/2039	2,875		52,987		43,456


Total Warrants								214,640

Total Investments – 99.1%					$	56,406,681	$	62,359,089

Cash Equivalents – 1.9%⁽¹⁷⁾							$	1,223,616
Other Assets & Liabilities, net – (1.0%)							$	(635,428	)

Net Assets – 100.0%							$	62,947,277

⁽¹⁾

Unless otherwise noted, the Company did not “control” and was not an “affiliated person” of any of its portfolio companies, each as defined in the Investment Company Act of 1940, as amended (the “1940 Act”). In general, under the 1940 Act, the Company would be presumed to “control” a portfolio company if it owned 25% or more of its voting securities or had the power to exercise control over the management or policies of such portfolio company, and would be an “affiliated person” of a portfolio company if it owned 5% or more of its voting securities. Additionally, companies under common control (e.g., companies with a common owner of greater than 25% of their respective voting securities) are affiliates under the 1940 Act.

⁽²⁾	All investments are denominated in United States Dollars.

⁽³⁾	Amortized cost represents the original cost adjusted for the amortization of premiums and/or accretion of discounts, as applicable, on investments.

~~See Notes to Financial Statements.~~

~~NexPoint Capital, Inc.~~

~~Schedule of Investments (continued)~~

~~As of September 30, 2021~~

~~(Unaudited)~~

⁽⁴⁾

Senior secured loans in which the Company invests generally pay interest at rates which are periodically determined by reference to a base lending rate plus a spread (unless otherwise identified, all senior secured loans carry a variable rate of interest). These base lending rates are generally (i) the Prime Rate offered by one or more major United States banks, (ii) the lending rate offered by one or more European banks such as the London Interbank Offered Rate (“LIBOR”) or (iii) the coupon rate. Rate shown represents the actual rate at ~~September 30, 2021.~~March 31, 2022. Senior secured loans, while exempt from registration under the Securities Act of 1933 (the “1933 Act”), contain certain restrictions on resale and cannot be sold publicly. Senior secured floating rate loans often require prepayments from excess cash flow or permit the borrower to repay at its election. The degree to which borrowers repay, whether as a contractual requirement or at their election, cannot be predicted with accuracy. As a result, the actual remaining maturity may be substantially less than the stated maturity shown.

⁽⁵⁾

The interest rate on these investments is subject to a base rate of ~~3-Month~~ LIBOR, which at September 30, 2021 was 0.13%. The LIBOR rate used to calculate interest is the higher of the prevailing 3 month LIBOR rate in effect on the date of the quarterly reset, or the LIBOR base rate floor shown.

⁽⁶⁾

~~The interest rate on these investments is subject to a base rate of~~ 1-Month LIBOR, which at ~~September 30, 2021~~March 31, 2022 was ~~0.08%~~0.45%. The LIBOR rate used to calculate interest is the higher of the prevailing 1 month LIBOR rate in effect on the date of the monthly reset, or the LIBOR base rate floor shown.

⁽⁷⁾⁽⁶⁾

The investment is not a qualifying asset under Section 55 of the 1940 Act. A business development company, such as the Company, ~~(“BDC”),~~ may not acquire any asset other than a qualifying asset, unless at the time the acquisition is made, qualifying assets represent at least 70% of the business development company’s total assets. Non-qualifying assets represented ~~13.2%~~13.3% of the Company’s total assets as of ~~September 30, 2021.~~March 31, 2022.

⁽⁸⁾⁽⁷⁾

~~The interest rate on~~Classified as Level 3 within the three-tier fair value hierarchy. Please see Note 2 for an explanation of this hierarchy, as well as a list of unobservable inputs used in the valuation of these ~~investments is subject to a base rate of~~ ~~6-Month~~ LIBOR, which at September 30, 2021 was 0.16%. The LIBOR rate used to calculate interest is the higher of the prevailing 6 month LIBOR rate in effect on the date of the semiannual reset, or the LIBOR base rate floor shown.instruments.

See Notes to Financial Statements.

NexPoint Capital, Inc.

Schedule of Investments (continued)

As of March 31, 2022

(Unaudited)

⁽⁹⁾⁽⁸⁾

Represents fair value as determined by the Company’s Board of Directors (the “Board”), or its designee in good faith, pursuant to the policies and procedures approved by the Board. The Board considers fair valued securities to be securities for which market quotations are not readily available and these securities may be valued using a combination of observable and unobservable inputs. Securities with a total aggregate value of ~~$17,206,459~~$25,187,689 or ~~26.8%~~40.2% of net assets were fair valued under the Company’s valuation procedures as of ~~September 30, 2021.~~March 31, 2022.

⁽⁹⁾	The interest rate on these investments is subject to a base rate of 3-Month LIBOR, which at March 31, 2022 was 0.96%. The LIBOR rate used to calculate interest is the higher of the prevailing 3 month LIBOR rate in effect on the date of the quarterly reset, or the LIBOR base rate floor shown.

⁽¹⁰⁾	Classified as Level 3 within the three-tier fair value hierarchy. Please see Note 2 for an explanation of this hierarchy, as well as a list of unobservable inputs used in the valuation of these instruments.

⁽¹¹⁾

Securities exempt from registration under Rule 144A of the 1933 Act. These securities may only be resold in transactions exempt from registration to qualified institutional buyers. As of ~~September 30, 2021,~~March 31, 2022, these securities amounted to ~~$6,970,635,~~$6,769,802, or ~~10.9%~~10.8% of net assets.

^(12)(11)

The investment is considered to be the equity tranche of the issuer.

^(13)(12)

Securities of collateralized loan obligations where an affiliate of the Adviser serves as collateral manager.

⁽¹⁴⁾	(13) The issuer is in default of its payment obligation, or is in danger of default.

^(15)(14)

Non-income producing security.

^(16)(15)

Securities exempt from registration under the Securities Act of 1933 (the “Securities Act”), and may be deemed to be “restricted securities” under the Securities Act. As of ~~September 30, 2021,~~March 31, 2022, the aggregate fair value of these securities is ~~$483,600~~$330,400 or ~~0.8%~~0.5% of the Company’s net assets. The acquisition dates of the restricted securities are as follows:


Investment		Acquition Date
Amryt Pharma, PLC – Common Stock		12/7/20

^(17)(16)

Represents an affiliated issuer. Assets with a total aggregate market value of ~~$12,351,057,~~$14,537,708, or ~~19.2%~~23.1% of net assets, were affiliated with the Company as of ~~September 30, 2021. See~~March 31, 2022 see Note ~~10.~~9.

^(18)(17)

~~The issuer has suspended the quarterly dividend for this security.~~

⁽¹⁹⁾	State Street U.S. Government Money Market Fund.

Glossary

^PIK	Payment-in-Kind

See Notes to Financial Statements.

NexPoint Capital, Inc.

Schedule of Investments

As of December 31, ~~2020~~2021

Portfolio Company⁽¹⁾⁽²⁾
   Interest
Rate Base Rate
Floor Maturity
Date    Principal
Amount    Amortized
Cost⁽³⁾    Fair Value
Senior Secured Loans – 56.1%⁽⁴⁾

Energy – 0.7%

Fieldwood Energy, LLC (First Lien Term Loan)⁽⁵⁾
   4/11/2022    $ 1,800,549    $ 1,797,905    $ 422,004
Fieldwood Energy, LLC (Second Lien Term Loan)⁽⁵⁾
   4/11/2023    567,797    555,600    823


            422,827


Healthcare – 51.5%

Air Methods Corp. (First Lien Term Loan)⁽⁶⁾
   L + 350 1.00 % 4/22/2024    1,962,492    1,541,038    1,900,674
Auris Luxembourg III S.a.r.l. (First Lien Term
Loan)⁽⁷⁾(8)
   L + 375 0.00 % 2/27/2026    2,540,954    2,530,710    2,461,549
BioClinica Holding I, LP (First Lien Term Loan)⁽⁷⁾
   L + 425 1.00 % 10/20/2023    1,932,103    1,743,186    1,930,905
BW NHHC Holdco, Inc. (First Lien Term Loan)⁽⁶⁾
   L + 500 0.00 % 5/15/2025    4,513,889    3,048,509    3,988,698
CNT Holdings I Corp. (Second Lien Term Loan)⁽⁶⁾
   L + 675 0.75 % 10/16/2028    1,500,000    1,492,584    1,530,000
Covenant Surgical Partners, Inc. (First Lien Delayed Draw Term Loan)⁽⁹⁾
   4% Fixed 7/1/2026    333,333    761    (5,833 )
Covenant Surgical Partners, Inc. (First Lien Term Loan)⁽⁷⁾
   L + 400 0.00 % 7/1/2026    1,645,937    1,649,733    1,617,133
Envision Healthcare Corp. (First Lien Term Loan)⁽⁷⁾
   L + 375 0.00 % 10/10/2025    5,887,406    4,395,759    4,937,355
Global Medical Response, Inc. (First Lien Term Loan)⁽⁶⁾
   L + 425 1.00 % 3/14/2025    3,400,802    3,097,724    3,375,296
Patterson Medical Holdings, Inc. (First Lien Term Loan)⁽⁶⁾
   L + 475 1.00 % 8/29/2022    2,421,410    2,165,282    2,345,741
RadNet, Inc. (First Lien Term Loan)⁽⁶⁾(8)
   L + 375 1.00 % 6/30/2023    3,462,143    3,370,868    3,461,711
RxBenefits, Inc. (First Lien Term Loan)⁽⁶⁾
   L + 525 0.75 % 12/17/2027    4,000,000    3,920,077    3,980,000
Sound Inpatient Physicians (Second Lien Term Loan)⁽⁷⁾
   L + 675 1.00 % 6/26/2026    1,555,556    1,448,342    1,547,778


            33,071,007


Manufacturing – 2.6%

Truck Hero, Inc. (Second Lien Term Loan)⁽⁷⁾
   L + 825 1.00 % 4/17/2025    1,666,667    1,245,903    1,666,667


Telecommunication Services – 1.3%

TerreStar Corp. (First Lien Term Loan E)⁽¹⁰⁾(11)
   11% PIK 2/27/2022    653,280    653,280    653,280
TerreStar Corp. (First Lien Term Loan F)⁽¹⁰⁾(11)
   11% PIK 2/28/2022    154,659    154,659    154,659
TerreStar Corp. (First Lien Term Loan G)⁽¹⁰⁾(11)
   11% PIK 2/28/2022    27,631    27,631    27,631
TerreStar Corp. (First Lien Term Loan H)⁽¹⁰⁾(11)
   11% PIK 2/28/2022    26,000    26,000    26,000


            861,570


Total Senior Secured Loans
            36,022,071


Asset-Backed Securities – 0.5%

Financials – 0.5%

Grayson Investor Corp. ⁽⁸⁾(10) (11) (12) (13) (14)
   11/1/2021    800    456,000    286,000
PAMCO CLO 1997-1A B ⁽⁸⁾(10) (11) (12) (14) (15)
      374,239    215,187    77,767


            363,767


Total Asset-Backed Securities
            363,767


Corporate Bonds – 10.7%

Healthcare – 10.2%

Hadrian Merger Sub, Inc. ⁽¹²⁾
   8.500% 5/1/2026    2,728,000    2,343,691    2,826,371
Surgery Center Holdings ⁽⁸⁾(12)
   6.750% 7/1/2025    3,630,000    3,494,669    3,704,869


            6,531,240


Media/Telecommunications – 0.5%

iHeartCommunications, Inc. ⁽⁸⁾
   8.375% 5/1/2027    214,073    584,792    228,903
iHeartCommunications, Inc. ⁽⁸⁾
   6.375% 5/1/2026    $ 115,507    $ 313,455    $ 123,809


            352,712


Total Corporate Bonds
            6,883,952


Portfolio Company⁽¹⁾⁽²⁾	Interest Rate	Base Rate Floor			Maturity Date		Principal Amount		Amortized Cost⁽³⁾		Fair Value

Senior Secured Loans – 40.1%⁽⁴⁾
Healthcare – 38.6%
Auris Luxembourg III S.a.r.l. (First Lien Term Loan)⁽⁵⁾⁽⁶⁾	L + 375		0.09	%		2/27/2026	$	2,515,096	$	2,506,780	$	2,500,169
BW NHHC Holdco, Inc. (First Lien Term Loan)⁽⁷⁾	L + 500		0.16	%		5/15/2025		4,467,593		3,274,720		3,824,818
CNT Holdings I Corp (Second Lien Term Loan)⁽⁷⁾	L + 675		0.75	%		11/16/2028		1,500,000		1,493,315		1,513,125
Covenant Surgical Partners, Inc. (First Lien Delayed Draw Term Loan)	4% Fixed					7/1/2026		333,333		333,956		330,027
Covenant Surgical Partners, Inc. (First Lien Term Loan)⁽⁵⁾	L + 400		0.09	%		7/1/2026		1,629,539		1,632,667		1,613,375
Envision Healthcare Corp. (First Lien Term Loan)⁽⁵⁾	L + 375		0.09	%		10/10/2025		4,580,543		3,578,822		3,700,232
NMSC Holdings, Inc. (First Lien Term Loan)⁽⁵⁾	L + 500		1.00	%		4/19/2023		1,007,994		1,006,001		1,008,246
RxBenefits, Inc. (First Lien Term Loan)⁽⁷⁾	L + 500		5.25	%		12/17/2027		3,211,980		3,155,476		3,222,017
Sapience Therapeutics, Inc (First Lien Term Loan)^(8) (9)	8% Fixed					12/9/2023		4,000,000		4,000,000		4,000,000
Sound Inpatient Physicians (Second Lien Term Loan)⁽⁵⁾	L + 675		0.09	%		6/26/2026		1,555,556		1,464,678		1,559,444
Wellpath Holdings, Inc. (First Lien Term Loan)⁽⁵⁾	L + 550		0.09	%		10/1/2025		994,872		988,966		983,525

												24,254,978


Telecommunication Services – 1.5%
TerreStar Corp. (First Lien Term Loan E)^{(8) (9)}	11% PIK					2/27/2022		729,979		729,979		729,979
TerreStar Corp. (First Lien Term Loan F)^{(8) (9)}	11% PIK					2/28/2022		172,817		172,817		172,817
TerreStar Corp. (First Lien Term Loan G)^{(8) (9)}	11% PIK					2/28/2022		30,875		30,875		30,875
TerreStar Corp. (First Lien Term Loan H)^{(8) (9)}	11% PIK					2/28/2022		28,807		28,807		28,807

												962,478


Total Senior Secured Loans												25,217,456


Asset-Backed Securities – 0.6%
Financials – 0.6%
Grayson Investor Corp.^{(6) (8) (9) (10) (11)}^{(12) (13)}						11/1/2021		800		218,665		304,000
PAMCO CLO 1997-1A B^{(6) (8) (9) (10) (12) (13)}								354,096		203,606		101,040

												405,040


Total Asset-Backed Securities												405,040


Corporate Bonds – 10.9%
Healthcare – 10.3%
Hadrian Merger Sub, Inc.⁽¹⁰⁾	8.500%					5/1/2026		2,728,000		2,398,666		2,819,320
Surgery Center Holdings, Inc.^{(6) (10)}	6.750%					7/1/2025		3,630,000		3,520,855		3,661,000

												6,480,320

Media/Telecommunications – 0.6%
iHeartCommunications, Inc.⁽⁶⁾	6.375%					5/1/2026		115,507		313,455		119,965
iHeartCommunications, Inc.⁽⁶⁾	8.375%					5/1/2027		214,073		584,792		225,981

												345,946


Total Corporate Bonds												6,826,266


							Shares

Common Stocks – 29.1%
Chemicals – 0.1%
MPM Holdings, Inc.^{(8) (9) (14)}								8,500		17,000		42,500

Energy – 1.7%
Quarternorth Energy, Inc.								11,534		981,429		1,092,846

Financials – 3.5%
American Banknote Corp.^{(8) (9) (14)}								750,000		2,062,500		2,208,750

Healthcare – 0.7%
Amryt Pharma, PLC^{(6) (14) (15)}								40,000		500,000		432,000

Real Estate – 12.5%
IQHQ, Inc.^{(8) (9)}								100,000		1,500,000		1,823,000
Nexpoint Real Estate Finance, Inc.⁽¹⁶⁾								315,631		6,686,306		6,075,895

												7,898,895

See Notes to Financial Statements.

NexPoint Capital, Inc.

Schedule of Investments (continued)

As of December 31, ~~2020~~2021

      Shares
Common Stocks – 15.0%

Chemicals – 0.1%

MPM Holdings, Inc. ⁽¹⁶⁾
      8,500    17,000    42,500


Financials – 1.8%

American Banknote Corp. ⁽¹⁰⁾^{(11) (16)}
      750,000    2,062,500    1,125,000


Healthcare – 0.9%

Amryt Pharma, PLC ⁽⁸⁾^{(16) (17)}
      40,000    500,000    566,400


SteadyMed Ltd. ⁽⁸⁾^{(10) (11) (16)}
      54,749    14,508    40,405


            606,805


Real Estate – 2.6%

IQHQ, Inc. ⁽¹⁰⁾⁽¹¹⁾
      100,000    1,500,000    1,661,000


Real Estate Investment Trust (REIT) – 1.5%

NexPoint Residential Trust, Inc. ⁽⁸⁾⁽¹⁸⁾
      22,640    708,025    957,898


Retail – 0.8%

Tru Kids, Inc. ⁽¹⁰⁾^{(11) (16)}
      237    1,119,168    532,642


Service – 0.1%

Wayne Services Legacy Inc. ⁽¹⁰⁾^{(11) (16)}
      237    253,404    59,183


Telecommunication Services – 7.2%

TerreStar Corp. ⁽¹⁰⁾^{(11) (16)}
      14,035    1,599,990    4,630,427


Total Common Stocks
            9,615,455


LLC Interests – 10.2%

Consumer Products – 3.2%

US GAMING LLC ⁽¹⁰⁾^{(11) (16)}
      2,000    2,000,000    2,070,427


Real Estate – 6.6%

SFR WLIF III, LLC ⁽¹⁰⁾^{(11) (18)}
      1,651,112    1,651,112    1,493,629


SFR WLIF II, LLC ⁽¹⁰⁾^{(11) (18)}
      3,348,888    3,348,888    2,742,974


            4,236,603


Real Estate Investment Trust (REIT) – 0.4%

NexPoint Capital REIT, LLC ⁽¹⁰⁾^{(11) (18) (19)}
      100    —      228,215


Total LLC Interests
            6,535,245


Partnership Units – 8.1%

Real Estate – 8.1%

NexPoint Real Estate Finance Operating Partnership,
LP ⁽¹⁸⁾
      315,631    6,312,618    5,214,223


Total Partnership Units
            5,214,223


   Preferred
Dividend
Rate
Preferred Stocks – 0.0%

Real Estate Investment Trust (REIT) – 0.0%

RAIT Financial Trust ⁽²⁰⁾
   8.875 %    148,057    3,051,714    —


Total Preferred Stocks



Warrants – 0.1%

Healthcare – 0.0%

Galena Biopharma, Inc. ⁽¹⁰⁾^{(11) (16)}
   1/12/2021    1,500,054    —      1
Gemphire Therapeutics, Inc. ⁽¹⁰⁾^{(11) (16)}
   3/15/2022    4,752    —      —
SCYNEXIS, Inc. ⁽¹⁰⁾^{(11) (16)}
   6/21/2021    19,500    —      —


            1


Media/Telecommunications – 0.1%

iHeartMedia, Inc. ⁽⁸⁾⁽¹⁶⁾
   5/1/2039    2,875    52,988    33,901


Total Warrants
            33,902


Total Investments – 100.7%
         $ 66,465,260    $ 64,668,615




Cash Equivalents – 0.8%⁽²¹⁾
            $ 525,975
Other Assets & Liabilities, net – (1.5%)
            $ (1,004,118 )


Net Assets – 100.0%
            $ 64,190,472

~~See Notes to Financial Statements.~~

~~NexPoint Capital, Inc.~~

~~Schedule of Investments (continued)~~

~~As of December 31, 2020~~


Real Estate Investment Trust (REIT) – 3.1%
NexPoint Residential Trust, Inc.^{(6) (16)}					23,173	$	707,883	$	1,942,593

Service – 0.0%
Wayne Services Legacy Inc.^{(8) (9) (14)}					237		253,404		5,172

Telecommunication Services – 7.5%
TerreStar Corp.^{(8) (9) (14)}					14,035		1,599,990		4,706,357


Total Common Stocks									18,329,113


LLC Interests – 12.0%
Consumer Products – 4.5%
US GAMING LLC^{(8) (9) (14)}					2,000		2,000,000		2,812,212

Real Estate – 7.5%
SFR WLIF II, LLC^{(8) (9) (16)}					3,348,888		3,348,888		3,196,246
SFR WLIF III, LLC^{(8) (9) (16)}					1,651,112		1,651,112		1,563,916

									4,760,162


Total LLC Interests									7,572,374


	Preferred Dividend Rate

Preferred Stocks – 2.7%
Financials – 2.7%
777 PARTNERS LLC		10.000	%		750		750,000		750,000
United Fidelity Bank FSB		7.000	%		1,000		1,000,000		975,000

									1,725,000


Total Preferred Stocks									1,725,000


Warrants – 0.3%
Energy – 0.2%
QUARTERNORTH TRANCHE 1⁽¹⁴⁾				8/27/2029	5,738		16,122		48,056
QUARTERNORTH TRANCHE 2⁽¹⁴⁾				8/27/2029	11,051		5,175		64,002

									112,058

Healthcare – 0.0%
Gemphire Therapeutics, Inc.^{(8) (9) (14)}				3/15/2022	4,752		—		—

Media/Telecommunications – 0.1%
iHeartMedia, Inc.^{(6) (14)}				5/1/2039	2,875		52,987		49,004


Total Warrants									161,062

Total Investments – 95.7%						$	54,770,694	$	60,236,311

Cash Equivalents – 4.3%⁽¹⁷⁾								$	2,704,193
Other Assets & Liabilities, net – 0.0%								$	(1,596	)

Net Assets – 100.0%								$	62,938,908

⁽¹⁾

⁽²⁾	All investments are denominated in United States Dollars.

⁽³⁾	Amortized cost represents the original cost adjusted for the amortization of premiums and/or accretion of discounts, as applicable, on investments.

⁽⁴⁾

Senior secured loans in which the Company invests generally pay interest at rates which are periodically determined by reference to a base lending rate plus a spread (unless otherwise identified, all senior secured loans carry a variable rate of interest). These base lending rates are generally (i) the Prime Rate offered by one or more major United States banks, (ii) the lending rate offered by one or more European banks such as the London Interbank Offered Rate (“LIBOR”) or (iii) the coupon rate. Rate shown represents the actual rate at December 31, ~~2020.~~2021. Senior secured loans, while exempt from registration under the Securities Act of 1933 (the “1933 Act”), contain certain restrictions on resale and cannot be sold publicly. Senior secured floating rate loans often require prepayments from excess cash flow or permit the borrower to repay at its election. The degree to which borrowers repay, whether as a contractual requirement or at their election, cannot be predicted with accuracy. As a result, the actual remaining maturity may be substantially less than the stated maturity shown.

⁽⁵⁾	~~The investment is on~~ ~~non-accrual~~ ~~status as of December 31, 2020.~~

⁽⁶⁾

~~The interest rate on these investments is subject to a base rate of~~ ~~3-Month~~ LIBOR, which at December 31, 2020 was 0.24%. The LIBOR rate used to calculate interest is the higher of the prevailing 3 month LIBOR rate in effect on the date of the quarterly reset, or the LIBOR base rate floor shown.

⁽⁷⁾

The interest rate on these investments is subject to a base rate of 1-Month LIBOR, which at December 31, ~~2020~~2021 was ~~0.14%~~0.10%. The LIBOR rate used to calculate interest is the higher of the prevailing 1 month LIBOR rate in effect on the date of the monthly reset, or the ~~LIBOR~~ base rate floor shown.

⁽⁸⁾⁽⁶⁾

The investment is not a qualifying asset under Section 55 of the 1940 Act. A business development company, such as the Company (“BDC”), may not acquire any asset other than a qualifying asset, unless at the time the acquisition is made, qualifying assets represent at least 70% of the business development company’s total assets. Non-qualifying assets represented ~~18.2%~~14.8% of the Company’s total assets as of December 31, ~~2020.~~2021.

⁽⁹⁾⁽⁷⁾

The ~~investment has an unfunded commitment as of December 31, 2020. The unfunded loan commitment may be~~interest rate on these investments is subject to a ~~commitment termination date that may expire prior~~base rate of 3-Month LIBOR, which at December 31, 2021 was 0.21%. The LIBOR rate used to ~~the maturity date stated. The negative cost, if applicable,~~calculate interest is the ~~result~~higher of the ~~capitalized discount being greater than the principal amount outstanding~~prevailing 3 month LIBOR rate in effect on the ~~loan. The negative fair value, if applicable, is the result~~date of the ~~capitalized discount on~~quarterly reset, or the ~~loan. For further details see Note 8.~~base rate floor shown.

See Notes to Financial Statements.

NexPoint Capital, Inc.

Schedule of Investments (continued)

As of December 31, 2021

^(10)(8)

Classified as Level 3 within the three-tier fair value hierarchy. Please see Note 2 for an explanation of this hierarchy, as well as a list of unobservable inputs used in the valuation of these instruments.

⁽¹¹⁾

Represents fair value as determined by the Company’s Board of Directors (the “Board”), or its designee in good faith, pursuant to the policies and procedures approved by the Board. The Board considers fair valued securities to be securities for which market quotations are not readily available and these securities may be valued using a combination of observable and unobservable inputs. Securities with a total aggregate value of ~~$15,809,240~~$21,683,171 or ~~24.6%~~34.5% of net assets were fair valued under the Company’s valuation procedures as of December 31, ~~2020.~~2021.

⁽¹²⁽⁹⁾

⁾⁽¹⁰⁾

Securities exempt from registration under Rule 144A of the 1933 Act. These securities may only be resold in transactions exempt from registration to qualified institutional buyers. As of December 31, ~~2020,~~2021, these securities amounted to ~~$6,895,007,~~$6,885,360, or ~~10.7%~~10.9% of net assets.

^(13)(11)

The investment is considered to be the equity tranche of the issuer.

^(14)(12)

Securities of collateralized loan obligations where an affiliate of the Adviser serves as collateral manager. ~~(15)~~(13) The issuer is in default of its payment obligation, or is in danger of default.

^(16)(14)

Non-income producing security.

^(17(15)⁾

Securities exempt from registration under the ~~Securities~~1933 Act ~~of 1933 (the “Securities Act”),~~ and may be deemed to be “restricted securities” under the Securities Act. As of December 31, ~~2020,~~2021, the aggregate fair value of these securities is ~~$566,400~~$432,000 or ~~0.9%~~0.7% of the Company’s net assets. The acquisition dates of the restricted securities are as follows:


Investment		~~Acquisition~~Acquition Date
Amryt Pharma, PLC – Common Stock		12/7/20

^(18(16)⁾

Represents an affiliated issuer. Assets with a total aggregate fair value of ~~$10,636,939,~~$12,778,650, or ~~16.6%~~20.3% of net assets, were affiliated with the Company as of December 31, ~~2020.~~2021. See Note ~~10.~~9.

^(19)(17)

The investment is deemed to be a “controlled affiliated person” of the Company because the Company owns, either directly or indirectly, 25% or more of the portfolio company’s outstanding voting securities or has the power to exercise control over management or policies of such portfolio company. See Note 4 “Related Party Transactions and Arrangements”.

⁽²⁰⁾	~~The issuer has suspended the quarterly dividend for this security.~~

⁽²¹⁾	State Street U.S. Government Money Market Fund.

Glossary

^PIK	Payment-in-Kind

See Notes to Financial Statements.

NexPoint Capital, Inc.

Notes to Financial Statements (Unaudited)

Note 1 — Organization

NexPoint Capital, Inc. (the “Company”) is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). The Company follows the investment company accounting and reporting guidance of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 946 Financial Services - Investment Companies. The Company’s investment objective is to generate current income and capital appreciation primarily through investments in middle-market healthcare companies, middle-market companies in non-healthcare sectors, syndicated floating rate debt of large public and nonpublic companies and collateralized loan obligations. The Company has elected to be treated for federal income tax purposes, and intends to qualify annually thereafter, as a regulated investment company (“RIC”), under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). In this report, “we,” “us” and “our” refer to NexPoint Capital, Inc.

The Company was formed in Delaware on September 30, 2013 and formally commenced operations on September 2, 2014 upon satisfying the minimum offering requirement by raising gross proceeds of $10.0 million in connection with a private placement with NexPoint Advisors, L.P. (the “Adviser”), our external advisor. In aggregate as of ~~September 30, 2021,~~March 31, 2022, the Adviser controls 2,549,002 total shares (or ~~24.33%~~25.70%) of the Company, including reinvestment of dividends, for a net amount of approximately ~~$16.3~~$16.2 million.

The Company has retained the Adviser to manage certain aspects of its affairs on a day-to-day basis. NexPoint Securities, Inc. (the “Dealer Manager”), an entity under common ownership with the Adviser, served as the dealer manager of the Company’s continuous public offering prior to the termination of the offering. The Adviser and Dealer Manager are related parties and will receive fees and other compensation for services related to the investment and management of the Company’s assets and the continuous public offering. The Company’s continuous public offering ended on February 14, 2018.

Note 2 — Summary of Significant Accounting Policies

Basis of Accounting

The accompanying financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Additionally, the accompanying financial statements of the Company and related financial information have been prepared pursuant to the requirements for reporting on Form 10-Q and Article 10 of Regulation S-X. The current period’s results of operations will not necessarily be indicative of results that ultimately may be achieved for the fiscal year ending December 31, ~~2021.~~2022. The interim financial data as of ~~September 30, 2021~~March 31, 2022 and for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022 and 2021 ~~and 2020~~ is unaudited. In the opinion of management, the interim financial data includes all adjustments, consisting only of the normal recurring adjustments, necessary to a fair statement of the results for the interim ~~periods presented.~~periods.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of increases and decreases in net assets from operations during the reporting period. Actual results could differ from those estimates.

Statements of Cash Flows

Information on financial transactions which have been settled through the receipt or disbursement of cash is presented in the Statements of Cash Flows. The cash amount shown in the Statements of Cash Flows is the amount included within the Company’s Statements of Assets and Liabilities and includes cash on hand at its custodian bank.

Cash and Cash Equivalents

The Company considers liquid assets deposited with a bank, money market funds, and certain short-term debt instruments with original maturities of three months or less to be cash equivalents. These investments represent amounts held with financial institutions that are readily accessible to pay Company expenses or purchase investments. Cash and cash equivalents are valued at cost plus accrued interest, which approximates fair value. The value of cash equivalents denominated in foreign currencies, if any, is determined by converting to U.S. dollars on the date of the Statements of Assets and Liabilities. As of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, the Company had cash and cash equivalents of ~~$2,159,475~~$1,279,391 and ~~$729,467,~~$2,811,171, respectively. As of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020, $2,033,024~~2021, $1,223,616 and ~~$525,975~~$2,704,193 was held in the State Street U.S. Government Money Market Fund, and ~~$126,451~~$55,775 and ~~$203,492~~$106,978 was held in a custodial account with State Street Bank and Trust Company, respectively.

Securities Sold Short and Restricted Cash

The Company may sell securities short. A security sold short is a transaction in which the Company sells a security it does not own in anticipation that the market price of that security will decline. When the Company sells a security short, it must borrow the security sold short from a broker-dealer and deliver it to the buyer upon conclusion of the transaction. The Company may have to pay a fee to borrow particular securities and is often obligated to pay over any dividends or other payments received on such borrowed securities. Cash held as collateral for securities sold short is classified as restricted cash on the Statements of Assets and Liabilities, when applicable. Securities held as collateral for securities sold short are shown on the Schedules of Investments for the Company, as applicable. As of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, the Company did not have any securities sold short.

When securities are sold short, the Company intends to limit exposure to a possible market decline in the value of its portfolio companies through short sales of securities that the Adviser believes possess volatility characteristics similar to those being hedged. In addition, the Company may use short sales for non-hedging purposes to pursue its investment objective. Subject to the requirements of the 1940 Act and the Code, the Company will not make a short sale if, after giving effect to such sale, the market value of all securities sold short by the Company exceeds 25% of the value of its total assets.

Other Fee Income

Fee income may consist of origination/closing fees, amendment fees, administrative agent fees, transaction break-up fees and other miscellaneous fees. Origination fees, amendment fees, and other similar fees are non-recurring fee sources. Such fees are received on a transaction by transaction basis and do not constitute a regular stream of income. For the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022 and March 31, 2021, the Company recognized ~~$6,181~~$0 and ~~$6,181 of fee income, respectively. For the three and nine months ended September 30, 2020, the Company recognized $1 and $108,555~~$0 of fee income, respectively.

Fair Value of Financial Instruments

It is the Company’s policy to hold the investments at fair value. Accounting Standards Codification Topic 820, Fair Value Measurements and Disclosure (“ASC Topic 820”) defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, which includes inputs such as quoted prices for similar securities in active markets and quoted prices for identical securities where there is little or no activity in the market; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The Company determines the net asset value of its investment portfolio each quarter, or more frequently as needed. Securities that are publicly-traded are valued at the reported closing price on the valuation date. Securities that are not publicly-traded are valued at fair value as determined in good faith by the Board of Directors of the Company (the “Board”) or by the Adviser, pursuant to board-approved policies and procedures. In connection with that determination, the Adviser will provide the Board with portfolio company valuations which are based on relevant inputs, including indicative dealer quotes, values of like securities, recent portfolio company financial statements and forecasts, and valuations prepared by third-party valuation services.

With respect to investments for which market quotations are not readily available, the Board and the Adviser undertake a multi-step valuation process each quarter, as described below:

The valuation process begins with each portfolio company or investment being initially valued by investment professionals of the Adviser responsible for credit monitoring or independent third party valuation firms.

Preliminary valuation conclusions are then documented and discussed with a committee comprised of certain senior management employees of the Adviser (the “Valuation Committee”).

The Audit and Qualified Legal Compliance Committee of the Board , in assistance of Board valuation oversight, reviews portfolio valuation, including oversight of valuations determined by the Adviser and the Valuation Committee pursuant to the policies and procedures approved by the Board.

At least once each quarter, the valuations for approximately one quarter of the portfolio investments that have been fair valued are reviewed by an independent valuation firm such that, over the course of a year, each material portfolio investment that has been fair valued shall have been reviewed by an independent valuation firm at least once.

Based on this information, the Board discusses valuations and determines the fair value of each investment in the portfolio in good faith pursuant to board-approved policies and procedures.

As of ~~September 30,~~March 31, 2022, the Company held the following investments for which a sufficient level of current, reliable market quotations were not available:


Instrument	Type	Fair value

Grayson Investor Corp.	Asset-Backed Securities	$	312,000
PAMCO CLO 1997-1A B	Asset-Backed Securities		87,848
American Banknote Corp.	Common Stocks		1,605,300
IQHQ, Inc.	Common Stocks		1,964,000
TerreStar Corp.	Common Stocks		4,611,901
Wayne Services Legacy Inc.	Common Stocks		5,172
SFR WLIF III, LLC	LLC Interests		1,550,641
US GAMING LLC	LLC Interests		2,981,638
Sapience Therapeutics, Inc	Preferred Stocks		8,080,000
CCS Medical, Inc.	Senior Secured Loans		3,000,000
TerreStar Corp.	Senior Secured Loans		750,238
TerreStar Corp.	Senior Secured Loans		177,613
TerreStar Corp.	Senior Secured Loans		31,732
TerreStar Corp.	Senior Secured Loans		29,606

As of December 31, 2021, the Company held the following investments for which a sufficient level of current, reliable market quotations were not available:


~~Instrument~~	~~Type~~	~~Fair value~~

~~Grayson Investor Corp.~~	~~Asset-Backed Securities~~	$	~~352,500~~
~~PAMCO CLO~~ ~~1997-1A~~ B	~~Asset-Backed Securities~~		~~89,759~~
~~American Banknote Corp.~~	~~Common Stocks~~		~~1,717,500~~
~~IQHQ, Inc.~~	~~Common Stocks~~		~~1,661,000~~
~~MPM Holdings, Inc.~~	~~Common Stocks~~		~~42,500~~
~~TerreStar Corp.~~	~~Common Stocks~~		~~4,740,040~~
~~Wayne Services Legacy Inc.~~	~~Common Stocks~~		~~17,196~~
~~SFR WLIF III, LLC~~	~~LLC Interests~~		~~1,540,685~~
~~SFR WLIF II, LLC~~	~~LLC Interests~~		~~3,234,434~~
~~US GAMING LLC~~	~~LLC Interests~~		~~2,874,640~~
~~TerreStar Corp.~~	~~Senior Secured Loans~~		~~168,100~~
~~TerreStar Corp.~~	~~Senior Secured Loans~~		~~710,053~~
~~TerreStar Corp.~~	~~Senior Secured Loans~~		~~30,032~~
~~TerreStar Corp.~~	~~Senior Secured Loans~~		~~28,020~~
~~Gemphire Therapeutics, Inc.~~	~~Warrants~~		—

~~As of December 31, 2020, the Company held the following investments for which a sufficient level of current, reliable market quotations were not available:~~


Instrument	Type	Fair value

Grayson Investor Corp.	Asset-Backed Securities	$	304,000
PAMCO CLO 1997-1A B	Asset-Backed Securities		101,040
American Banknote Corp.	Common Stocks		2,208,750
IQHQ, Inc.	Common Stocks		1,823,000
TerreStar Corp.	Common Stocks		4,706,357


~~Instrument~~	~~Type~~	~~Fair value~~

~~Grayson Investor Corp.~~	~~Asset-Backed Securities~~	$	~~286,000~~
~~PAMCO CLO~~ ~~1997-1A~~ B	~~Asset-Backed Securities~~		~~77,767~~
~~American Banknote Corp.~~	~~Common Stocks~~		~~1,125,000~~
~~IQHQ,~~Wayne Services Legacy Inc.	Common Stocks		~~1,661,000~~
~~SteadyMed Ltd.~~	~~Common Stocks~~		~~40,405~~
~~TerreStar Corp.~~	~~Common Stocks~~		~~4,630,427~~
~~Tru Kids, Inc.~~	~~Common Stocks~~		~~532,642~~
~~Western States Life Insurance~~	~~Common Stocks~~		~~59,183~~
~~NexPoint Capital REIT, LLC~~	~~LLC Interests~~		~~228,215~~5,172
SFR WLIF III, LLC	LLC Interests		~~1,493,629~~1,563,916
SFR WLIF II, LLC	LLC Interests		~~2,742,974~~3,196,246
US GAMING LLC	LLC Interests		~~2,070,427~~2,812,212
Sapience Therapeutics, Inc	Senior Secured Loans		4,000,000
TerreStar Corp.	Senior Secured Loans		~~653,280~~729,979
TerreStar Corp.	Senior Secured Loans		~~154,659~~172,817
TerreStar Corp.	Senior Secured Loans		~~27,631~~30,875
TerreStar Corp.	Senior Secured Loans		~~26,000~~
~~Galena Biopharma, Inc.~~	~~Warrants~~		128,807
Gemphire Therapeutics, ~~Inc.~~	~~Warrants~~		—
~~SCYNEXIS,~~ Inc.	Warrants		—

Determination of fair value involves subjective judgments and estimates. Accordingly, the notes to the Company’s financial statements will refer to the uncertainty with respect to the possible effect of such valuations, and any change in such valuations, in the Company’s financial statements. Below is a description of factors that the Valuation Committee and the Board may consider when valuing the Company’s debt and equity investments.

Valuation of fixed income investments, such as loans and debt securities, depends upon a number of factors, including prevailing interest rates for like securities, expected volatility in future interest rates, call features, put features and other relevant terms of the debt. For investments without readily available market prices, the Company may incorporate these factors into discounted cash flow models to arrive at fair value. Other factors that the Valuation Committee and the Board may consider include the borrower’s ability to adequately service its debt, the fair market value of the portfolio company in relation to the face amount of its outstanding debt and the quality of collateral securing the Company’s debt investments.

The Company’s equity investments in portfolio companies for which there is no liquid public market will be valued at fair value. The Valuation Committee and the Board, in its analysis of fair value, may consider various factors, such as multiples of earnings before interest, taxes, depreciation and amortization (“EBITDA”), cash flows, net income, revenues or, in limited instances, book value or liquidation value. All of these factors may be subject to adjustments based upon the particular circumstances of a portfolio company or the Company’s actual investment position. For example, adjustments to EBITDA may take into account compensation to previous owners or acquisition, recapitalization, restructuring or other related items.

The Valuation Committee and the Board may also look to private merger and acquisition statistics, public trading multiples discounted for illiquidity and other factors, valuations implied by third-party investments in the portfolio companies or industry practices in determining fair value. The Valuation Committee and the Board may also consider the size and scope of a portfolio company and its specific strengths and weaknesses, as well as any other factors it deems relevant in assessing the value. Generally, the value of the Company’s equity interests in public companies for which market quotations are readily available will be based upon the most recent closing public market price.

If the Company receives warrants or other equity-linked securities at nominal or no additional cost in connection with an investment in a debt security, the Company will allocate the cost basis in the investment between the debt securities and any such warrants or other equity-linked securities received at the time of origination. The Valuation Committee and the Board will subsequently value these warrants or other equity-linked securities received at fair value.

As applicable, the Company values its Level 2 assets by using the midpoint of the prevailing bid and ask prices from dealers on the date of the relevant period end, which is provided by an independent third-party pricing service and screened for validity by such service. For investments for which the third-party pricing service is unable to obtain quoted prices, the Company obtains bid and ask prices directly from dealers who make a market in such investments.

To the extent that the Company holds investments for which no active secondary market exists and, therefore, no bid and ask prices can be readily obtained, the Valuation Committee and the Board utilize an independent third-party valuation service to value such investments in a manner consistent with the Company’s multistep valuation process previously described.

The Company periodically benchmarks the bid and ask prices received from the third-party pricing service and/or dealers, as applicable, and valuations received from the third-party valuation service against the actual prices at which it purchases and sells its investments. The Company believes that these prices are reliable indicators of fair value. The Valuation Committee and the Board review and approve the valuation determinations made with respect to these investments in a manner consistent with the Company’s valuation procedures.

As of ~~September 30, 2021,~~March 31, 2022, the Company’s investments consisted of senior secured loans, ~~bonds,~~ asset-backed securities, common stocks, LLC interests, preferred stocks, corporate bonds, and warrants, which may be purchased for a fraction of the price of the underlying securities. The fair value of the Company’s loans, bonds and asset-backed securities are generally based on quotes received from brokers or independent pricing services. Loans, bonds and asset-backed securities with quotes that are based on actual trades with a sufficient level of activity on or near the measurement date are classified as Level 2 assets. Loans, bonds and asset-backed securities that are priced using quotes derived from implied values, indicative bids or a limited number of actual trades are classified as Level 3 assets because the inputs used by the brokers and pricing services to derive the values are not readily observable.

The fair value of the Company’s common stocks and options that are not actively traded on national exchanges are generally priced using quotes derived from implied values, indicative bids, or a limited amount of actual trades and are classified as Level 3 assets because the inputs used by the brokers and pricing services to derive the values are not readily observable. Exchange traded options are valued based on the last trade price on the primary exchange on which they trade. If an option does not trade, the mid-price is utilized to value the option.

Prior to its termination, the Company valued the total return swaps (“TRS”) in accordance with the agreement (the “TRS Agreement”) with BNP Paribas (“BNP Paribas”) that established the TRS. Pursuant to the TRS Agreement, the value of the TRS was based on the increase or decrease in the value of the loans underlying the TRS, together with accrued interest income, interest expense and certain other expenses incurred under the TRS. The loans underlying the TRS were valued based on indicative bid prices provided by an independent third-party pricing service. Bid prices reflected the highest price that market participants may have been willing to pay. These valuations were sent to the Company for review and testing. For additional information on the TRS, see Note 7.

At the end of each calendar quarter, the Adviser evaluates the Level 2 and 3 investments for changes in liquidity, including: whether a broker is willing to execute at the quoted price, the depth and consistency of prices from third party services, and the existence of contemporaneous, observable trades in the market. Additionally, management evaluates the Level 1 and 2 assets and liabilities on a quarterly basis for changes in listings or delistings on national exchanges.

Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market price, the fair value of the Company’s investments may fluctuate from period to period. Additionally, the fair value of investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values the Company may ultimately realize. Further, such investments may be subject to legal and other restrictions on resale or otherwise less liquid than publicly traded securities.

The inputs or methodology used for valuing investments are not necessarily an indication of the risk associated with investing in those investments. The following are summaries of the Company’s investments categorized within the fair value hierarchy as of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020:~~2021:


		September 30, 2021									March 31, 2022
Investments		Level 1		Level 2		Level 3		Total			Level 1		Level 2		Level 3		Total

Assets	Assets									Assets
Senior Secured Loans	Senior Secured Loans									Senior Secured Loans
Healthcare		$	—	$	28,036,763	$	—	$	28,036,763		$	—	$	13,648,667	$	3,000,000	$	16,648,667
Telecommunication Services			—		—		936,205		936,205			—		—		989,189		989,189
Asset-Backed Securities	Asset-Backed Securities									Asset-Backed Securities
Financials			—		—		442,259		442,259			—		—		399,848		399,848
Corporate Bonds	Corporate Bonds									Corporate Bonds
Healthcare			—		6,528,376		—		6,528,376			—		6,369,954		—		6,369,954
Media/Telecommunications			—		351,137		—		351,137			—		342,247		—		342,247
Common Stocks	Common Stocks									Common Stocks
Chemicals			—		—		42,500		42,500			—		42,500		—		42,500
Energy			—		917,254		—		917,254			—		1,585,925		—		1,585,925
Financials			—		—		1,717,500		1,717,500			—		—		1,605,300		1,605,300
Healthcare			483,600		—		—		483,600			330,400		—		—		330,400
Real Estate			6,148,490		—		1,661,000		7,809,490			10,885,734		—		1,964,000		12,849,734
Real Estate Investment Trusts (REITs)			1,427,448		—		—		1,427,448			2,101,333		—		—		2,101,333
Service			—		—		17,196		17,196			—		—		5,172		5,172
Telecommunication Services			—		—		4,740,040		4,740,040			—		—		4,611,901		4,611,901
LLC Interests	LLC Interests									LLC Interests
Consumer Products			—		—		2,874,640		2,874,640			—		—		2,981,638		2,981,638
Real Estate			—		—		4,775,119		4,775,119			—		—		1,550,641		1,550,641
Preferred Stocks	Preferred Stocks									Preferred Stocks
Financials			—		1,750,000		—		1,750,000			—		1,650,000		—		1,650,000
Healthcare												—		—		8,080,000		8,080,000
Warrants	Warrants									Warrants
Energy			—		65,766		—		65,766			—		171,184		—		171,184
Healthcare⁽¹⁾			—		—		—		—
Media/Telecommunications			—		71,861		—		71,861			—		43,456		—		43,456

Total Assets		$	8,059,538	$	37,721,157	$	17,206,459	$	62,987,154		$	13,317,467	$	23,853,933	$	25,187,689	$	62,359,089

Total Investments		$	8,059,538	$	37,721,157	$	17,206,459	$	62,987,154
Total Investments net of Securities Sold Short											$	13,317,467	$	23,853,933	$	25,187,689	$	62,359,089


	December 31, 2021
Investments	Level 1		Level 2		Level 3		Total

Assets
Senior Secured Loans
Healthcare	$	—	$	20,254,978	$	4,000,000	$	24,254,978
Telecommunication Services		—		—		962,478		962,478
Asset-Backed Securities
Financials		—		—		405,040		405,040
Corporate Bonds
Healthcare		—		6,480,320		—		6,480,320
Media/Telecommunications		—		345,946		—		345,946
Common Stocks
Chemicals		—		42,500		—		42,500
Energy		—		1,092,846		—		1,092,846
Financials		—		—		2,208,750		2,208,750
Healthcare		432,000		—		—		432,000
Real Estate		6,075,895		—		1,823,000		7,898,895
Real Estate Investment Trusts (REITs)		1,942,593		—		—		1,942,593
Service		—		—		5,172		5,172
Telecommunication Services		—		—		4,706,357		4,706,357
LLC Interests
Consumer Products		—		—		2,812,212		2,812,212
Real Estate		—		—		4,760,162		4,760,162
Preferred Stocks
Financials		—		1,725,000		—		1,725,000
Warrants
Energy		—		112,058				112,058
Healthcare⁽¹⁾		—		—		—		—
Media/Telecommunications		—		49,004		—		49,004

Total Assets	$	8,450,488	$	30,102,652	$	21,683,171	$	60,236,311

Total Investments net of Securities Sold Short	$	8,450,488	$	30,102,652	$	21,683,171	$	60,236,311

⁽¹⁾	Gemphire Therapeutics, Inc. Warrants at zero value.

   December 31, 2020
Investments
   Level 1    Level 2    Level 3    Total

Assets

Senior Secured Loans

Energy
   $ —      $ 422,827    $ —      $ 422,827
Healthcare
   —      33,071,007    —      33,071,007
Manufacturing
   —      1,666,667    —      1,666,667
Telecommunication Services
   —      —      861,570    861,570
Asset-Backed Securities

Financials
   —      —      363,767    363,767
Corporate Bonds

Healthcare
   —      6,531,240    —      6,531,240
Media/Telecommunications
   —      352,712    —      352,712
Common Stocks

Chemicals
   —      42,500    —      42,500
Financials
   —      —      1,125,000    1,125,000
Healthcare
   566,400    —      40,405    606,805
Real Estate
   —      —      1,661,000    1,661,000
Real Estate Investment Trusts (REITs)
   957,898    —      —      957,898
Retail
   —      —      532,642    532,642
Service
   —      —      59,183    59,183
Telecommunication Services
   —      —      4,630,427    4,630,427
LLC Interests

Consumer Products
   —      —      2,070,427    2,070,427
Real Estate
   —      —      4,236,603    4,236,603
Real Estate Investment Trusts (REITs)
   —      —      228,215    228,215

Partnership Units

Real Estate
   —      5,214,223    —      5,214,223
Preferred Stock⁽¹⁾
   —      —      —      —
Warrants

Healthcare
   —      —      1    1
Media/Telecommunications
   —      33,901    —      33,901








Total Assets
   $ 1,524,298    $ 47,335,077    $ 15,809,240    $ 64,668,615








Total Investments
   $ 1,524,298    $ 47,335,077    $ 15,809,240    $ 64,668,615

⁽¹⁾	~~Includes RAIT Financial Trust Preferred Stock at zero value~~.

The table below sets forth a summary of changes in the Company’s Level 3 investments (measured at fair value using significant unobservable inputs) for the ~~nine~~three months ended ~~September 30, 2021.~~March 31, 2022.


Investments:	Balance as of December 31, 2020		Transfers into Level 3		Transfer out of Level 3		Net amortization (accretion) of premium/ (discount)		Distribution to Return Capital			Net realized gains/ (losses)			Net change in unrealized gains/ (losses)			Purchases/ PIK		(Sales and redemptions)			Balance as of September 30, 2021		Change in unrealized gain/(loss) on Level 3 securities still held at period end			Balance as of December 31, 2021		Transfers into Level 3		Transfers out of Level 3		Net amortization (accretion) of premium/ (discount)		Distribution to Return Capital		Net realized gains/ (losses)			Net change in unrealized gains/ (losses)			Purchases/ PIK			(Sales and redemptions)			Balance as of March 31, 2022		Change in unrealized gain/(loss) on Level 3 securities still held at period end

Assets
Senior Secured Loans
Telecommunication Services	$	861,570	$	—	$	—	$	—	$	—		$	—		$	—		$	74,635	$	—		$	936,205	$	—		$	962,478	$	—	$	—	$	—	$	—	$	—		$	—		$	26,711		$	—		$	989,189	$	—
Healthcare																													4,000,000		—		—		3,809		—		—			86,191			2,990,000			(4,080,000	)^(a)		3,000,000		86,191
Asset-Backed Securities
Financials		363,767		—		—		—		—			—			78,492			—		—			442,259		78,492			405,040		—		—		—		—		—			11,787			—			(16,979	)		399,848		11,787
Common Stocks
Chemicals		—		42,500		—		—		—			—			—			—		—			42,500		—
Financials		1,125,000		—		—		—		—			—			592,500			—		—			1,717,500		592,500			2,208,750		—		—		—		—		—			(603,450	)		—			—			1,605,300		(603,450	)
Healthcare		40,405		—		—		—		—			(14,509	)		(25,896	)		—		—			—		—
Real Estate		1,661,000		—		—		—		—			—			—			—		—			1,661,000		—			1,823,000		—		—		—		—		—			141,000			—			—			1,964,000		141,000
Retail		532,642		—		—		—		—			(515,500	)		586,525			—		(603,667	)		—		—
Service		59,183		—		—		—		—			—			(41,987	)		—		—			17,196		(41,987	)		5,172		—		—		—		—		—			—			—			—			5,172		—
Telecommunication Services		4,630,427		—		—		—		—			—			109,613			—		—			4,740,040		109,613			4,706,357		—		—		—		—		—			(94,456	)		—			—			4,611,901		(94,456	)
LLC Interests
Consumer Products		2,070,427		—		—		—		—			—			804,213			—		—			2,874,640		804,213			2,812,212		—		—		—		—		—			169,426			—			—			2,981,638		169,426
Real Estate		4,236,603		—		—		—		—			—			538,516			—		—			4,775,119		538,516			4,760,162		—		—		—		—		(74,603	)		139,367			—			(3,274,285	)^(b)		1,550,641		(13,275	)
Real Estate Investment Trusts (REITs)		228,215		—		—		—		(200,000	)		—			(28,215	)		—		—			—		—
Warrants
Preferred Stocks
Healthcare		1		—		—		—		—			—			(1	)		—		—			—		(1	)		—		—		—		—		—		—			—			8,080,000	^(a)		—			8,080,000		—

Total	$	15,809,240	$	42,500	$	—	$	—	$	(200,000	)	$	(530,009	)	$	2,613,760		$	74,635	$	(603,667	)	$	17,206,459	$	2,027,235		$	21,683,171	$	—	$	—	$	3,809	$	—	$	(74,603	)	$	(150,135	)	$	11,096,711		$	(7,371,264	)	$	25,187,689	$	(302,777	)

^(a)	Denotes Sapience’s $4,080,000 promissory notes and paid in kind interest conversion to preferred stock.

^(b)	Denotes SFR II’s LLC Interests conversion into NREF common shares.

Investments:
Balance as of
December 31,
2019 Transfers
into
Level 3 Transfer
out of
Level 3 Net
amortization
(accretion) of
premium/
(discount) Net
realized
gains/
(losses) Net change in
unrealized
gains/
(losses) Purchases/
PIK (Sales
and
redemptions) Balance as of
September 30,
2020 Change in
unrealized
gain/(loss)
on Level 3
securities still
held at period
end

Assets

Senior Secured Loans

Telecommunication Services
$ 721,602 $ —   $ —   $ —   $ —   $ 633 $ 89,713 $ —   $ 811,948 $ 633
Unsecured Loans

Materials
3,713,191 —   —   124,719 (2,746,641 ) 482,389 313,727 (1,887,385 ) —   —
Asset-Backed Securities

Financials
139,629 333,764 —   —   —   (191,083 ) —   —   282,310 (191,083 )
Common Stocks

Financials
2,467,500 —   —   —   —   (735,000 ) —   —   1,732,500 (735,000 )
Healthcare
40,405 —   —   —   —   —   —   —   40,405 —
Materials
20,898 —   —   —   —   (20,898 ) —   —   —   (20,898 )
Real Estate
—   1,500,000 —   —   —   161,000 —   —   1,661,000 161,000
Telecommunication Services
3,890,081 —   —   —   —   814,872 —   —   4,704,953 814,872
LLC Interests

Consumer Products
2,000,000 —   —   —   —   —   —   —   2,000,000 —
Real Estate
4,932,657 —   —   —   —   (1,003,967 ) —   —   3,928,690 (1,003,967 )
Real Estate Investment Trusts
(REITs)
2,425,989 —   —   —   —   10,689 —   (2,189,561 ) 247,117 10,689
Warrants

Healthcare
—   29,837 —   —   —   (29,577 ) —   —   260 (29,577 )
Materials
647 —   —   —   —   (647 ) —   —   —   (647 )

Total
$ 20,352,599 $ 1,863,601 $ —   $ 124,719 $ (2,746,641 ) $ (511,589 ) $ 403,440 $ (4,076,946 ) $ 15,409,183 $ (993,978 )

Liabilities

Total Return
Swaps⁽¹⁾
$ (2,745,042 ) $ —   $ —   $ —   $ (6,929,996 ) $ 2,745,042 $ 7,425,035 $ (495,039 ) $ —   $ —

⁽¹⁾

During the nine months ended September 30, 2020, the Company recognized a net realized loss on the TRS amounting to $6,929,996. The realized losses of the derivative instruments during the nine months ended September 30, 2020 serve as indicators of the volume of derivative activity for the Company. The Company received $483,581 in cash payments from the TRS during the period and paid $7,425,035, with a decrease of $11,458 in payable from BNP Paribas for the nine months ended September 30, 2020.


Investments:	Balance as of December 31, 2020		Transfers into Level 3		Transfers out of Level 3		Net amortization (accretion) of premium/ (discount)		Net realized gains/ (losses)			Net change in unrealized gains/ (losses)			Purchases/ PIK		(Sales and redemptions)			Balance as of March 31, 2021		Change in unrealized gain/(loss) on Level 3 securities still held at period end

Assets
Senior Secured Loans
Telecommunication Services	$	861,570	$	—	$	—	$	—	$	—		$	—		$	23,684	$	—		$	885,254	$	—
Asset-Backed Securities
Financials		363,767		—		—		—		—			10,948			—		—			374,715		10,948
Common Stocks
Financials		1,125,000		—		—		—		—			(7,500	)		—		—			1,117,500		(7,500	)
Healthcare		40,405		—		—		—		—			(40,405	)		—		—			—		(40,405	)
Real Estate		1,661,000		—		—		—		—			—			—		—			1,661,000		—
Retail		532,642		—		—		—		(515,501	)		586,525—			—		(603,666	)		—		—
Service		59,183		—		—		—		(1	)		—			—		—			59,182		—
Telecommunication Services		4,630,427		—		—		—		—			(56,140	)		—		—			4,574,287		(56,140	)
LLC Interests
Consumer Products		2,070,427		—		—		—		—			(245	)		—		—			2,070,182		(245	)
Real Estate		4,236,603		—		—		—		—			371,032			—		—			4,607,635		371,032
Real Estate Investment Trusts (REITs)		228,215		—		—		—		—			(8,200	)		—		—			220,015		(8,200	)
Warrants
Healthcare		1		—		—		—		—			1,206			—		—			1,207		1,206

Total	$	15,809,240	$	—	$	—	$	—	$	(515,202	)	$	857,221		$	23,684	$	(603,666	)	$	15,570,977	$	270,696

Investments designated as Level 3 may include investments valued using quotes or indications furnished by brokers which are based on models or estimates and may not be executable prices. In light of the developing market conditions, the Adviser continues to search for observable data points and evaluate broker quotes and indications received for investments. Determination of fair values is uncertain because it involves subjective judgments and estimates that are unobservable. Transfers from Level 2 to Level 3 are due to a decrease in market activity (e.g. frequency of trades), which resulted in a decrease of available market inputs to determine price. For the ~~nine~~three months ended September 30, 2021, there was one private placement equity position that transferred in to Level 3. Determination of fair value is uncertain because it involves subjective judgments and estimates that are unobservable. For the nine months ended September 30, 2020,March 31, 2022, there were ~~five~~no transfers from Level 2 to Level ~~3 due~~3. For the three months ended March 31, 2021, there were no transfers from Level 2 to ~~decreases in market activity.~~Level 3. Transfers from Level 3 to Level 2 and from Level 2 to Level 1 are due to an increase in market activity (e.g. frequency of trades), which resulted in an increase of available market inputs to determine price.

The following are summaries of significant unobservable inputs used in the fair valuations of investments categorized within Level 3 of the fair value hierarchy as of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020:~~2021:

Investment

Fair value at
September 30, 2021

Valuation
technique

Unobservable
inputs

Range of input value(s)
(weighted average)

Fair value at
March 31, 2022

Valuation
technique

Unobservable
inputs

Range of input value(s)
(weighted average)

LLC Interest

4,532,279

Discounted Cash Flow

Multiples Analysis

Discount Rate

Multiple of EBITDA

1.49% - 5.43% (3.46%)

6.0x - 8.15x (7.13x)

Common Stock

8,186,373

Discounted Cash Flow

Multiples Analysis

Transaction Indication of Value

Liquidation Analysis

Discount Rate

Multiple of EBITDA

Unadjusted Price/MHz-PoP

NAV

Enterprise Value ($mm)

Recovery Rate

15.50%

2.75x - 3.75x (3.25x)

$0.09 - $0.95 ($0.515)

$19.64

$835

75% - 100% (94%)

Preferred Stock

8,080,000

Transaction Indication of Value

Cost Price

N/A

Senior Secured Loans

3,989,189

Discounted Cash Flow

Discount Rate

11.00%

Asset-Backed Securities

399,848

Discounted Cash Flow

Third Party Indication of Value

Discount Rate

Broker Quote

21.00%

Various

Total

25,187,689

Investment

Fair value at
December 31, 2021

Valuation
technique

Unobservable
inputs

Range of input value(s)
(weighted average)

LLC Interest

7,649,759

Discounted Cash Flow

Net Asset Value

Multiples Analysis

Discount Rate

N/A

Multiple of EBITDA

1.49% - 5.43% (3.46%)

N/A

5.95x - 7.85x (6.95x)

7,572,374

Discounted Cash Flow

Net Asset Value

Multiples Analysis

Discount Rate

N/A

Multiple of EBITDA

1.49% - 5.43% (3.46%)

N/A

6.3x - 8.2x (7.25x)

Common Stock

8,178,236

Discounted Cash Flow

Multiples Analysis

Transaction Indication of Value

Liquidation Analysis

Discount Rate

Multiple of EBITDA

Unadjusted Price/MHz-PoP

Liquidity Discount

Enterprise Value ($mm)

Transaction Price Per Share

Recovery Rate

Claim Value

16.10%

3.00x - 8.00x (5.50x)

$0.09 - $0.95 ($0.52)

25%

$841

$16.61

75% - 100% (94%)

8,743,279

Discounted Cash Flow

Multiples Analysis

Transaction Indication of Value

Liquidation Analysis

Discount Rate

Multiple of EBITDA

Unadjusted Price/MHz-PoP

NAV / sh multiple

Enterprise Value ($mm)

Recovery Rate

14.5% - 16.5% (15.5%)

2.75x - 3.75x (3.25x)

$0.09 - $0.95 ($0.52)

0.75x - 1.00x (0.875x)

$841

75% - 100% (94%)

Senior Secured Loans

936,205

Discounted Cash Flow

Discount Rate

11.00%

4,962,478

Discounted Cash Flow

Transaction Indication of Value

Discount Rate

Cost Price

11.00%

N/A

Asset-Backed Securities

442,259

Discounted Cash Flow

Third Party Indication of Value

Discount Rate

Broker Quote

21.00%

Various

405,040

Discounted Cash Flow

Third Party Indication of Value

Discount Rate

Broker Quote

21.00%

Various

Warrants

—

Black-Scholes Model

Volatility Assumption

97.4%

—

Black-Scholes Model

Volatility Assumption

181.3%

Total

17,206,459

21,683,171

Investment
   Fair value at
December 31, 2020    Valuation
technique    Unobservable
inputs Range of input value(s)
(weighted average)

LLC Interest
   $ 6,535,245
Discounted Cash Flow
Net Asset Value
Multiples Analysis

   Discount Rate
Long Term Growth Rate
Net Asset Value
Multiple of EBITDA

1.28% - 11.30%
6.90%
$0.82 - $2,282.15
3.50x - 7.95x

Common Stock
   8,048,657
Discounted Cash Flow
Multiples Analysis
Transaction Indication of Value
Probability Weighted Expected Return

   Discount Rate
Multiple of EBITDA
Unadjusted Price/MHz-PoP
Liquidity Discount
Enterprise Value ($mm)
Transaction Price Per Share
Multiple of EBITDA
Cash Offer per Share
Probability Assessment

15.50%
3.50x - 7.00x
$0.09 - $0.95
25%
$771.00
$2.75 - $16.61
8.00x
$2,500
20%

Senior Secured Loans
   861,570    Discounted Cash Flow    Discount Rate 11.00%
Asset-Backed Securities
   363,767
Discounted Cash Flow
Third Party Indication of Value

   Discount Rate
Broker Quote

21.00%
Various

Warrants
   1    Black-Scholes Model    Volatility Assumption 78.9% - 429.9%



Total
   $ 15,809,240

The significant unobservable inputs used in the fair value measurement of the Company’s LLC interests are: discount rate and multiples of EBITDA. Significant increases (decreases) in those inputs in isolation could result in a significantly lower (higher) fair value measurement.

The significant unobservable inputs used in the fair value measurement of the Company’s common equity securities are: multiple of EBITDA, price/MHz-PoP multiple, liquidity discount, discount rate, enterprise value, and transaction price. Significant increases (decreases) in any of those inputs in isolation could result in a significantly lower (higher) fair value measurement.

The significant unobservable inputs used in the fair value measurement of the Company’s bank loan securities are: discount rate and spread adjustment. Significant increases (decreases) in either of those inputs in isolation could result in a significantly lower (higher) fair value measurement.

The significant unobservable inputs used in the fair value measurement of the Company’s asset-backed securities are: discount rate and broker quote indication of value. Significant increases (decreases) in either of those inputs in isolation could result in a significantly lower (higher) fair value measurement.

The significant unobservable input used in the fair value measurement of the Company’s warrant securities is: volatility assumption. Significant increases (decreases) in this input in isolation could result in a significantly lower (higher) fair value measurement.

Derivative Transactions

The Company is subject to equity price risk, interest rate risk and foreign currency exchange rate risk in the normal course of pursuing its investment objective. The Company may invest without limitation in warrants and may also use derivatives, primarily swaps (including equity, variance and volatility swaps), options and futures contracts on securities, interest rates, commodities and/or currencies, as substitutes for direct investments the Company can make. The Company may also use derivatives such as swaps, options (including options on futures), futures, and foreign currency transactions (e.g., foreign currency swaps, futures and forwards) to any extent deemed by the Adviser to be in the best interest of the Company, and to the extent permitted by the 1940 Act, to hedge various investments for risk management and speculative purposes. ~~For additional information on the TRS, please see Note 7.~~

Options

The Company purchases options, subject to certain limitations. The Company may invest in options contracts to manage its exposure to the stock and bond markets and fluctuations in foreign currency values. Writing puts and buying calls tend to increase the Company’s exposure to the underlying instrument while buying puts and writing calls tend to decrease the Company’s exposure to the underlying instrument, or economically hedge other Company investments. The Company’s risks in using these contracts include changes in the value of the underlying instruments, nonperformance of the counterparties under the contracts’ terms and changes in the liquidity of the secondary market for the contracts. Options are valued at the last sale price, or if no sales occurred on that day, at the last quoted bid price. As of and during the ~~nine~~three months ended ~~September 30,~~March 31, 2022 and March 31, 2021, ~~and September 30, 2020,~~ the Company did not hold options.

Investment Transactions

Investment transactions are accounted for on trade date. Realized ~~gains/~~gains (losses) on investments sold are recorded on the basis of specific identification method for both financial statement and U.S. federal income tax purposes. Payable for investments purchased and receivable for investments sold on the Statements of Assets and Liabilities, if any, represents the cost of purchases and proceeds from sales of investment securities, respectively, for trades that have been executed but not yet settled.

Income Recognition

Corporate actions (including cash dividends from common stock and equity tranches of asset-backed securities) are recorded on the ex-dividend date, net of applicable withholding taxes, except for certain foreign corporate actions, which are recorded as soon after the ex-dividend date as such information becomes available. Interest income is recorded on the accrual basis. The Company does not accrue as a receivable for interest or dividends on loans, asset-backed securities and other securities if there is a reason to doubt the Company’s ability to collect such income. For loans with contractual PIK (payment-in-kind) interest income, which represents contractual interest accrued and added to the loan balance that generally becomes due at maturity, we will not accrue PIK interest if we believe that the PIK interest is no longer collectible. Loan origination fees, original issue discount

and market discount are capitalized and such amounts are amortized as interest income over the respective term of the loan or security. Upon the prepayment of a loan or security, any unamortized loan origination fees and original issue discount are recorded as interest income.

Accretion of discounts and amortization of premiums on taxable bonds, loans and asset-backed securities are computed to the call or maturity date, whichever is shorter, using the effective yield method. Withholding taxes on foreign dividends have been provided for in accordance with the Company’s understanding of the applicable country’s tax rules and rates.

Organization and Offering Costs

Organization costs are paid by the Adviser and include the cost of incorporating, such as the cost of legal services and other fees pertaining to our organization. Offering costs include legal fees, promotional costs and other costs pertaining to the public offering of our shares of common stock and are also paid by the Adviser. Prior to the termination of the offering, as we raised proceeds, these organization and offering costs were expensed and became payable to the Adviser. Organization and offering costs are limited to 1% of total gross proceeds raised and are not due and payable to the Adviser to the extent they exceed that amount. Please refer to Note 4 for additional information on Organization and Offering Costs.

Paid-in Capital

The proceeds from the issuance of common stock as presented on the Company’s Statements of Changes in Net Assets is presented net of selling commissions and fees for the ~~nine~~three months ended ~~September 30, 2021~~March 31, 2022 and ~~September 30, 2020.~~March 31, 2021. Selling commissions and fees of $0 and $0 were paid for the ~~nine~~three months ended ~~September 30,~~March 31, 2022 and March 31, 2021, ~~and September 30, 2020,~~ respectively.

Earnings Per Share

In accordance with the provisions of ASC Topic 260—Earnings per Share (“ASC Topic 260”), basic earnings per share is computed by dividing earnings available to common stockholders by the weighted average number of shares outstanding during the period. Other potentially dilutive common shares, and the related impact to earnings, are considered when calculating earnings per share on a diluted basis.

2221

The following table sets forth the computation of the weighted average basic and diluted net increase in net assets per share from operations:

   For the Three Months Ended
September 30,    For the Nine Months Ended
September 30,

   2021    2020    2021    2020

Net increase (decrease) in net assets from operations
   $ (18,453 )    $ 2,652,096    $ 5,575,029    $ (23,564,609 )
Weighted average common shares outstanding
   10,141,588    10,528,658    10,316,029    10,520,781
Earnings (loss) per common share-basic and diluted
   $ —      $ 0.25    $ 0.54    $ (2.24 )


	For the three months ended March 31,

	2022		2021

Net increase (decrease) in net assets resulting from operations	$	1,145,017	$	2,274,057
Weighted average common shares outstanding		9,990,797		10,508,636
Earnings per common share-basic and diluted	$	0.11	$	0.22

Distributions

Distributions to the Company’s stockholders will be recorded as of the record date. Subject to the discretion of the Board and applicable legal restrictions, the Company intends to authorize and declare ordinary cash distributions on a weekly basis and pay such distributions on a quarterly basis. Net realized capital gains, if any, will generally be distributed or deemed distributed at least every 12-month period.

On June 24, 2020, the Board approved a change in its dividend and capital gains distribution schedule from monthly distributions to quarterly distributions, effective immediately. The first quarterly distribution was paid on October 12, 2020 to shareholders of record as of September 30, 2020. The dividends are expected to be declared in the amount of $0.09 per share of the Company’s common stock to the stockholders of record at each quarter end.

Recent Accounting Pronouncements

In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” which provides optional exceptions for applying GAAP to contract modifications, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. ASU No. 2020-04 is elective and effective for all entities as of March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of ASU No. 2020-04. Please refer to Note 8 for additional information.

2322

Note 3 — Investment Portfolio

The following table shows the composition of the Company’s invested assets by industry classification at fair value at ~~September 30, 2021:~~March 31, 2022:


	Fair value		Percentage			Fair value		Percentage
Assets
Healthcare	$	35,048,739		55.6	%	$	31,429,021		50.4	%
Real Estate		12,584,609		20.0	%		14,400,375		23.1	%
Telecommunication Services		5,676,245		9.0	%		5,601,090		9.0	%
Financials		3,909,759		6.2	%		3,655,148		5.8	%
Consumer Products		2,874,640		4.5	%		2,981,638		4.8	%
Real Estate Investment Trusts (REITs)		1,427,448		2.3	%		2,101,333		3.4	%
Energy		983,020		1.6	%		1,757,109		2.8	%
Media/Telecommunications		422,998		0.7	%		385,703		0.6	%
Chemicals		42,500		0.1	%		42,500		0.1	%
Service		17,196		0.0	%		5,172		0.0	%

Total Assets	$	62,987,154		100.0	%	$	62,359,089		100.0	%

The following table shows the composition of the Company’s invested assets by industry classification at fair value at December 31, ~~2020:~~2021:


	Fair value		Percentage			Fair value		Percentage
Assets
Healthcare	$	40,209,053		62.2	%	$	31,167,298		51.7	%
Real Estate		11,111,826		17.2	%		12,659,057		21.0	%
Telecommunication Services		5,491,997		8.5	%		5,668,835		9.4	%
Financials							4,338,790		7.2	%
Consumer Products		2,070,427		3.2	%		2,812,212		4.7	%
Manufacturing		1,666,667		2.6	%
Financials		1,488,767		2.3	%
Real Estate Investment Trusts (REITs)		1,186,113		1.8	%		1,942,593		3.2	%
Retail		532,642		0.8	%
Energy		422,827		0.6	%		1,204,904		2.0	%
Media/Telecommunications		386,613		0.6	%		394,950		0.7	%
Chemicals							42,500		0.1	%
Service		59,183		0.1	%		5,172		0.0	%
Chemicals		42,500		0.1	%

Total Assets	$	64,668,615		100.0	%	$	60,236,311		100.0	%

2423

The following table summarizes the amortized cost and the fair value of the Company’s invested assets by class of financial asset as of ~~September 30, 2021:~~March 31, 2022:


		Amortized Cost		Fair value		Percentage of Portfolio (at Fair Value)			Amortized Cost		Fair value		Percentage of Portfolio (at Fair Value)
Assets	Assets
Senior Secured Loans - First Lien		$	23,805,854	$	25,882,233		41.1	%	$	15,052,670	$	14,590,403		23.4	%
Senior Secured Loans - Second Lien			2,953,559		3,090,735		4.9	%		2,962,432		3,047,453		4.9	%
Asset-Backed Securities			671,187		442,259		0.7	%		405,292		399,848		0.6	%
Corporate Bonds			6,796,510		6,879,513		10.9	%		6,839,289		6,712,201		10.8	%
Common Stocks			14,056,989		17,155,028		27.3	%		17,591,602		23,132,265		37.1	%
LLC Interests			7,000,000		7,649,759		12.1	%		3,651,112		4,532,279		7.3	%
Preferred Stocks			1,750,000		1,750,000		2.8	%		9,830,000		9,730,000		15.6	%
Warrants			52,988		137,627		0.2	%		74,284		214,640		0.3	%

Total Assets		$	57,087,087	$	62,987,154		100.0	%	$	56,406,681	$	62,359,089		100.0	%

The following table summarizes the amortized cost and the fair value of the Company’s invested assets by class of financial asset as of December 31, ~~2020:~~2021:


		Amortized cost		Fair value		Percentage of portfolio (at fair value)			Amortized Cost		Fair value		Percentage of Portfolio (at Fair Value)
Assets	Assets
Senior Secured Loans – First Lien		$	30,123,122	$	31,276,803		48.3	%
Senior Secured Loans – Second Lien			4,742,429		4,745,268		7.3	%
Senior Secured Loans - First Lien									$	21,439,866	$	22,144,887		36.7	%
Senior Secured Loans - Second Lien										2,957,993		3,072,569		5.1	%
Asset-Backed Securities			671,187		363,767		0.6	%		422,271		405,040		0.7	%
Corporate Bonds			6,736,607		6,883,952		10.6	%		6,817,768		6,826,266		11.3	%
Common Stocks			7,774,595		9,615,455		14.9	%		14,308,512		18,329,113		30.4	%
LLC Interests			7,000,000		6,535,245		10.1	%		7,000,000		7,572,374		12.6	%
Partnership Units			6,312,618		5,214,223		8.1	%
Preferred Stocks			3,051,714		—		0.0	%		1,750,000		1,725,000		2.9	%
Warrants			52,988		33,902		0.1	%		74,284		161,062		0.3	%

Total Assets		$	66,465,260	$	64,668,615		100.0	%	$	54,770,694	$	60,236,311		100.0	%

2524

The following table shows the composition of the Company’s invested assets by geographic classification at ~~September 30, 2021:~~March 31, 2022:


Geography		Fair value		Percentage			Fair value		Percentage
Assets	Assets
Cayman Islands⁽¹⁾		$	442,259		0.7	%	$	399,848		0.7	%
Great Britain⁽¹⁾			483,600		0.8	%
Luxembourg⁽¹⁾			2,503,443		4.0	%		1,445,661		2.3	%
United Kingdom⁽¹⁾								330,400		0.5	%
United States			59,557,852		94.5	%		60,183,180		96.5	%

Total Assets		$	62,987,154		100.0	%	$	62,359,089		100.0	%

⁽¹⁾	Investment denominated in USD.

The following table shows the composition of the Company’s invested assets by geographic classification at December 31, ~~2020:~~2021:


Geography		Fair value		Percentage			Fair value		Percentage
Assets	Assets
Cayman Islands⁽¹⁾		$	363,767		0.6	%	$	405,040		0.7	%
Great Britain⁽¹⁾			566,400		0.9	%		432,000		0.7	%
Luxembourg⁽¹⁾			2,461,549		3.8	%		2,500,169		4.1	%
United States			61,276,899		94.7	%		56,899,102		94.5	%

Total Assets		$	64,668,615		100.0	%	$	60,236,311		100.0	%

⁽¹⁾	Investment denominated in USD.

Note 4 — Related Party Transactions and Arrangements

Investment Advisory Fee

Payments for investment advisory services under the Company’s investment advisory agreement (the “Investment Advisory Agreement”) and administrative services agreement (the “Administration Agreement”) are equal to (a) a base management fee calculated at an annual rate of 2.0% of the average value of the Company’s gross assets at the end of the two most recently completed calendar quarters and (b) an incentive fee based on the Company’s performance. Effective June 5, 2017, the Investment Advisory Agreement and the Administration Agreement were amended to exclude cash and cash equivalents from the calculation of gross assets for the purpose of calculating investment advisory and administration fees.

For the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022 and March 31, 2021, the Company incurred investment advisory fees payable to the Adviser of ~~$291,857~~$299,270 and ~~$900,559, respectively. For the three and nine months ended September 30, 2020, the Company incurred investment advisory fees payable to the Adviser of $201,136 and $829,100,~~$303,707, respectively. Amounts waived for investment advisory fees or administrative fees pertaining to periods prior to ~~September 30, 2018~~June 10, 2016 are not recoupable, but amounts waived for investment advisory fees or administrative fees pertaining to periods from and after ~~September 30, 2018~~June 10, 2016 are subject to recoupment by the Adviser within three years from the date that such fees were otherwise payable, provided that the recoupment will be limited to the amount of such voluntarily waived fees from and after ~~September 30, 2018~~June 10, 2016 and will not cause the sum of the Company’s investment advisory fees, administration fees, Other Expenses (as defined under “Expense Limits and Reimbursements” below), and any recoupment to exceed the annual rate of 3.40% of average gross assets. Effective December 20, 2017, the Adviser ended its voluntary waiver of advisory fees.

Incentive Fee

The incentive fee consists of two parts. The first part, which is referred to as the subordinated incentive fee on income, is calculated and payable quarterly in arrears, and equals 20.0% of “pre-incentive fee net investment income” for the immediately preceding quarter and is subject to a hurdle rate, expressed as a rate of return on the Company’s net assets, as defined in the Investment Advisory Agreement, equal to 1.875% per quarter. As a result, the Adviser will not earn this incentive fee for any quarter until the Company’s pre-incentive fee net investment income for such quarter

exceeds the hurdle rate of 1.875%. Once the Company’s

pre-incentive fee net investment income in any quarter exceeds the hurdle rate, the Adviser will be entitled to a “catch-up” fee equal to the amount of the pre-incentive fee net investment income in excess of the hurdle rate, until the Company’s pre-incentive fee net investment income for such quarter equals 2.34375% of the Company’s net assets at the end of such quarter. This “catch-up” feature allows the Adviser to recoup the fees foregone as a result of the existence of the hurdle rate in that quarter. Thereafter, the Adviser will receive 20.0% of the Company’s pre-incentive fee net investment income from the quarter.

The second part of the incentive fee, which is referred to as the incentive fee on capital gains, is determined and payable in arrears as of the end of each calendar year (or upon termination of the Investment Advisory Agreement). This fee equals 20.0% of the Company’s incentive fee capital gains, which will equal the Company’s realized capital gains on a cumulative basis from formation, calculated as of the end of the applicable period, computed net of all realized capital losses (proceeds less amortized cost) and unrealized capital depreciation on a cumulative basis, less the aggregate amount of any previously paid capital gains incentive fees. The Company will accrue for the capital gains incentive fee, which, if earned, will be paid annually. The Company will accrue for the capital gains incentive fee based on net realized and unrealized gains; however, under the terms of the Investment Advisory Agreement, the fee payable to the Adviser will be based on realized gains and no such fee will be payable with respect to unrealized gains unless and until such gains are actually realized.

For the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022 and March 31, 2021, the Company incurred $0 and ~~$0 of incentive fees on capital gains, respectively. For the three and nine months ended September 30, 2020, the Company incurred $0 and~~recognized a reduction $0 of incentive fees on capital gains, respectively. Since inception, the Company has accrued $0 of incentive fees on capital gains in aggregate. Effective December 20, 2017, the Adviser ended its voluntary waiver of incentive fees. No such fees have been paid with respect to realized gains to the Adviser as of ~~September 30, 2021.~~March 31, 2022.

Administration Fee

Pursuant to the Administration Agreement with the Adviser, the Company also reimburses the Adviser for expenses necessary for its performance of services related to the Company’s administration and operations. The amount of the reimbursement will be the lesser of (1) the Company’s allocable portion of overhead and other expenses incurred by the Adviser in performing its obligations under the Administration Agreement and (2) 0.40% of the Company’s average gross assets, (excluding cash and cash equivalents). The Adviser is required to allocate the cost of such services to the Company based on objective factors such as assets, revenues, time allocations and/or other reasonable metrics. The Board assesses the reasonableness of such reimbursements based on the breadth, depth and quality of such services as compared to the estimated cost to the Company of obtaining similar services from third-party service providers known to be available. In addition, the Board will consider whether any single third-party service provider would be capable of providing all such services at comparable cost and quality. Finally, the Board will compare the total amount paid to the Adviser for such services as a percentage of the Company’s net assets to the same ratio as reported by other comparable BDCs.

For the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022 and March 31, 2021, the Company incurred administration fees payable to the Adviser of ~~$61,568~~$59,601 and ~~$183,308, respectively. For the three and nine months ended September 30, 2020, the Company incurred administration fees payable to the Adviser of $59,839 and $185,433,~~$62,539, respectively. Amounts waived for management fees or administrative services expenses pertaining to periods prior to ~~September 30, 2018~~June 10, 2016 are not recoupable, but amounts waived for management fees or administrative services, expenses pertaining to periods from and after ~~September 30, 2018~~June 10, 2016 are subject to recoupment by the Adviser within three years from the date that such fees were otherwise payable, provided that the recoupment will be limited to the amount of such voluntarily waived fees from and after ~~September 30, 2018~~June 10, 2016 and will not cause the sum of the Company’s advisory fees, administration fees, Other Expenses, and any recoupment to exceed the annual rate of 3.40% of average gross assets. Effective December 20, 2017, the Adviser ended its voluntary waiver of administration fees.

Organization and Offering Costs

Organization costs include the cost of incorporating, such as the cost of legal services and other fees pertaining to our organization, and are paid by the Adviser. For the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022 and March 31, 2021, ~~and September 30, 2020,~~ the Adviser did not incur or pay organization costs on our behalf.

Offering costs include legal fees, promotional costs and other costs pertaining to the public offering of our shares of common stock, and are capitalized and amortized to expense over one year. The Company’s continuous public offering ended on February 14, 2018.

Organization costs and offering costs are limited to 1% of total gross proceeds raised in the offering and are not due and payable to the Adviser to the extent they exceed that amount. As of ~~September 30, 2021,~~March 31, 2022, the cumulative aggregate amount of $5,327,574 of organization and offering costs exceeds 1% of total proceeds raised. Subsequent to the termination of the offering, the Adviser forfeited the right to reimbursement of the remaining $4,305,091 of these costs.

Fees Paid to Officers and Directors

Each director who oversees all of the portfolios in the Fund Complex receives an annual retainer of $150,000 payable in quarterly installments and allocated among each portfolio in the Fund Complex based on relative net assets. The annual retainer for a director who does not oversee all of the portfolios in the Fund Complex is prorated based on the portion of the $150,000 annual retainer allocable to the portfolios overseen by such director. Directors are reimbursed for actual out-of-pocket expenses relating to attendance at ~~meetings, however,~~meetings. In addition, the Chairman of the Board and the Chairman of the Audit and Qualified Legal Committee each receive an additional payment of $10,000 payable in quarterly installments and allocated among each portfolio in the Fund Complex based on relative net assets. The Directors do not receive any separate compensation in connection with service on Committees or for attending Board or Committee Meetings. They do not have any pension or retirement plan. The “Fund Complex” consists of all of the RICs advised by the Adviser and any affiliates as of the period covered by this report. The Company pays no compensation to any of its officers, all of whom are employed by the Adviser, its affiliates or Skyview Group, Inc. (“Skyview”). In light of certain relationships between John Honis, a director of the Company, and historically affiliated entities of the Adviser, including prior affiliate Highland Capital Management, L.P. (“HCMLP”), arising out of HCMLP’s pending Chapter 11 proceedings, Mr. Honis is treated as an “interested person” of the Company (as defined in the 1940 Act) effective January 28, 2020.

For the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022 and March 31, 2021, the Company recorded an expense relating to director fees of ~~$4,695~~$3,731 and ~~$13,460, respectively. For the three and nine months ended September 30, 2020, the Company recorded an expense relating to director fees of $6,238 and $16,127,~~$4,057, respectively, which represents the allocation of the director fees to the Company. As of ~~September 30, 2021,~~March 31, 2022, there ~~was~~were no expenses payable relating to director fees.

Expense Limits and Reimbursements

Pursuant to an expense limitation agreement, the Adviser is contractually obligated to waive fees and, if necessary, pay or reimburse certain other expenses to limit the ordinary “Other Expenses” to 1.0% of the quarter-end value of the Company’s gross assets through the one year anniversary of the effective date of the registration statement (the “Expense Limitation Agreement”). Under the Expense Limitation Agreement, “Other Expenses” are all expenses with the exception of advisor and administration fees, organization and offering costs and the following: (i) interest, taxes, dividends tied to short sales, brokerage commissions, and other expenditures which are capitalized in accordance with GAAP; (ii) expenses incurred indirectly as a result of investments in other investment companies and pooled investment vehicles; (iii) other expenses attributable to, and incurred as a result of, our investments; (iv) expenses payable to the Adviser, as administrator, for providing significant managerial assistance to our portfolio companies; and (v) other extraordinary expenses (including litigation expenses) not incurred in the ordinary course of our business. The obligation will automatically renew for one-year terms unless it is terminated by the Company or the Adviser upon written notice within 60 days of the end of the current term or upon termination of the Investment Advisory Agreement. The Expense Limitation Agreement will continue through at least April 30, ~~2022.~~2023.

Any expenses waived or reimbursed by the Adviser pursuant to the Expense Limitation Agreement are subject to possible recoupment by the Adviser within three years from the date of the waiver or reimbursement. The recoupment by the Adviser will be limited to the amount of previously waived or reimbursed expenses and cannot cause the Company’s expenses to exceed any expense limitation in place at the time of recoupment or waiver.

Reimbursable Expenses Table

The cumulative total of fees waived by the Adviser under the Expense Limitation Agreement, which are recoupable as of ~~September 30, 2021~~March 31, 2022 is ~~$976,335.~~$814,815. This balance, and the balances in the tables below, only include amounts pertaining to the Expense Limitation Agreement, and do not include waived advisory and administration fees subject to recoupment discussed earlier in Note 4. The following table reflects the fee waivers and expense reimbursements due from the Adviser as of March 31, 2022, which may become subject to recoupment by the Adviser.


Period ended	Yearly cumulative other expense		Yearly expense limitation		Yearly cumulative expense reimbursement		Quarterly recoupable/ (recouped) amount		Recoupment eligibility expiration
March 31, 2022	$	211,896	$	150,135	$	61,761	$	61,761		March 31, 2025

The following table reflects the fee waivers and expense reimbursements due from the Adviser as of December 31, 2021, September 30, 2021, June 30, 2021 and March 31, 2021, which may become subject to recoupment by the Adviser.


Period ended	Yearly cumulative other expense		Yearly expense limitation		Yearly cumulative expense reimbursement		Quarterly recoupable/ (recouped) amount		Recoupment eligibility expiration		Yearly cumulative other expense		Yearly expense limitation		Yearly cumulative expense reimbursement		Quarterly recoupable/ (recouped) amount		Recoupment eligibility expiration
December 31, 2021											$	892,640	$	597,379	$	295,261	$	94,762		December 31, 2024
September 30, 2021	$	664,052	$	463,553	$	200,499	$	68,134		September 30, 2024	$	664,052	$	463,553	$	200,499	$	68,134		September 30, 2024
June 30, 2021	$	436,866	$	304,501	$	132,365	$	68,919		June 30, 2024	$	436,866	$	304,501	$	132,365	$	68,919		June 30, 2024
March 31, 2021	$	220,126	$	156,680	$	63,446	$	63,446		March 31, 2024	$	220,126	$	156,680	$	63,446	$	63,446		March 31, 2024

The following table reflects the fee waivers and expense reimbursements due from the Adviser as of December 31, 2020, September 30, 2020, June 30, 2020 and March 31, 2020, which may become subject to recoupment by the Adviser.


Period ended	Yearly cumulative other expense		Yearly expense limitation		Yearly cumulative expense reimbursement		Quarterly recoupable/ (recouped) amount			Recoupment eligibility expiration
December 31, 2020	$	989,447	$	639,959	$	349,488	$	101,541			December 31, 2023
September 30, 2020		687,228		439,281		247,947		94,039			September 30, 2023
June 30, 2020		445,585		291,677		153,908		(30,539	)		June 30, 2023
March 31, 2020		257,226		72,779		184,447		184,447			March 31, 2023

The following table reflects the fee waivers and expense reimbursements due from the Adviser as of December 31, 2019, September 30, 2019, June 30, 2019 and March 31, 2019, which may become subject to recoupment by the Adviser.

Period ended
   Yearly cumulative
other expense    Yearly expense
limitation    Yearly cumulative
expense
reimbursement    Quarterly
recoupable/
(recouped)
amount Recoupment
eligibility
expiration
December 31, 2019
   $ 1,098,789    $ 951,520    $ 147,269    $ 50,130 December 31, 2022
September 30, 2019
   849,345    752,206    97,139    (17,417 ) September 30, 2022
June 30, 2019
   586,411    471,855    114,556    75,592 June 30, 2022
March 31, 2019
   295,177    256,213    38,964    38,964 March 31, 2022

The following table reflects the fee waivers and expense reimbursements due from the Adviser as of December 31, 2018, September 30, 2018, June 30, 2018 and March 31, 2018, which may become subject to recoupment by the Adviser.

Period ended
   Yearly cumulative
other expense    Yearly expense
limitation    Yearly cumulative
expense
reimbursement    Quarterly
recoupable
amount    Recoupment
eligibility
expiration
December 31, 2018
   $ 1,352,097    $ 924,677    $ 427,420    $ 279,079    December 31, 2021
September 30, 2018
   950,045    801,704    148,341    —      Expired
June 30, 2018
   613,809    489,460    124,349    —      Expired
March 31, 2018
   341,882    261,736    80,146    —      Expired


Period ended	Yearly cumulative other expense		Yearly expense limitation		Yearly cumulative expense reimbursement		Quarterly recoupable/ (recouped) amount			Recoupment eligibility expiration
December 31, 2019	$	1,098,789	$	951,520	$	147,269	$	50,130			December 31, 2022
September 30, 2019		849,345		752,206		97,139		(17,417	)		September 30, 2022
June 30, 2019		586,411		471,855		114,556		75,592			June 30, 2022
March 31, 2019		295,177		256,213		38,964		—			Expired

During the three ~~and nine~~ months ended ~~September 30, 2021, $23,992 and $148,341, respectively,~~March 31, 2022, $38,964 of expense reimbursements that were eligible for recoupment by the Adviser expired.

2928

There can be no assurance that the Expense Limitation Agreement will remain in effect or that the Adviser will reimburse any portion of the Company’s expenses in future quarters not covered by the Expense Limitation Agreement. Amounts shown do not include the amounts committed by the Adviser to voluntarily reimburse the Company for unrealized losses, all of which are not recoupable.

Net Increase from Amounts Committed by Affiliates

For the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022 and March 31, 2021, ~~and September 30, 2020,~~ the Adviser did not voluntarily reimburse the Company for unrealized losses sustained. Cumulatively since inception, the Adviser has committed $2,275,000 to voluntarily reimburse the Company for such losses. Had these commitments not been made, since inception, the net asset value (“NAV”) as of ~~September 30, 2021~~March 31, 2022 would have been lower by approximately this amount.

Amounts committed and paid by the Adviser to reimburse for unrealized losses are nonrecurring, and investors should not expect the Adviser to make similar commitments or payments in the future.

Receivable from Adviser / Payable to Adviser

As of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020, $61,306~~2021, $58,376 and ~~$101,542~~$95,458 were owed from the Adviser to the Company, respectively, largely related to the expense limitation agreement.

As of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, the Company owed ~~$354,231~~$359,236 and ~~$423,537,~~$378,587, respectively, to the Adviser, largely related to advisory fees, and administration fees.

Indemnification

Under the Company’s organizational documents, the officers and Directors have been granted certain indemnification rights against certain liabilities that may arise out of performance of their duties to the Company. Additionally, in the normal course of business, the Company may enter into contracts with service providers that contain a variety of indemnification clauses. The Company’s maximum exposure under these arrangements is dependent on future claims that may be made against the Company and, therefore, cannot be estimated.

Note 5 — U.S. Federal Income Tax Information

The Company has elected to be treated for federal income tax purposes, and intends to qualify annually, as a RIC under Subchapter M of the Code. To maintain its qualification as a RIC, the Company must, among other things, meet certain source-of-income and asset diversification requirements and distribute to its stockholders, for each taxable year, at least 90% of its “investment company taxable income,” which is generally the Company’s net ordinary income plus the excess, if any, of realized net short-term capital gains over realized net long-term capital losses. As a RIC, the Company will not be subject to corporate-level federal income taxes on any income that it timely distributes to its stockholders. The Company intends to make distributions in an amount sufficient to maintain its RIC status each year and to avoid any federal income taxes on income so distributed. The Company will also be subject to nondeductible federal excise taxes if it does not distribute at least 98% of net ordinary income, 98.2% of any capital gain net income, if any, and any recognized and undistributed income from prior years on which it paid no federal income taxes.

The character of income and capital gains to be distributed is determined in accordance with the Code, U.S. Treasury regulations, and other applicable authority, which may differ from GAAP. These differences include (but are not limited to) investments organized as partnerships for tax purposes, total return swaps, loan investments, and losses deferred due to wash sale transactions. Reclassifications are made to the Company’s capital accounts to reflect income and gains available for distribution (or available capital loss carryovers) under the Code, U.S. Treasury regulations, and other applicable authority. These reclassifications have no impact on net investment income, realized gains or losses, or net asset value of the Company. The calculation of net investment income per share in the Financial Highlights table excludes these adjustments.

3029

Uncertainty in Income Taxes

The Company will evaluate its tax positions to determine if the tax positions taken meet the minimum recognition threshold in connection with accounting for uncertainties in income tax positions taken or expected to be taken for the purposes of measuring and recognizing tax benefits or liabilities in the financial statements. Recognition of a tax benefit or liability with respect to an uncertain tax position is required only when the position is “more likely than not” to be sustained assuming examination by taxing authorities. The Company’s tax returns are subject to examination by the Internal Revenue Service for a period of three fiscal years after they are filed. The Company recognizes interest and penalties, if any, related to unrecognized tax liabilities as income tax expense in the Statements of Operations. During the ~~nine~~three months ended ~~September 30,~~March 31, 2022 and March 31, 2021, ~~and September 30, 2020,~~ the Company did not incur any interest or penalties. Furthermore, management of the Company is also not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly change in the next 12 months.

Note 6 — Share Repurchase Program

On a quarterly basis, the Company intends to offer to repurchase shares of common stock on such terms as may be determined by the Board in its complete and absolute discretion unless, in the judgment of directors who are not “interested persons” of the Company (as defined in the 1940 Act), such repurchases would not be in the best interests of the Company’s stockholders or would violate applicable law. The Company will conduct such repurchase offers in accordance with the requirements of Rule 13e-4 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the 1940 Act. Any offer to repurchase shares of common stock will be conducted solely through tender offer materials mailed to each stockholder.

The Company currently intends to limit the number of shares of common stock to be repurchased during any calendar year to the number of shares of common stock it can repurchase with the proceeds it receives from the sale of shares of common stock under its distribution reinvestment plan. At the discretion of the Board, the Company may also use cash on hand, cash available from borrowings and cash from liquidation of securities investments as of the end of the applicable period to repurchase shares of common stock. In addition, the Company will limit the number of shares of common stock to be repurchased in any calendar year to 10.0% of the weighted average number of shares of common stock outstanding in the prior calendar year, or 2.5% in each quarter, though the actual number of shares of common stock that the Company offers to repurchase may be less in light of the limitations noted above. The Company intends to offer to repurchase such shares of common stock at a price (i) not less than the net asset value per share (the “NAV Per Share”) of the Company’s common stock next calculated following the Expiration Date, and (ii) not more than 2.5% greater than the NAV Per Share as of such date. The Board may amend, suspend or terminate the share repurchase program at any time, upon 30 days’ notice.

The Company conducted its quarterly tender offer for the ~~third~~first quarter of ~~2021~~2022 from ~~August 20, 2021,~~February 23, 2022, until expiration of ~~September 20, 2021~~March 23, 2022 at 4:~~00 p.m.~~00p.m. New York City time, during which the Company offered to purchase for cash up to 2.5% of its outstanding shares of common stock. During the ~~third~~first quarter tender offer, ~~119,019~~85,998.88 shares of the Company were tendered for repurchase, constituting approximately ~~1.17%~~0.86% of the Company’s outstanding shares.

For the ~~nine~~three months ended ~~September 30, 2021,~~March 31, 2022, the Company repurchased 0 shares as part of its death and disability repurchase program.

Note 7 ~~— Credit Facility and Leverage Facilities~~

On October 19, 2017, the Company entered into a financing arrangement (the “Financing Arrangement”) with BNP Paribas Prime Brokerage International, Ltd., BNP Prime Brokerage, Inc., and BNP Paribas (together, the “BNPP Entities”). Under the Financing Agreement, the BNPP Entities may make margin loans to the Company at a rate of ~~one-month~~ LIBOR + 1.30%. The BNPP Entities have the right to cap the amount of margin loans with prior notice to the Company. The Financing Arrangement may be terminated by either the Company or the BNPP Entities with 179 days notice. On April 15, 2020, the Financing Arrangement was paid down and closed. At September 30, 2021, there were no current outstanding or fair value amounts.

~~For the three and nine months ended September 30, 2020, the components of total interest expense were as follows:~~

   Three months ended
September 30, 2020    Nine months ended
September 30, 2020
Direct interest expense
   $ —      $ 176,911
Commitment fees
   —      (204 )
Amortization of financing costs
   —      —




Total interest expense
   $ —      $ 176,707




Average daily amount outstanding
   —      22,670,341 ⁽¹⁾
Weighted average interest rate
   —      2.67 %⁽¹⁾

~~(1)~~

The Financing Arrangement with BNP was fully paid down and closed as of April 15, 2020, the average daily amount outstanding is calculated through April 15, 2020. The 2.67% represents the weighted average interest rate from January 1, 2020 through April 15, 2020.

The Company is required to maintain 200% asset coverage with respect to its borrowings outstanding. Asset coverage is calculated by subtracting the Company’s total liabilities, not including any amount representing bank loans and senior securities, from the Company’s total assets and dividing the result by the principal amount of the borrowings outstanding. As of the dates indicated below, the Company’s borrowings outstanding and asset coverage was as follows:


~~Period~~ ~~ended~~	~~Total amount~~ ~~outstanding~~		~~% of asset~~ ~~coverage~~
~~09/30/2021~~	$	—		—	%
~~06/30/2021~~		—		—	%
~~03/31/2021~~		—		—	%
~~12/31/2020~~		—		—	%

~~BNP Paribas Total Return Swap~~

On June 13, 2017, the Company entered into the TRS with BNP Paribas over one or more loans, with a maximum aggregate notional amount of the portfolio debt securities subject to the TRS of $40 million. The agreements between the Company and BNP Paribas, which collectively establish the TRS, are referred to herein as the “TRS Agreement.”

On April 2, 2018, the Company amended and restated the TRS Agreement with BNP Paribas. The amended and restated TRS Agreement, effective April 10, 2018 increased the maximum aggregate notional amount of the portfolio debt securities subject to the TRS to $60 million. On June 10, 2020, the TRS expired.

~~Under the terms of the TRS, the Company or BNP Paribas were required to post additional collateral, on a~~ ~~dollar-for-dollar~~ basis, in certain circumstances, including in the event of depreciation or appreciation in the value of the underlying loans. The limit on the additional collateral that the Company was required to post pursuant to the TRS was equal to the difference between the full notional amount of the loans underlying the TRS and the amount of cash collateral already posted by the Company. The amount of collateral required to be posted was determined primarily on the basis of the aggregate value of the underlying securities.

~~The Company had the option to terminate the TRS at any time more than one month prior to the TRS’s scheduled termination date upon providing no less than 30 days’ prior notice to BNP Paribas.~~

For purposes of the asset coverage ratio test applicable to the Company as a BDC, the Company would have treated the outstanding notional amount of the TRS, less the initial amount of any cash collateral required to be posted by the Company under the TRS, as a senior security for the life of that instrument. As of and for the nine months ended September 30, 2021, the Company has $0 in receivable from BNP Paribas.

Further, for purposes of Section 55(a) under the 1940 Act, the Company treats each security underlying the TRS as a qualifying asset if such security is a loan and the obligor on such loan is an eligible portfolio company, and as a ~~non-qualifying~~ ~~asset if the obligor is not an eligible portfolio company.~~

~~As of and for the period ended September 30, 2021, there were no positions held in the TRS.~~

As a result of decreases in the market value of certain of the Company’s assets pledged at derivative counterparties, the Company was required to post additional collateral relating to its margin requirements. The Company experienced delays posting collateral with one counterparty and received an Event of Default notice dated March 23, 2020; however, the Company covered the margin call on March 24, 2020 and received a formal waiver on the Event of Default notice from the counterparty dated April 2, 2020.

~~Note 8~~ — Economic Dependency and Commitments and Contingencies

The Adviser has entered into a Services Agreement with Skyview, effective February 25, 2021, pursuant to which the Adviser will receive administrative and operational support services to enable it to provide the required advisory services to the Company. The Adviser, and not the Company, will compensate Skyview.

From time to time, the Company may be involved in legal proceedings in the normal course of its business. Although the outcome of such litigation cannot be predicted with any clarity, management is of the opinion, based on the advice of legal counsel, that final dispositions of any litigation should not have a material adverse effect on the financial position of the Company as of ~~September~~ March 31, 2022.

30 ~~2021.~~

Unfunded commitments to provide funds to portfolio companies are not recorded in the Company’s Statements of Assets and Liabilities. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. The Company has sufficient liquidity to fund these commitments. As of ~~September 30, 2021,~~March 31, 2022, the Company had no unfunded debt commitments.

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties that provide general indemnification. The Company’s maximum exposure under these agreements is unknown, as this would involve future claims that may be made against the Company that have not occurred. The Company believes the risk of material obligations under these indemnities to be low.

Note 98 — Market and Other Risk Factors

The primary risks of investing in the Company are described below in alphabetical order:

Concentration Risk

The Company is classified as a non-diversified investment company within the meaning of the 1940 Act, which means that it is not limited by the 1940 Act with respect to the proportion of the Company’s assets that it may invest in securities of a single issuer. To the extent that the Company assumes large positions in the securities of a small number of issuers, the Company’s net asset value may fluctuate to a greater extent than that of a diversified investment company as a result of changes in the financial condition or the market’s assessment of the issuer. The Company may also be more susceptible to any single economic or regulatory occurrence than a diversified investment company. Beyond the asset diversification requirements associated with the Company’s qualification as a RIC under the Code and certain contractual diversification requirements under a credit facility or other agreements, the Company does not have fixed guidelines for diversification, and its investments could be concentrated in relatively few portfolio companies. As a result, the aggregate returns the Company realizes may be significantly adversely affected if a small number of investments perform poorly or if the Company needs to write down the value of any one investment. Additionally, the Company’s investments may be concentrated in relatively few industries. As a result, a downturn in any particular industry in which the Company is invested could also significantly impact the aggregate returns realized.

Covenant-Lite Loans Risk

Loans in which the Company invests include covenant-lite loans, which carry more risk to the lender than traditional loans as they may contain fewer or less restrictive covenants on the borrower than traditionally included in loan documentation or may contain other borrower friendly characteristics. The Company may experience relatively greater difficulty or delays in enforcing its rights on its holdings of certain covenant-lite loans and debt securities than its holdings of loans or securities with the usual covenants.

Counterparty Credit Risk

Counterparty credit risk is the potential loss the Company may incur as a result of the failure of a counterparty or an issuer to make payments according to the terms of a contract. Counterparty credit risk is measured as the loss the Company would record if its counterparties failed to perform pursuant to the terms of their obligations to the Company. Because the Company may enter into over-the-counter forwards, options, swaps and other derivative financial instruments, the Company may be exposed to the credit risk of its counterparties. To limit the counterparty credit risk associated with such transactions, the Company conducts business only with financial institutions judged by the Adviser to present acceptable credit risk.

Credit Risk

Debt securities are subject to the risk of non-payment of scheduled interest and/or principal. Non-payment would result in a reduction of income to the Company, a reduction in the value of the obligation experiencing non-payment and a potential decrease in the Company’s net asset value.

Investments rated below investment grade are commonly referred to as high-yield, high risk or “junk debt.” They are regarded as predominantly speculative with respect to the issuing company’s continuing ability to meet principal and/or interest payments. Investments in high yield debt and high yield senior loans may result in greater net asset value fluctuation than if the Company did not make such investments. Corporate debt obligations, including senior loans, are subject to the risk of non-payment of scheduled interest and/or principal.

Non-payment would result in a reduction of income to the Company, a reduction in the value of the corporate debt obligation experiencing non-payment and a potential decrease in the net asset value of the Company. Some of the loans the Company makes or acquires may provide for the payment by borrowers of Payment-In-Kind (“PIK”) interest or accreted original issue discount at maturity. Such loans have the effect of deferring a borrower’s payment obligation until the end of the term of the loan, which may make it difficult for the Company to identify and address developing problems with borrowers in terms of their ability to repay debt. Particularly in a rising interest rate environment, loans containing PIK and original issue discount provisions can give rise to negative amortization on a loan, resulting in a borrower owing more at the end of the term of a loan than what it owed when the loan was originated. Any such developments may increase the risk of default on the Company’s loans by borrowers.

Because loans are not ordinarily registered with the SEC or any state securities commission or listed on any securities exchange, there is usually less publicly available information about such instruments. In addition, loans may not be considered “securities” for purposes of the anti-fraud protections of the federal securities laws and, as a result, as a purchaser of these instruments, the Company may not be entitled to the anti-fraud protections of the federal securities laws. In the course of investing in such instruments, the Company may come into possession of material nonpublic information and, because of prohibitions on trading in securities of issuers while in possession of such information, the Company may be unable to enter into a transaction in a publicly-traded security of that issuer when it would otherwise be advantageous for us to do so. Alternatively, the Company may choose not to receive material nonpublic information about an issuer of such loans, with the result that the Company may have less information about such issuers than other investors who transact in such assets.

Foreign Securities Risk

Investments in foreign securities involve certain factors not typically associated with investing in U.S. securities, such as risks relating to (i) currency exchange matters, including fluctuations in the rate of exchange between the U.S. dollar (the currency in which the books of the Company are maintained) and the various foreign currencies in which the Company’s portfolio securities will be denominated and costs associated with conversion of investment principal and income from one currency into another; (ii) differences between the U.S. and foreign securities markets, including the absence of uniform accounting, auditing and financial reporting standards and practices and disclosure requirements, and less government supervision and regulation; (iii) political, social or economic instability; and (iv) the extension of credit, especially in the case of sovereign debt.

Illiquid Securities Risk

The Company will generally make investments in private companies. Substantially all of these investments will be subject to legal and other restrictions on resale or will otherwise be less liquid than publicly traded securities. The illiquidity of the Company’s investments may make it difficult for the Company to sell such investments if the need arises. In addition, if it is required to liquidate all or a portion of its portfolio quickly, the Company may realize significantly less than the value at which it has previously recorded its investments. In addition, it may face other restrictions on its ability to liquidate an investment in a portfolio company to the extent that it has material non-public information regarding such portfolio company or if an investment is held by one of its subsidiaries and is subject to contractual limitations on sale, such as the limitations on transfer of assets under certain circumstances under a credit facility.

The Company may seek to address its short-term liquidity needs by carefully managing the settlements of its portfolio transactions, including transactions in loans, by maintaining short-term liquid assets sufficient to meet reasonably anticipated obligations, and by maintaining a credit facility.

Interest Rate Risk

Interest Rate risk is the risk that fixed income securities will decline in value because of changes in interest rates. When interest rates decline, the value of fixed rate securities already held by the Company can be expected to rise. Conversely, when interest rates rise, the value of existing fixed rate portfolio securities can be expected to decline. A company with a longer average portfolio duration will be more sensitive to changes in interest rates than a fund with a shorter average portfolio duration Recent and potential future changes in government monetary policy may affect the level of interest rates.

On July 27, 2017, the head of the United Kingdom’s Financial Conduct Authority announced a desire to phase out the use of LIBOR by the end of 2021. Please refer to “LIBOR Transition and Associated Risk” for more information.

Investments in Foreign Markets Risk

Investments in foreign markets involve special risks and considerations not typically associated with investing in the United States. These risks include revaluation of currencies, high rates of inflation, restrictions on repatriation of income and capital, and adverse political and economic developments. Moreover, securities issued in these markets may be less liquid, subject to government ownership controls, tariffs and taxes, subject to delays in settlements, and their prices may be more volatile. The Company may be subject to capital gains and repatriation taxes imposed by certain countries in which they invest. Such taxes are generally based on income and/or capital gains earned or repatriated. Taxes are accrued based upon net investment income, net realized gains and net unrealized appreciation as income and/or capital gains are earned.

Leverage Risk

The Company may use leverage in its investment program, including the use of borrowed funds and investments in certain types of options, such as puts, calls and warrants, which may be purchased for a fraction of the price of the underlying securities. While such strategies and techniques increase the opportunity to achieve higher returns on the amounts invested, they also increase the risk of loss. To the extent the Company purchases securities with borrowed funds, its net assets will tend to increase or decrease at a greater rate than if borrowed funds are not used. If the interest expense on borrowings were to exceed the net return on the portfolio securities purchased with borrowed funds, the Company’s use of leverage would result in a lower rate of return than if the Company were not leveraged.

LIBOR Transition and Associated Risk

Due to manipulation allegations in 2012 and reduced activity in the financial markets that it measures, in July 2017, the Financial Conduct Authority (the “FCA”), the United Kingdom financial regulatory body, announced a desire to phase out the use of LIBOR by the end of 2021 and that it will stop encouraging banks to provide the quotations needed to sustain LIBOR. The ICE Benchmark Administration Limited, the administrator of LIBOR, ~~is expected to cease~~ceased publishing most LIBOR maturities, including some US LIBOR maturities, on December 31, 2021, and is expected to cease publishing the remaining and most liquid US LIBOR maturities on June 30, 2023. ~~Before the end of 2021, it~~It is expected that market participants have or will transition to the use of alternative reference or benchmark ~~rates. However,~~rates prior to the applicable LIBOR publication cessation date. Additionally, although regulators have encouraged the development and adoption of alternative rates, such as the Secured Overnight Financing Rate (“SOFR”), ~~there is currently no definitive information regarding~~ the future utilization of LIBOR or of any particular replacement ~~rate.~~rate remains uncertain.

Although the transition process away from LIBOR has become increasingly well defined in advance of the anticipated discontinuation dates, the impact on certain debt securities, derivatives and other financial instruments remains uncertain. It is expected that market participants will adopt alternative rates such as SOFR or otherwise amend financial instruments referencing LIBOR to include fallback provisions and other measures that contemplate the discontinuation of LIBOR or other similar market disruption events, but neither the effect of the transition process nor the viability of such measures is known. Further, uncertainty and risk remain regarding the willingness and ability of issuers and lenders to include alternative rates and revised provisions in new and existing contracts or instruments. To facilitate the transition of legacy derivatives contracts referencing LIBOR, the International Swaps and Derivatives Association, Inc. launched a protocol to incorporate fallback provisions. ~~However,~~While the transition process away from LIBOR has become increasingly well defined in advance of the expected LIBOR cessation dates, there are obstacles to converting certain longer term securities and transactions to a new benchmark or benchmarks and the effectiveness of one alternative reference rate versus multiple alternative reference rates in new or existing financial instruments and products has not been determined. Furthermore, the risks associated with the cessation of LIBOR and transition to replacement rates may be exacerbated if an orderly transition to alternative reference rates is not completed in a timely manner. Certain proposed replacement rates to LIBOR, such as SOFR, which is a broad measure of secured overnight US Treasury repo rates, are materially different from LIBOR, and changes in the applicable spread for financial instruments transitioning away from LIBOR will need to be made to

accommodate the differences. Furthermore, the risks associated with the expected discontinuation of LIBOR and transition to replacement rates may be exacerbated if an orderly transition to an alternative reference rate is not completed in a timely manner. As market participants transition away from LIBOR, LIBOR’s usefulness may ~~deteriorate.~~deteriorate and the effects could be experienced until the permanent cessation of the majority of U.S. LIBOR rates in 2023. The transition process may lead to increased volatility and illiquidity in markets that currently rely on LIBOR to determine interest rates. LIBOR’s deterioration may adversely affect the liquidity and/or market value of securities that use LIBOR as a benchmark interest rate.

Operational and Technology Risk

The risk that ~~cyberattacks,~~cyber-attacks, disruptions, or failures that affect the Funds’ service providers, counterparties, market participants, or issuers of securities held by the Funds may adversely affect the Funds and its shareholders, including by causing losses for the Funds or impairing Fund operations.

Options Risk

There are several risks associated with transactions in options on securities. For example, there are significant differences between the securities and options markets that could result in an imperfect correlation between these markets, causing a given transaction not to achieve its objectives. A transaction in options or securities may be unsuccessful to some degree because of market behavior or unexpected events.

When the Company writes a covered call option, the Company forgoes, during the option’s life, the opportunity to profit from increases in the market value of the security covering the call option above the sum of the premium and the strike price of the call, but retains the risk of loss should the price of the underlying security decline. The writer of an option has no control over the time when it may be required to fulfill its obligation and once an option writer has received an exercise notice, it must deliver the underlying security in exchange for the strike price.

When the Company writes a covered put option, the Company bears the risk of loss if the value of the underlying stock declines below the exercise price minus the put premium. If the option is exercised, the Company could incur a loss if it is required to purchase the stock underlying the put option at a price greater than the market price of the stock at the time of exercise plus the put premium the Company received when it wrote the option. While the Company’s potential gain in writing a covered put option is limited to distributions earned on the liquid assets securing the put option plus the premium received from the purchaser of the put option, the Company risks a loss equal to the entire exercise price of the option minus the put premium.

Pandemics and Associated Economic Disruption Risk

An outbreak of respiratory disease caused by a novel coronavirus was first detected in China in December 2019 and subsequently spread globally. This coronavirus has resulted and may continue to result in the closing of borders, enhanced health screenings, healthcare service preparation and delivery, quarantines, cancellations, disruptions to supply chains and customer activity, as well as general anxiety and economic uncertainty. The impact of this coronavirus may be short-term or may last for an extended period of time and has resulted in a substantial economic downturn. Health crises caused by outbreaks of disease, such as the coronavirus, may exacerbate other pre-existing political, social and economic risks. This outbreak, and other epidemics and pandemics that may arise in the future, could negatively affect the global economy, as well as the economies of individual countries, individual companies and the market in general in significant and unforeseen ways. For example, a widespread health crisis such as a global pandemic could cause substantial market volatility, exchange trading suspensions and closures, impact the Company’s ability to complete tender offer requests, and affect Company performance. Any such impact could adversely affect the Company’s performance, the performance of the issuers in which the Company invests, lines of credit available to the Company and may lead to losses on your investment in the Company. In addition, the increasing interconnectedness of markets around the world may result in many markets being affected by events or conditions in a single country or region or events affecting a single or small number of issuers.

The United States responded to the coronavirus pandemic and resulting economic distress with fiscal and monetary stimulus packages, including the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) passed in late March 2020. The CARES ACT provides for over $2.2 trillion in resources to small businesses, state and local governments, and individuals adversely impacted by the COVID-19 pandemic. In mid

March 2020, the U.S. Federal Reserve (the “Fed”) cut interest rates to historically low levels and announced a new round of quantitative easing, including purchases of corporate and municipal government bonds. The Fed also enacted various programs to support liquidity operations and funding in the financial markets, including expanding its reverse repurchase agreement operations, which added $1.5 trillion of liquidity to the banking system; establishing swap lines with other major central banks to provide dollar funding; establishing a program to support money market funds; easing various bank capital buffers; providing funding backstops for businesses to provide bridging loans for up to four years; and providing funding to help credit flow in asset-backed securities markets. In addition, the Fed extended credit to small and medium-sized businesses. As the Fed “tapers” or reduces the amount of securities it purchases pursuant to quantitative easing, and/or if the Fed raises the federal funds rate, there is a risk that interest rates will rise, which could expose fixed-income and related markets to heightened volatility and could cause the value of a fund’s investments, and the fund’s NAV, to decline, potentially suddenly and significantly. As a result, the fund may experience high redemptions and, as a result, increased portfolio turnover, which could increase the costs that the Fund incurs and may negatively impact the fund’s performance. There is no assurance that the U.S. government’s support in response to COVID-19 economic distress will offset the adverse impact to securities in which the Funds may invest and future governmental support is not guaranteed.

Senior Loans Risk

The risk that the issuer of a senior loan may fail to pay interest or principal when due, and changes in market interest rates may reduce the value of the senior loan or reduce the Company’s returns. The risks associated with senior loans are similar to the risks of high yield debt securities. Senior loans and other debt securities are also subject to the risk of price declines and to increases in interest rates, particularly long-term rates. Senior loans are also subject to the risk that, as interest rates rise, the cost of borrowing increases, which may increase the risk of default. In addition, the interest rates of floating rate loans typically only adjust to changes in short-term interest rates; long-term interest rates can vary dramatically from short-term interest rates. Therefore, senior loans may not mitigate price declines in a long-term interest rate environment. The Company’s investments in senior loans are typically below investment grade and are considered speculative because of the credit risk of their issuers.

LIBOR is the average offered rate for various maturities of short-term loans between major international banks who are members of the British Bankers Association. LIBOR is the most common benchmark interest rate index used to make adjustments to variable-rate loans. It is used throughout global banking and financial industries to determine interest rates for a variety of financial instruments (such as debt instruments and derivatives) and borrowing arrangements. Due to manipulation allegations in 2012 and reduced activity in the financial markets that it measures, in July 2017, the Financial Conduct Authority, the United Kingdom financial regulatory body, announced a desire to phase out the use of LIBOR by the end of 2021. Please refer to “LIBOR Transition and Associated Risk” for more information.

Structured Finance Securities Risk

A portion of the Company’s investments may consist of equipment trust certificates, collateralized mortgage obligations, collateralized bond obligations, collateralized loan obligations (“CLO”) or similar instruments. Such structured finance securities are generally backed by an asset or a pool of assets, which serve as collateral. Depending on the type of security, the collateral may take the form of a portfolio of mortgage loans or bonds or other assets. The Company and other investors in structured finance securities ultimately bear the credit risk of the underlying collateral. In some instances, the structured finance securities are issued in multiple tranches, offering investors various maturity and credit risk characteristics, often categorized as senior, mezzanine and subordinated/equity according to their degree of risk. The riskiest securities are the equity tranche, which bears the bulk of defaults from the bonds or loans serving as collateral, and thus may protect the other, more senior tranches from default. If there are defaults or the relevant collateral otherwise underperforms, scheduled payments to senior tranches of such securities take precedence over those of mezzanine tranches, and scheduled payments to mezzanine tranches take precedence over those to subordinated/equity tranches. A senior tranche typically has higher ratings and lower yields than the underlying securities, and may be rated investment grade. Despite the protection from the equity tranche, other tranches can experience substantial losses due to actual defaults, increased sensitivity to defaults due to previous defaults and the disappearance of protecting tranches, market anticipation of defaults and aversion to certain structured finance securities as a class.

3735

Short-Selling Risk

Short sales by the Company that are not made where there is an offsetting long position in the asset that it is being sold short theoretically involve unlimited loss potential since the market price of securities sold short may continuously increase. Short selling allows the Company to profit from declines in market prices to the extent such decline exceeds the transaction costs and costs of borrowing the securities. However, since the borrowed securities must be replaced by purchases at market prices in order to close out the short position, any appreciation in the price of the borrowed securities would result in a loss. Purchasing securities to close out the short position can itself cause the price of securities to rise further, thereby exacerbating the loss. The Company may mitigate such losses by replacing the securities sold short before the market price has increased significantly. Under adverse market conditions, the Company might have difficulty purchasing securities to meet margin calls on its short sale delivery obligations, and might have to sell portfolio securities to raise the capital necessary to meet its short sale obligations at a time when fundamental investment considerations would not favor such sales. Further, if other short positions of the same security are closed out at the same time, a “short squeeze” can occur where demand exceeds the supply for the security sold short. A short squeeze makes it more likely that the

Adviser will need to replace the borrowed security at an unfavorable price.

Valuation Risk

Certain of the Company’s assets are fair valued, including the Company’s investment in equity issued by TerreStar Corporation (“TerreStar”). TerreStar does not currently generate revenue and primarily derives its value from holding licenses of two wireless spectrum assets. The license with respect to one such spectrum asset was previously terminated by the FCC and subsequently restored on April 30, 2020 on a limited conditional basis. The restoration of such license requires TerreStar to meet certain deployment milestones for wireless medical telemetry service (“WMTS”) during a 39-month period. Upon satisfaction of the deployment milestones, TerreStar will be able use such spectrum for other services besides WMTS as long as those services do not interfere with WMTS and TerreStar continues to provide WMTS.

If TerreStar is unsuccessful in satisfying such deployment milestones, or if other services cannot be implemented in a manner that does not interfere with WMTS, the value of the TerreStar equity would likely be materially negatively impacted. In determining the fair value of TerreStar, the Adviser has assigned a high probability of success on both conditions based on consultation with the company and its consultants.

Note 109 — Affiliated Investments

Under Section 2(a)(3) of the 1940 Act, a portfolio company is defined as “affiliated” if a fund owns five percent or more of its outstanding voting securities or if the portfolio company is under common control. The table below shows affiliated issuers of the Company as of ~~September 30, 2021:~~March 31, 2022:


Affiliated investments	Shares at December 31, 2020		Fair value as of December 31, 2020		Transfers in (at cost)		Purchases		Sales			Realized gains (losses)		Change in unrealized appreciation (depreciation)			Fair value as of September 30, 2021			Shares at September 30, 2021		Affiliated Dividend income		Shares at December 31, 2021		Fair value as of December 31, 2021		Transfers in (at cost)		Purchases			Sales			Realized gains (losses)			Change in unrealized appreciation (depreciation)			Fair value as of March 31, 2022		Shares at March 31, 2022		Affiliated Dividend income
NexPoint Residential Trust, Inc.		22,640	$	957,898	$	—	$	23,338	$	—		$	—	$	446,212		$	1,427,448			23,068	$	23,415		23,173	$	1,942,593	$	—	$	8,806		$	—		$	—		$	149,934		$	2,101,333		23,268	$	8,824

NexPoint Capital REIT, LLC⁽¹⁾		100		228,215		—		—		—			—		(228,215	)		—			—		200,000

NexPoint Real Estate Finance Operating Partnership, LP		315,631		5,214,223		—		—		(6,691	)		378,757		1,098,395			6,684,684			315,631		299,849

NexPoint Real Estate Finance, Inc.		—		—		—		6,691		—			—		(542,885	)		(536,194	)		—		149,925		315,631		6,075,895		—		3,274,285	⁽¹⁾		—			—			1,535,554			10,885,734		481,670		240,835

SFR WLIF III, LLC		1,651,112		1,493,629		—		—		—			—		47,056			1,540,685			1,651,112		58,493		1,651,112		1,563,916		—		—			—			—			(13,275	)		1,550,641		1,651,112		—

SFR WLIF II, LLC		3,348,888		2,742,974		—		—		—			—		491,460			3,234,434			3,348,888		199,246		3,348,888		3,196,246		—		1			(3,274,285	)⁽¹⁾		(74,604	)		152,642			—		—		—

Total affiliated investments		5,338,371	$	10,636,939	$	—	$	30,029	$	(6,691	)	$	378,757	$	1,312,023		$	12,351,057			5,338,699	$	930,928		5,338,804	$	12,778,650	$	—	$	3,283,092		$	(3,274,285	)	$	(74,604	)	$	1,824,855		$	14,537,708		2,156,050	$	249,659

⁽¹⁾

3936

Note 1110 — Financial Highlights

Selected data for a share outstanding throughout the ~~nine~~three months ended ~~September 30,~~March 31, 2022 and March 31, 2021 ~~and September 30, 2020~~ is as follows:


		For the Nine Months Ended September 30, 2021 (Unaudited)			For the Nine Months Ended September 30, 2020 (Unaudited)				For the Three Months Ended March 31, 2022 (Unaudited)			For the Three Months Ended March 31, 2021 (Unaudited)
Common shares per share operating performance:	Common shares per share operating performance:							Common shares per share operating performance:
Net asset value, beginning of period		$	6.13		$	8.53			$	6.32		$	6.13
Income from investment operations:	Income from investment operations:							Income from investment operations:
Net investment income⁽¹⁾			0.19			0.22				0.05			0.05
Net realized and unrealized gain (loss)			0.35			(2.46	)			0.07			0.16

Total from investment operations			0.54			(2.24	)			0.12			0.21

Less distribution declared to common shareholders:	Less distribution declared to common shareholders:							Less distribution declared to common shareholders:
From net investment income			(0.27	)		(0.33	)			(0.09	)		(0.09	)

Total distributions declared to common shareholders			(0.27	)		(0.33	)			(0.09	)		(0.09	)

Capital share transactions
Capital share transaction								Capital share transaction
Issuance of common stock⁽²⁾			—			—				—			—
Shares tendered⁽¹⁾			—			—	⁽³⁾			—			—

Net asset value, end of period		$	6.40		$	5.96			$	6.35		$	6.25
Net asset value total return⁽⁵⁾⁽⁴⁾			8.89	%		(26.38	)%			1.83	%		3.43	%

Ratio and supplemental data:
Net assets, end of period (in 000’s)		$	64,218		$	62,597			$	62,947		$	64,224
Shares outstanding, end of period			10,037,423			10,494,309				9,918,671			10,268,218
Common share information at end of period:	Common share information at end of period:							Common share information at end of period:
Ratios based on weighted average net assets of common shares:	Ratios based on weighted average net assets of common shares:							Ratios based on weighted average net assets of common shares:
Gross operating expenses⁽⁶⁾⁽⁵⁾			3.68	%		3.86	%			3.72	%		3.89	%
Fees and expenses waived or reimbursed⁽⁶⁾⁽⁵⁾			(0.41	)%		(0.50	)%			(0.39	)%		(0.39	)%
Net operating expenses⁽⁶⁾⁽⁵⁾			3.27	%		3.36	%			3.33	%		3.50	%
Net investment income (loss) before fees waived or reimbursed⁽⁶⁾⁽⁵⁾			3.52	%		4.15	%			2.73	%		2.98	%
Net investment income (loss) after fees waived or reimbursed⁽⁶⁾⁽⁵⁾			3.93	%		4.65	%			3.12	%		3.38	%
Ratio of interest and credit facility expenses to average net assets⁽⁶⁾			—	%		0.36	%
Portfolio turnover rate⁽⁵⁾			7	%		72	%
Portfolio turnover rate⁽⁴⁾										26	%		—	%
Asset coverage ratio			—	%		—	%			—	%		—	%
Weighted average commission rate paid⁽⁷⁾		$	—		$	0.0328
Weighted average commission rate paid⁽⁶⁾									$	—		$	—

⁽¹⁾	Per share data was calculated using weighted average shares outstanding during the period.

⁽²⁾

The continuous issuance of common stock may cause an incremental increase in net asset value per share due to the sale of shares at the then prevailing public offering price and the receipt of net proceeds per share by the Company in excess of net asset value per share on each subscription closing date. The per share data was derived by computing (i) the sum of (A) the number of shares issued in connection with subscriptions and/or distribution reinvestment on each share transaction date times (B) the differences between the net proceeds per share and the net asset value per share on each share transaction date, divided by (ii) the total shares outstanding at the end of the period. The Company’s continuous public offering ended on February 14, 2018.

⁽³⁾	~~Amount rounds to less than $0.005 per share.~~

⁽⁴⁾

Total returns are historical and assume changes in share price and reinvestment of dividends and capital gains distributions, and assume no sales charge. Distributions, if any, are assumed for purposes of this calculation to be reinvested at prices obtained under the Company’s Dividend Reinvestment Plan. Had the Adviser not absorbed a portion of expenses, total returns would have been lower.

⁽⁵⁾⁽⁴⁾

Not annualized.

⁽⁶⁾⁽⁵⁾

Annualized.

⁽⁷⁾⁽⁶⁾

Represents the total dollar amount of commissions paid on portfolio transactions divided by total number of portfolio shares purchased and sold for which commissions were charged.

Note 1211 — Subsequent Events

The ~~Adviser~~Company has evaluated ~~the impact of all~~ subsequent events ~~on the Company~~ through the date ~~the~~on which these financial statements were ~~issued and has determined that there were no such subsequent events to report which have not already been recorded or disclosed in these financial statements and accompanying notes.~~issued.

4137

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The information contained in this section should be read in conjunction with our unaudited financial statements and related notes thereto included elsewhere in this quarterly report on Form 10-Q. In this report, “we,” “us” and “our” refer to NexPoint Capital, Inc.

Forward-Looking Statements

Some of the statements in this quarterly report on Form 10-Q constitute forward-looking statements because they relate to future events or our future performance or financial condition. The forward-looking statements contained in this quarterly report on Form 10-Q may include statements as to:

our future operating results;

changes in healthcare technologies, finance and regulations adversely affecting our portfolio companies or financing model;

changes in political, economic or industry conditions, the interest rate environment or conditions affecting the financial and capital markets, which could result in changes to the value of our assets;

our business prospects and the prospects of the companies in which we may invest;

the impact of the investments that we expect to make;

the impact of increased competition;

our contractual arrangements and relationships with third parties;

the dependence of our future success on the general economy and its impact on the industries in which we may invest;

the ability of our portfolio companies to achieve their objectives;

impact and effects of the recent outbreak of COVID-19 on the future financial performance of the Company;

the relative and absolute performance of our Adviser;

our current and expected financings and investments;

our ability to make distributions to our stockholders;

the adequacy of our cash resources, financing sources and working capital;

the timing and amount of cash flows, distributions and dividends, if any, from our portfolio companies;

our use of financial leverage;

the ability of the Adviser to locate suitable investments for us and to monitor and administer our investments;

the ability of the Adviser or its affiliates to attract and retain highly talented professionals;

our ability to maintain our qualification as a regulated investment company, or RIC, and as a BDC;

the impact on our business of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the rules and regulations issued thereunder;

the effect of changes to tax legislation and our tax position; and

the tax status of the enterprises in which we may invest.

Such forward-looking statements may include statements preceded by, followed by or that otherwise include the words “may,” “might,” “will,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “estimate,” “anticipate,” “predict,” “potential,” “plan” or similar words. The forward-looking statements contained in this quarterly report on Form 10-Q involve risks and uncertainties. Our actual results could differ materially from those implied or expressed in the forward-looking statements for any reason, including the factors set forth elsewhere in this quarterly report on Form 10-Q and as “Risk Factors” in the prospectus relating to the continuous public offering of our common stock.

We have based the forward-looking statements included in this quarterly report on Form 10-Q on information available to us on the date of this quarterly report on Form 10-Q. Except as required by the federal securities laws, we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. Stockholders are advised to consult any additional disclosures that we may make directly to stockholders or through reports that we may file in the future with the U.S. Securities and Exchange Commission (the “SEC”), including annual reports on Form 10-K, quarterly reports on

Form 10-Q and current reports on Form 8-K. The forward-looking statements and projections contained in this quarterly report on

Form 10-Q are excluded from the safe harbor protection provided by Section 27A of the ~~Securities~~1933 Act, ~~of 1933,~~ as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This quarterly report on Form 10-Q may contain statistics and other data that have been obtained from or compiled from information made available by third-party service providers. We have not independently verified such statistics or data.

Overview

We were formed in Delaware on September 30, 2013 and formally commenced operations on September 2, 2014. We are an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a BDC under the Investment Company Act of 1940, as amended (the “1940 Act”). In addition, for U.S. federal income tax purposes, we have elected to be treated as a RIC (Regulated Investment Company) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”) with retroactive effect to the date we elected to be treated as a BDC. As a BDC, we are also subject to certain constraints, including limitations imposed by the 1940 Act and the Code.

NexPoint Advisors, L.P. (the “Adviser”), which serves as the adviser of the Company, is registered with the SEC as an adviser under the Investment Advisers Act of 1940, as amended. Under the general supervision of our board of directors (the ~~“Board”~~“ Board”) the Adviser will carry out the investment and reinvestment of the net assets of the Company, will furnish continuously an investment program with respect to the Company, and determine which securities should be purchased, sold or exchanged. In addition, the Adviser will supervise and provide oversight of the Company’s service providers.

The Adviser has also entered into a Services Agreement with Skyview Group (“Skyview”), effective February 25, 2021, pursuant to which the Adviser will receive administrative and operational support services to enable it to provide the required advisory services to the Company. The Adviser will compensate all Adviser and Skyview personnel who provide services to the Company.

Our investment objective is to generate high current income and long-term capital appreciation. We seek to achieve our objective by using the experience of the healthcare, credit and structured products teams of the Adviser and its affiliates to source, evaluate and structure investments, identify attractive investment opportunities that are primarily debt investments that generate high income without creating undue risk for the portfolio, make equity investments where we believe there will be attractive risk-adjusted returns that compensate for the lack of current income, and make investments in debt and equity tranches of collateralized loan obligations, or CLOs, that deliver income and high relative value. We will focus on companies that are stable, have positive cash flow and the ability to grow their business model.

Our investment policy is to invest, under normal circumstances, at least 80% of our total assets in debt and equity of middle-market companies, with an emphasis on healthcare companies, syndicated floating rate debt of large public and nonpublic companies and mezzanine and equity tranches of CLOs. Middle-market companies include companies with annual revenues between $50,000,000 and $2,500,000,000 and syndicated floating rate debt refers to loans and other instruments originated by a bank to a corporation that are sold off, or syndicated, to investors in pieces. We consider a healthcare company to be a company that is engaged in the design, development, production, sale, management or distribution of products, services or facilities used for or in connection with the healthcare industry. Additionally, we consider companies that are materially impacted by the healthcare industry (such as a contractor that derives significant revenue or profit from the construction of hospitals) as being engaged in the healthcare industry. We may invest without limit in companies that are not in the healthcare sector.

We will leverage the expertise of our Adviser with regard to distressed investing and restructuring to make opportunistic investments in distressed companies. We will utilize the Adviser’s credit underwriting capability to identify the types of companies we believe will provide high current income and/or long-term capital appreciation. In addition to the investments in the healthcare industry, we may invest a portion of our capital in other opportunistic investments in which the Adviser has expertise and where we believe an opportunity exists to achieve above average risk adjusted yields and returns. These types of opportunities may include: (1) direct lending or origination investments, (2) investments in stressed or distressed situations, (3) structured product investments, (4) equity investments and (5) other investment opportunities not typically available in other BDCs. Opportunistic investments may range from broadly syndicated deals to direct lending deals in both private and public companies and may include foreign investments. We believe this is the best approach to achieving our dual mandate of attempting to generate a high yield while also attempting to produce capital appreciation.

We seek to invest primarily in securities deemed by the Adviser to be high income generating debt investments and income generating equity securities of privately held companies in the United States. We expect the portfolio will be concentrated primarily in senior floating rate debt securities, although we may invest without limit in securities which rank lower than senior secured

instruments and may invest without limit in investments with a fixed rate of interest. We will buy syndicated loans, various tranches of CLOs and other debt instruments in the secondary market as well as originate debt so we can tailor the investment parameters more precisely to our needs. We also intend to invest a portion of the portfolio in equity securities that are non-income producing, when doing so will help us achieve our objective of long-term capital appreciation. We expect the size of our positions will range from less

than $1,000,000 to $20,000,000, although investments may be larger as our asset base increases. We may selectively make investments in amounts larger than $20,000,000 in some of our portfolio companies. While our asset base increases, we may make smaller investments. We may invest up to 15% of our net assets in entities that are excluded from registration under the 1940 Act by virtue of section 3(c)(1) and 3(c)(7) of the 1940 Act (such as private equity funds or hedge funds). This limitation does not apply to any CLOs, certain of which may rely on Section 3(c)(1) or 3(c)(7) of the 1940 Act.

We expect that many of the securities in which we invest will be rated below investment grade by independent rating agencies or would be rated below investment grade if they were rated. These securities, which may be referred to as “junk”, have predominantly speculative characteristics with respect to the issuer’s capacity to pay interest and repay principal. In addition, we expect that many of our debt investments will include floating interest rates that reset on a periodic basis and typically will not require the borrowers to pay down the outstanding principal of such debt prior to maturity.

We and the Adviser have obtained an exemptive order dated April 19, 2016 from the SEC to permit co-investments among the Company and certain other accounts managed by the Adviser or its affiliates, subject to certain conditions.

Public Offering

As a result of a series of private placements to the Adviser, we successfully satisfied the minimum offering requirement and officially commenced operations on September 2, 2014. In connection with the satisfaction of the minimum offering requirement and the commencement of our operations, the Investment Advisory Agreement became effective and the base management fee and any incentive fees, as applicable, payable to the Adviser under the Investment Advisory Agreement began to accrue. In aggregate as of ~~September 30, 2021,~~March 31, 2022, the Adviser controls 2,549,002 total shares of common stock of the Company, including reinvestment of dividends, for a net amount of approximately ~~$16.3~~$16.2 million. In February 2018, we closed our continuous public offering of shares of common stock.

Revenues

We generate a significant portion of our total revenue in the form of interest on the debt securities that we hold. We expect that the senior debt we invest in will generally have stated terms of 3 to 5 years and that the subordinated debt we invest in will generally have stated terms of 5 to 7 years. Our senior and subordinated debt investments bear interest at a fixed or floating rate. Interest on debt securities is generally payable monthly, quarterly or semiannually. In addition, some of our investments provide for deferred interest payments or payment-in-kind, or PIK, interest. We may also generate revenues in the form of dividends and other distributions on the equity or other securities we may hold. In addition, we may generate revenues in the form of commitment, closing, origination, structuring or diligence fees, monitoring fees, fees for providing managerial assistance, consulting fees, prepayment fees and performance-based fees. Any such fees generated in connection with our investments will be recognized as earned.

Expenses

We expect that our primary operating expenses will include the payment of fees to the Adviser under the Investment Advisory Agreement, our allocable portion of overhead expenses under the Administration Agreement and other operating costs described below. Prior to December 20, 2017, the Adviser was waiving most fees, subject to possible recoupment for expenses pertaining to periods from and after June 10, 2016. Effective December 20, 2017, the Adviser ended its voluntary waiver of advisory and administration fees. We bear all out-of-pocket costs and expenses of our operations and transactions, including:

our organization (expenses initially paid by the Adviser until sufficient equity proceeds are raised);

calculating our net asset value and net asset value per share (including the costs and expenses of independent valuation firms);

fees and expenses, including travel expenses, incurred by the Adviser or payable to third parties in performing due diligence on prospective portfolio companies, monitoring our investments and, if necessary, enforcing our rights;

interest payable on debt, if any, incurred to finance our investments;

the costs of this and all future offerings of common shares and other securities, and other incurrence of debt;

the base management fee and any incentive fee;

distributions on our shares;

administration fees payable to the Adviser under the Administration Agreement;

transfer agent and custody fees and expenses;

the actual costs incurred by the Adviser as our administrator in providing managerial assistance to those portfolio companies that request it;

amounts payable to third parties relating to, or associated with, evaluating, making and disposing of investments;

brokerage fees and commissions;

registration fees;

listing fees;

taxes;

director fees and expenses;

costs associated with our reporting and compliance obligations under the 1940 Act and applicable U.S. federal and state securities laws;

the costs of any reports, proxy statements or other notices to our stockholders, including printing costs;

costs of holding stockholder meetings;

our fidelity bond;

directors and officers/errors and omissions liability insurance, and any other insurance premiums;

litigation, indemnification and other non-recurring or extraordinary expenses;

direct costs and expenses of administration and operation, including audit and legal costs;

fees and expenses associated with marketing efforts, including deal sourcing fees and marketing to financial sponsors;

dues, fees and charges of any trade association of which we are a member; and

all other expenses reasonably incurred by us or the Adviser in connection with administering our business.

During periods of asset growth, we expect our general and administrative expenses to be relatively stable or decline as a percentage of total assets and increase during periods of asset declines.

Expense Limitation

Pursuant to an expense limitation agreement (the “Expense Limitation Agreement”), the Adviser is contractually obligated to waive fees and, if necessary, pay or reimburse certain other expenses to limit ordinary “Other Expenses” to 1.0% of the quarter-end value of the Company’s gross assets through the one-year anniversary of the effective date of the registration statement. Under the Expense Limitation Agreement, “Other Expenses” are all expenses with the exception of advisor and administration fees, organization and offering costs and the following: (i) interest, taxes, dividends tied to short sales, brokerage commissions, and other expenditures which are capitalized in accordance with U.S. GAAP; (ii) expenses incurred indirectly as a result of investments in other investment companies and pooled investment vehicles; (iii) other expenses attributable to, and incurred as a result of, our investments; (iv) expenses payable to the Adviser, as administrator, for providing significant managerial assistance to our portfolio companies; and (v) other extraordinary expenses (including litigation expenses) not incurred in the ordinary course of our business. The obligation will automatically renew for one-year terms unless it is terminated by the Company or the Adviser upon written notice within 120 days of the end of the current term or upon termination of the Investment Advisory Agreement. The Expense Limitation Agreement will continue through at least April 30, ~~2022.~~2023.

Reimbursable Expenses Table

The cumulative total of fees waived by the Adviser under the Expense Limitation Agreement which are recoupable as of ~~September 30, 2021,~~March 31, 2022, are ~~$976,335.~~$814,815. This balance, and the balances in the tables below, only include amounts pertaining to the Expense Limitation Agreement, and do not include waived advisory and administration fees subject to recoupment discussed elsewhere herein.

The following table reflects the 2022 quarterly fee waivers and expense reimbursements due from the Adviser as of March 31, 2022, which are subject to recoupment by the Adviser.


Quarter Ended	Yearly Cumulative Other Expenses		Yearly Expense Limitation		Yearly Cumulative Expense Reimbursement		Quarterly Recoupable/ (Recouped) Amount		Recoupment Eligibility Expiration
March 31, 2022	$	211,896	$	150,135	$	61,761	$	61,761		March 31, 2025

The following table reflects the 2021 quarterly fee waivers and expense reimbursements due from the Adviser as of ~~September 30,~~December 31, 2021, which are subject to recoupment by the Adviser.


Quarter Ended	Yearly Cumulative Other Expenses		Yearly Expense Limitation		Yearly Cumulative Expense Reimbursement		Quarterly Recoupable/ (Recouped) Amount		Recoupment Eligibility Expiration		Yearly Cumulative Other Expenses		Yearly Expense Limitation		Yearly Cumulative Expense Reimbursement		Quarterly Recoupable/ (Recouped) Amount		Recoupment Eligibility Expiration
December 31, 2021											$	892,640	$	597,379	$	295,261	$	94,762		December 31, 2024
September 30, 2021	$	664,052	$	463,553	$	200,499	$	68,134		September 30, 2024	$	664,052	$	463,553	$	200,499	$	68,134		September 30, 2024
June 30, 2021	$	436,866	$	304,501	$	132,365	$	68,919		June 30, 2024	$	436,866	$	304,501	$	132,365	$	68,919		June 30, 2024
March 31, 2021	$	220,126	$	156,680	$	63,446	$	63,446		March 31, 2024	$	220,126	$	156,680	$	63,446	$	63,446		March 31, 2024

The following table reflects the 2020 quarterly fee waivers and expense reimbursements due from the Adviser as of December 31, 2020, which are subject to recoupment by the Adviser.


Quarter Ended	Yearly Cumulative Other Expenses		Yearly Expense Limitation		Yearly Cumulative Expense Reimbursement		Quarterly Recoupable/ (Recouped) Amount			Recoupment Eligibility Expiration		Yearly Cumulative Other Expenses		Yearly Expense Limitation		Yearly Cumulative Expense Reimbursement		Quarterly Recoupable/ (Recouped) Amount			Recoupment Eligibility Expiration
December 31, 2020	$	989,447	$	639,959	$	349,488	$	101,541			December 31, 2023	$	989,447	$	639,959	$	349,488	$	101,541			December 31, 2023
September 30, 2020		687,228		439,281		247,947		94,039			September 30, 2023		687,228		439,281		247,947		94,039			September 30, 2023
June 30, 2020		445,585		291,677		153,908		(30,539	)		June 30, 2023		445,585		291,677		153,908		(30,539	)		June 30, 2023
March 31, 2020		257,226		72,779		184,447		184,447			March 31, 2023		257,226		72,779		184,447		184,447			March 31, 2023

The following table reflects the 2019 quarterly fee waivers and expense reimbursements due from the Adviser as of December 31, 2019, September 30, 2019, June 30, 2019, and March 31, 2019, which are subject to recoupment by the Adviser.

Quarter Ended
   Yearly Cumulative
Other Expenses    Yearly
Expense
Limitation    Yearly Cumulative
Expense
Reimbursement    Quarterly
Recoupable/
(Recouped)
Amount Recoupment
Eligibility Expiration
December 31, 2019
   $ 1,098,789    $ 951,520    $ 147,269    $ 50,130 December 31, 2022
September 30, 2019
   849,345    752,206    97,139    (17,417 ) September 30, 2022
June 30, 2019
   586,411    471,855    114,556    75,592 June 30, 2022
March 31, 2019
   295,177    256,213    38,964    38,964 March 31, 2022

The following table reflects the 2018 quarterly fee waivers and expense reimbursements due from the Adviser as of December 31, 2018, September 30, 2018, June 30, 2018, and March 31, 2018, which are subject to recoupment by the Adviser.


Quarter Ended	Yearly Cumulative Other Expenses		Yearly Expense Limitation		Yearly Cumulative Expense Reimbursement		Quarterly Recoupable/ (Recouped) Amount			Recoupment Eligibility Expiration
December 31, 2019	$	1,098,789	$	951,520	$	147,269	$	50,130			December 31, 2022
September 30, 2019		849,345		752,206		97,139		(17,417	)		September 30, 2022
June 30, 2019		586,411		471,855		114,556		75,592			June 30, 2022
March 31, 2019		295,177		256,213		38,964		—			Expired

Quarter Ended
   Yearly Cumulative
Other Expenses    Yearly
Expense
Limitation    Yearly Cumulative
Expense
Reimbursement    Quarterly
Recoupable/
(Recouped)
Amount    Recoupment
Eligibility Expiration
December 31, 2018
   $ 1,352,097    $ 924,677    $ 427,420    $ 279,079    December 31, 2021
September 30, 2018
   950,045    801,704    148,341    —      Expired
June 30, 2018
   613,809    489,460    124,349    —      Expired
March 31, 2018
   341,882    261,736    80,146    —      Expired

There can be no assurance that the Expense Limitation Agreement will remain in effect or that the Adviser will reimburse any portion of our expenses in future quarters not covered by the Expense Limitation Agreement. Amounts shown do not include the amounts committed by the Adviser to voluntarily reimburse the Company for unrealized losses, all of which are not recoupable.

Portfolio Investment Activity for the three ~~and nine~~ months ended ~~September 30, 2021~~March 31, 2022 and ~~September 30, 2020:~~March 31, 2021:

During the ~~nine~~three months ended ~~September 30, 2021,~~March 31, 2022, we made long investments in portfolio companies and other investments totaling ~~$4,164,636.~~$6,918,805. During the same period, we generated proceeds from sales and principal repayments on long investments of ~~$10,274,204.~~$5,643,969. As of ~~September 30, 2021,~~March 31, 2022, our investment portfolio, with a total fair value of ~~$63.0~~$62.4 million, consisted of 4136 interests in portfolio companies (calculated as a percentage of total invested assets: ~~41.1%~~23.4% in first lien senior secured loans, 4.9% in second lien senior secured loans, ~~10.9%~~10.8% in corporate bonds, ~~0.7%~~0.8% in asset-backed securities, ~~0.2%~~0.3% in warrants, ~~27.2%~~37.1% in common stock, ~~2.8%~~15.6% in preferred stock, and ~~12.1%~~7.3% in LLC interests). ~~As of September 30, 2021, there were no investments under the TRS with BNP Paribas in our portfolio.~~ On a look-through basis, the debt investments in our portfolio carry a weighted average cost price of ~~90.87%~~94.14% on par or stated value, as applicable, and our estimated gross annual portfolio yield (which represents the expected yield to be generated by us on our investment portfolio based on the composition of our portfolio as of such date), prior to leverage costs, was ~~5.28%~~3.18% based on the amortized cost of our investments. The portfolio yield does not represent an actual investment return to stockholders and does not include income from CLO equity.

During the ~~nine~~three months ended ~~September 30, 2020,~~March 31, 2021, we made long investments in portfolio companies and other investments totaling ~~$48,565,179.~~$7,726. During the same period, we generated proceeds from sales and principal repayments on long investments of ~~$69,041,052.~~$2,397,713. As of ~~September 30, 2020,~~March 31, 2021, our investment portfolio, with a total fair value of ~~$59.0~~$64.3 million, consisted of 4442 interests in portfolio companies (calculated as a percentage of total invested assets: ~~43.9%~~49.8% in first lien senior secured loans, ~~10.2%~~4.8% in second lien senior secured loans, ~~0.0% in unsecured loans, 0.0% in escrow loans, 11.3%~~10.8% in corporate bonds, ~~0.5%~~0.6% in asset-backed securities, ~~0.0% in~~ ~~closed-end~~ ~~mutual funds, 0.0%~~0.1% in warrants, ~~15.9%~~14.1% in common stock, 0.0% in preferred stock, ~~0.0% in mortgage-backed-securities, 10.4%~~10.7% in LLC interests, and ~~7.8%~~9.1% in ~~Partnership~~partnership units). ~~The~~On a look-through basis, the debt investments in our portfolio carry a weighted average cost price of ~~86.54%~~89.82% on par or stated value, as applicable, and our estimated gross annual portfolio yield (which represents the expected yield to be generated by us on our investment portfolio based on the composition of our portfolio as of such date), prior to leverage costs, was ~~5.55%~~5.42% based ~~upon~~on the amortized cost of our investments. The portfolio yield does not represent an actual investment return to stockholders and does not include income from CLO equity. ~~As of September 30, 2020, there were no positions held in the TRS.~~

Total Portfolio Activity

The following tables present selected information regarding our portfolio investment activity for the three ~~and nine~~ months ended ~~September 30, 2021,~~March 31, 2022, and ~~September 30, 2020:~~March 31, 2021:


Net Investment Activity	For the Three Months Ended September 30, 2021			For the Nine Months Ended September 30, 2021			For the Three Months Ended March 31, 2022			For the Three Months Ended March 31, 2021
Purchases	$	3,762,375		$	4,164,636		$	6,918,805		$	7,726
Payment-in-kind		25,832			74,634			106,711			23,684
Sales and Principal Repayments		(2,474,849	)		(10,274,204	)		(5,631,508	)		(2,397,713	)

Net Portfolio Activity	$	(1,313,358	)	$	(6,034,934	)	$	(1,394,008	)	$	(4,283,954	)


Net Investment Activity	For the Three Months Ended September 30, 2020			For the Nine Months Ended September 30, 2020
Purchases	$	6,319,587		$	48,565,179
Payment-in-kind		22,425			377,440
Sales and Principal Repayments		(8,317,408	)		(69,041,052	)

Net Portfolio Activity	$	(1,975,396	)	$	(20,098,433	)


	For the Three Months Ended September 30, 2021					For the Nine Months Ended September 30, 2021					For the Three Months Ended March 31, 2022					For the Three Months Ended March 31, 2021
New Investment Activity by Asset Class	Purchases		Percentage			Purchases		Percentage			Purchases		Percentage			Purchases		Percentage
Senior Secured Loans—First Lien	$	2,004,544		53.28	%	$	2,337,877		56.14	%	$	2,910,000		42.06	%	$	—		0.0	%
Senior Secured Loans—Second Lien		—		0.0	%		—		0.0	%		—		0.0	%		—		0.0	%
Corporate Bonds		—		0.0	%		—		0.0	%		—		0.0	%		—		0.0	%
Preferred Stocks		1,750,000		46.51	%		1,750,000		42.02	%		4,000,000		57.81	%		—		0.0	%
LLC Interests		—		0.0	%		—		0.0	%		—		0.0	%		—		0.0	%
Warrants		—		0.0	%		53,420		1.28	%		—		0.0	%		—		0.0	%
Common Stocks		7,830		0.21	%		23,339		0.56	%		8,806		0.13	%		7,726		100.0	%

Total Investment Activity	$	3,762,374		100.0	%	$	4,164,636		100.0	%	$	6,918,805		100.0	%	$	7,726		100.0	%

   For the Three Months Ended
September 30, 2020 For the Nine Months Ended
September 30, 2020
New Investment Activity by Asset Class
   Purchases    Percentage Purchases    Percentage
Senior Secured Loans—First Lien
   $ —      0.0 % $ 23,206,099    47.7 %
Senior Secured Loans—Second Lien
   —      0.0 % 4,807,222    9.9 %
Corporate Bonds
   —      0.0 % 4,842,635    10.0 %
Partnership Units
   6,312,618    99.9 % 6,312,618    13.0 %
Equities
   6,969    0.1 % 3,083,987    6.4 %
LLC Interests
   —      0.0 % 6,312,618    13.0 %






Total Investment Activity
   $ 6,319,587    100.0 % $ 48,565,179    100.0 %

4844

The following tables summarize the composition of our investment portfolio at amortized cost and fair value as of ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020:~~2021:


September 30, 2021
March 31, 2022								March 31, 2022
Portfolio Composition by Investment Type	Amortized Cost⁽¹⁾		Fair Value		Percentage of Portfolio (at fair value)				Amortized Cost⁽¹⁾		Fair Value		Percentage of Portfolio (at fair value)
Senior Secured Loans — First Lien	$	23,805,854		25,882,233		41.1	%		$	15,052,670		14,590,403		23.4	%
Senior Secured Loans — Second Lien		2,953,559		3,090,735		4.9	%			2,962,432		3,047,453		4.9	%
Asset-Backed Securities		671,187		442,259		0.7	%			405,292		399,848		0.6	%
LLC Interests		7,000,000		7,649,759		12.1	%			3,651,112		4,532,279		7.3	%
Corporate Bonds		6,796,510		6,879,513		10.9	%			6,839,289		6,712,201		10.8	%
Common Stocks		14,056,989		17,155,028		27.2	%			17,591,602		23,132,265		37.1	%
Preferred Stocks		1,750,000		1,750,000		2.8	%			9,830,000		9,730,000		15.6	%
Warrants		52,988		137,627		0.2	%			74,284		214,640		0.3	%

Total Invested Assets	$	57,087,087	$	62,987,154		100.0	%		$	56,406,681	$	62,359,089		100.0	%

⁽¹⁾	Amortized cost represents the original cost adjusted for the amortization of premiums and/or accretion of discounts, as applicable, on investments.


December 31, 2020
December 31, 2021								December 31, 2021
Portfolio Composition by Investment Type	Amortized Cost⁽¹⁾		Fair Value		Percentage of Portfolio (at fair value)				Amortized Cost⁽¹⁾		Fair Value		Percentage of Portfolio (at fair value)
Senior Secured Loans — First Lien	$	30,123,122	$	31,276,803		48.4	%		$	21,439,866	$	22,144,887		36.7	%
Senior Secured Loans — Second Lien		4,742,429		4,745,268		7.3	%			2,957,993		3,072,569		5.1	%
Asset-Backed Securities		671,187		363,767		0.6	%			422,271		405,040		0.7	%
LLC Interests		7,000,000		6,535,245		10.1	%			7,000,000		7,572,374		12.6	%
Corporate Bonds		6,736,607		6,883,952		10.6	%			6,817,768		6,826,266		11.3	%
Common Stocks		7,774,595		9,615,455		14.9	%			14,308,512		18,329,113		30.4	%
Preferred Stock		3,051,714		—		0.0	%			1,750,000		1,725,000		2.9	%
Warrants		52,988		33,902		0.1	%			74,284		161,062		0.3	%
Partnership Units		6,312,618		5,214,223		8.1	%

Total Invested Assets	$	66,465,260	$	64,668,615		100	%		$	54,770,694	$	60,236,311		100	%

⁽¹⁾	Amortized cost represents the original cost adjusted for the amortization of premiums and/or accretion of discounts, as applicable, on investments.

The following table presents certain selected information regarding the composition of our investment portfolio as of ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020:~~2021:


	September 30, 2021			December 31, 2020			March 31, 2022			December 31, 2021
Number of Investments		41			45			36			39
% Variable Rate (based on fair value)		78	%		82	%		81	%		63	%
% Non-Income Producing Equity or Other Investments (based on fair value)		20	%		18	%		21	%		21	%
Weighted Average Cost Price of Investments (as a % of par or stated value)		90.87	%		88.76	%		94.14	%		92.95	%
Weighted Average Credit Rating of Investments that were Rated		Caa1			Caa1			Caa1			Caa1
% of Fixed Income Investments on Non-Accrual (based on fair value)		0.2	%		0.2	%		0.4	%		0.3	%

4945

Portfolio Composition by Strategy and Industry

The table below summarizes the composition of our investment portfolio by strategy and enumerates the percentage, by fair value, of the total portfolio assets in such strategies as of ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020:~~2021:


	September 30, 2021					December 31, 2020					March 31, 2022					December 31, 2021
Portfolio Composition by Strategy	Fair Value		Percentage of Portfolio			Fair Value		Percentage of Portfolio			Fair Value		Percentage of Portfolio			Fair Value		Percentage of Portfolio
Broadly Syndicated – Private	$	5,676,245		12.2	%	$	5,491,997		9.2	%	$	5,601,092		13.9	%	$	5,668,835		9.4	%
Broadly Syndicated – Public		422,998		7.3	%		386,613		0.7	%		385,703		8.3	%		394,950		0.6	%
Middle-Market		56,445,652		75.6	%		58,426,238		90.3	%		55,972,446		72.2	%		53,767,486		89.3	%
Opportunistic/Other		442,259		4.9	%		363,767		0.6	%		399,848		5.6	%		405,040		0.7	%

Total Invested Assets	$	62,987,154		100.0	%	$	64,668,615		100.0	%	$	62,359,089		100.0	%	$	60,236,311		100.0	%

Broadly syndicated debt refers to loans and other instruments originated by a bank to a large corporation (both private and public) that are sold off, or syndicated, to investors in pieces. Middle-Market companies include companies with annual revenues between $50 million and $2.5 billion.

The table below describes investments by industry classification and enumerates the percentage, by fair value, of the total portfolio assets in such industries as of ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020:~~2021:


	September 30, 2021					December 31, 2020					March 31, 2022					December 31, 2021
Industry Classifications	Fair Value		Percentage of Portfolio			Fair Value		Percentage of Portfolio			Fair Value		Percentage of Portfolio			Fair Value		Percentage of Portfolio
Chemicals	$	42,500		0.1	%	$	42,500		0.1	%	$	42,500		0.1	%	$	42,500		0.1	%
Consumer Products		2,874,640		4.6	%		2,070,427		3.2	%		2,981,638		4.8	%		2,812,212		4.7	%
Energy		983,020		1.6	%		422,827		0.7	%		1,757,109		2.8	%		1,204,904		2.0	%
Financials		3,909,759		6.2	%		1,488,767		2.3	%		3,655,148		5.8	%		4,338,790		7.2	%
Healthcare		35,048,740		55.6	%		40,209,053		62.2	%		31,429,021		50.4	%		31,167,298		51.7	%
Media/Telecommunications		422,998		0.7	%		386,613		0.6	%		385,703		0.6	%		394,950		0.7	%
Real Estate Investment Trusts (REITs)		1,427,448		2.2	%		1,186,113		1.8	%		2,101,333		3.4	%		1,942,593		3.2	%
Real Estate		12,584,608		20.0	%		11,111,826		17.2	%		14,400,375		23.1	%		12,659,057		21.0	%
Retail		—		0.0	%		532,642		0.8	%
Service		17,196		0.0	%		59,183		0.1	%		5,172		0.0	%		5,172		0.0	%
Telecommunication Services		5,676,245		9.0	%		5,491,997		8.5	%		5,601,090		9.0	%		5,668,835		9.4	%
Manufacturing		—		0.0	%		1,666,667		2.6	%

Total Invested Assets	$	62,987,154		100.0	%	$	64,668,615		100.0	%	$	62,359,089		100.0	%	$	60,236,311		100.0	%

As of ~~September 30, 2021,~~March 31, 2022, the Company was an “affiliated person,” as defined in the 1940 Act, of NexPoint Real Estate Finance, Inc., ~~SFR WLIF II, LLC,~~ SFR WLIF III, and NexPoint Residential Trust, Inc. In general, under the 1940 Act, we are presumed to “control” a portfolio company if we owned 25% or more of its voting securities or we had the power to exercise control over the management or policies of such portfolio company and would be an “affiliated person” of a portfolio company if we owned 5% or more of its voting securities.

Summary Description of Portfolio Companies/Investments

As of ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020, 55.6%~~2021, 50.4% and ~~62.2%~~51.7% (based on fair value), respectively, of our portfolio consisted of healthcare related and opportunistic investments. Information regarding these investments is provided below. Information regarding these investments is provided below. This additional information is limited to publicly available information, and does not address credit worthiness or financial viability of the issuer, or our future plans as it relates to a specific investment:

Healthcare Investments

Sapience Therapeutics, Inc.: As of March 31, 2022, we held preferred shares of Sapience Therapeutics, Inc. with an aggregate fair value of $8.1 million. We did not hold preferred shares as of December 31, 2021 but held convertible promissory notes with an aggregate fair value of $4 million which converted in 2022. Sapience Therapeutics is a clinical stage biopharmaceutical company which addresses previously ‘undruggable’ molecular targets that address protein-protein interactions via the development of peptide-based drugs.

Surgery Center Holdings, Inc.: As of March 31, 2022, and December 31, 2021, we held corporate bonds of Surgery Center Holdings, Inc. with an aggregate fair value of $3.6 million and $3.7 million, respectively. Surgery Center Holdings, Inc. is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high-quality, cost-effective solutions for surgical and related ancillary care. As of March 31, 2022, the company owned or operated a portfolio of 127 surgical facilities, comprised of 108 ambulatory surgery centers and 19 surgical hospitals in 31 states.

RXBenefits, Inc.: As of March 31, 2022, and December 31, 2021, we held first lien senior secured loans of RXBenefits, Inc. with an aggregate fair value of $3.2 million and $3.2 million, respectively. RXBenefits, Inc. is a pharmacy benefits optimization platform that serves primarily the small and mid-sized employer market and provides a more curated and competitive pharmacy benefits marketplace for its employer customer base.

Envision Healthcare Corp.: As of ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020,~~2021, we held first lien senior secured loans of Envision Healthcare Corp. with an aggregate fair value of ~~$5.2~~$3.1 million and ~~$4.9~~$3.7 million, respectively. Envision Healthcare Corporation is a nationwide provider of healthcare clinical solutions, including physician-led services, ambulatory services, and post-acute services, in addition to being one of the largest owner and operator of ambulatory surgery centers. As of ~~September 30, 2021,~~March 31, 2022, the company delivered physician services to more than 2,000 clinical departments in healthcare facilities in 43 states through a 24,000 physician and other healthcare professional employee team. In addition, the company operated ~~255~~254 ambulatory surgery centers in 34 states with approximately 2,000 physician partners and 1,000 other affiliated physicians.

~~RXBenefits,~~CCS Medical, Inc.: As of ~~September 30, 2021, and December~~March 31, ~~2020,~~2022, we held first lien senior secured loans of ~~RXBenefits,~~CCS Medical, Inc. with an aggregate fair value of ~~$3.9 million and $4.0 million, respectively. RXBenefits, Inc. is a pharmacy benefits optimization platform that serves primarily the small and~~ ~~mid-sized~~ ~~employer market and provides a more curated and competitive pharmacy benefits marketplace for its employer customer base.~~

~~BW NHHC Holdco, Inc.: As~~$3.0 million. We did not hold any such investments as of ~~September 30, 2021, and~~ December 31, ~~2020, we held first lien senior secured loans~~2021. CCS Medical, Inc. provides direct-to-home delivery of ~~BW NHHC Holdco, Inc. with an aggregate fair value of $3.9 million and $4.0 million, respectively.~~medical supplies. The company is one of the nation’s largest providers of home-based care, with a footprint in the Northeast, Midwest and South. They are a transformational company, which provides quality comprehensive care continuum of personal care, skilled home health, hospiceCompany offers diabetes testing, insulin pumps, prescription medications, ostomy, urological, wound care, and ~~behavioral health. The company is comprised of 35,000 caregivers serving over 60,000 patients and their families daily, in 225 locations across 16 states.~~

Surgery Center Holdings, Inc.: As of September 30, 2021, and December 31, 2020, we held corporate bonds of Surgery Center Holdings, Inc. with an aggregate fair value of $3.7 million and $3.7 million, respectively. Surgery Center Holdings, Inc. is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high quality, cost effective solutions for surgical and related ancillary care. As of September 30, 2021, the company owned or operated a portfolio of 123 surgical facilities, comprised of 106 ambulatory surgery centers and 17 surgical hospitals in 30 states.

~~Global~~incontinence supplies. CCS Medical Response, Inc.: As of September 30, 2021, and December 31, 2020, we held first lien senior secured loans of Global Medical Response, Inc. with an aggregate fair value of $3.4 million and $3.3 million, respectively. Global Medical Response, Inc. is a medical transportation companyserves customers in the United ~~States that provides and manages community-based medical transportation services, including emergency,~~ ~~non-emergency~~ and managed transportation, fixed-wing air ambulance and disaster response. Additionally, they are one of the leaders in the ambulance industry and provides quality medical care and patient relocation services in the United States, and around the world through the utilization of more than 7,000 ground vehicles, 100 fire vehicles, 300 rotor-wing aircraft, and 100 fixed-wing aircraft.States.

Results of Operations for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022, and March 31, 2021 ~~and September 30, 2020~~

Revenues

We generate a significant portion of our investment income in the form of interest on the debt securities we purchase or originate. We have invested primarily in broadly syndicated bank loans of private companies. Bank loans generally pay interest at rates which are periodically determined by reference to a base lending rate plus a spread. The base lending rate is typically the three-month LIBOR. The settlement of bank loans differs from the settlement of many other equity or debt instruments. Bank loans are manually settled through the agent by assignment. As a result, settlement can take an undetermined amount of time. Currently, according to data provided by Markit Partners, bank loans settle, on average, on the seventeenth day after the trade date. Generally, interest does not begin to accrue to the buyer until seven business days after the trade date.

Our CLO equity pays quarterly dividends based on excess cash flow available after the CLO’s payment “waterfall” provisions. Both Grayson and PAMCO CLOs are past their respective investment periods, and as a result, excess cash flow is expected to decline over time. We, therefore, expect that the quarterly dividends paid by the investments will similarly decline.

Expenses

For the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022, we had total net operating expenses of $523,488 or $0.05 per share. For the three months ended March 31, 2021, we had total net operating expenses of ~~$527,218~~$562,925 or $0.05 per share and $1,603,762 or $0.16 per share, respectively. For the three and nine months ended September 30, 2020, we had total net operating expenses of $425,506 or $0.04 per share and $1,647,447 or $0.12 per share, respectively.share. Base management fees attributed to the Adviser were ~~$291,857 and $900,559~~$299,270 for the three ~~and nine~~ months ended ~~September 30, 2021.~~March 31, 2022. Base management fees attributed to the Adviser were ~~$201,136 and $829,100~~$303,707 for the three ~~and nine~~ months ended ~~September 30, 2020.~~March 31, 2021. Our expenses include administrative services expenses attributed to the Adviser of ~~$61,568~~$59,601 and ~~$183,308~~$62,539 for the three ~~and nine~~ months ended ~~September 30, 2021. respectively. Administrative services expenses attributed to the Adviser were $59,839~~March 31, 2022, and ~~$185,433 for the three and nine months ended September~~March 31, ~~2020,~~2021, respectively.

Amounts waived for management fees or administrative services expenses pertaining to periods prior to June 10, 2016 are not recoupable, but amounts waived for management fees or administrative services expenses pertaining to periods from and after June 10, 2016 are subject to recoupment by the Adviser within three years from the date that such fees were otherwise payable, provided that the recoupment will be limited to the amount of such voluntarily waived fees from and after June 10, 2016 and will not cause the sum of the Company’s advisory fees, administration fees, Other Expenses, and any recoupment to exceed the annual rate of 3.40% of average gross assets. Effective December 20, 2017, the Adviser ended its voluntary waiver of advisory fees.

5147

Our other expenses subject to the Expense Limitation Agreement for three ~~and nine~~ months ended ~~September 30,~~March 31, 2022 and March 31, 2021, were ~~$227,186~~$211,896 and ~~$664,052,~~$260,126, respectively, and consisted of the following:

   For the Three Months
Ended September 30, 2021    For the Nine Months
Ended September 30, 2021
Audit and tax fees
   $ 36,403    $ 132,743
Legal fees
   19,185    50,825
Custodian and accounting service fees
   77,329    229,575
Reports to stockholders
   28,798    46,034
Stock transfer fee
   53,383    154,869
Directors’ fees
   4,695    13,460
Other expenses
   7,393    36,546




Total
   $ 227,186    $ 664,052

~~Please refer to the Expense Limitation section above for further details on expense reimbursements.~~

~~Our other expenses subject to the Expense Limitation Agreement for the three and nine months ended September 30, 2020, were $241,643 and $687,228, respectively, and consisted of the following:~~


	For the Three Months Ended September 30, 2020		For the Nine Months Ended September 30, 2020		For the Three Months Ended March 31, 2022		For the Three Months Ended March 31, 2021
Audit and tax fees	$	46,114	$	140,397	$	39,474	$	54,641
Legal fees		27,538		52,854		18,218		12,756
Custodian and accounting service fees		81,522		234,657		76,747		75,821
Reports to stockholders		14,173		43,517		17,795		2,024
Stock transfer fee		59,005		175,227		50,183		49,333
Directors’ fees		6,238		16,127		3,731		4,057
Other expenses		7,053		24,449		5,748		61,494

Total	$	241,643	$	687,228	$	211,896	$	260,126

Please refer to the Expense Limitation section above for further details on expense reimbursements.

Net Investment Income

We earned net investment income of ~~$846,923~~$491,122 or ~~$0.08~~$0.05 per share, and ~~$694,133~~$544,553 or ~~$0.07~~$0.05 per share, for the three months ended ~~September 30,~~March 31, 2022, and March 31, 2021, and September 30, 2020, respectively. We earned net investment income of $1,925,632 or $0.19 per share, and $2,285,798 or $0.22 per share, for the nine months ended September 30, 2021, and September 30, 2020, respectively.

Net Realized Gains or Losses

We had sales or principal repayments of ~~$3,762,375~~$5,643,969 and ~~$8,317,408~~$2,397,713 during the three months ended ~~September 30,~~March 31, 2022, and March 31, 2021, ~~and September 30, 2020,~~ respectively, from which we realized a net gains/(losses) of ~~$(4,198,826)~~$167,104 and $(2,737,698), respectively. We had sales or principal repayments of $10,274,204 and $69,041,052 during the nine months ended September 30, 2021, and September 30, 2020, respectively, from which we realized a net gains/(losses) of $(4,047,315) and $(20,672,780)$(91,660), respectively. Additionally, during the three months ended ~~September 30,~~March 31, 2022, and March 31, 2021, ~~and September 30, 2020,~~ we realized gains/(losses) on total return swaps of $0 and $0, ~~respectively. During the nine months ended September 30, 2021, and September 30, 2020, we realized gains/(losses) on total return swaps of $0 and $(6,929,996),~~ respectively.

Net Change in Unrealized Appreciation (Depreciation) on Investments

For the three months ended ~~September 30,~~March 31, 2022, and March 31, 2021, ~~and September 30, 2020,~~ the net change in unrealized appreciation (depreciation) on investments totaled ~~$3,333,449~~$486,791 or ~~$0.32~~$0.05 per share, and $(4,695,661) or $(0.45) per share, ~~respectively. For the nine months ended September 30, 2021, and September 30, 2020, the net change in unrealized appreciation (depreciation) on investments~~

totaled $7,696,712 or $0.75 per share, and ($992,673) or ($0.09) per share, respectively. For the three months ended September 30, 2021 and September 30, 2020, the net change in unrealized appreciation (depreciation) on the TRS was $0, and $0, respectively. For the nine months ended September 30, 2021, and September 30, 2020, the net change in unrealized appreciation (depreciation) on the TRS was $0 and $2,745,042, respectively. The net change in unrealized appreciation (depreciation) on our investments during the three months ended ~~September 30, 2021,~~March 31, 2022, was primarily driven by the performance of ~~American Banknote Corp.~~NexPoint Residential Trust, Inc. The net change in unrealized appreciation (depreciation) on our investments during the three months ended September 30, 2020, was primarily driven by the performance of BW NHHC Holdco, Inc. Senior Secure Loan. The net change in unrealized appreciation (depreciation) on our investments during the nine months ended September 30,March 31, 2021, was primarily driven by the performance of NexPoint Real Estate Finance, Inc. The net change in unrealized appreciation (depreciation) on our investments during the nine months ended September 30, 2020, was primarily driven by the performance of BW NHHC Holdco, Inc. Senior Secure Loan.

Net Increase from Payment from Affiliates

For the year ended December 31, 2016, the Adviser committed $872,000 to the Company to voluntarily reimburse the Company for unrealized losses sustained. No amounts were committed for the three ~~and nine~~ months ended ~~September 30, 2021,~~March 31, 2022, and ~~2020.~~March 31, 2021. Cumulatively since inception, the Adviser has committed $2,275,000 to voluntarily reimburse the Company for such losses. Had these payments not been made, the NAV as of ~~September 30, 2021,~~March 31, 2022, would have been lower. These payments are shown in the Statement of Operations as net increase from amounts committed by affiliates, if applicable, and are not recoupable.

Net Increase (Decrease) in Net Assets Resulting from Operations

For the ~~nine~~three months ended ~~September 30,~~March 31, 2022, and March 31, 2021, ~~and September 30, 2020,~~ the net increase/(decrease) in net assets resulting from operations was ~~$5,575,029~~$1,145,017 or ~~$0.54~~$0.11 per share, and ~~($23,564,609)~~$2,274,057 or ~~($2.24)~~$0.22 per share, respectively.

   For the Nine Months
Ended September 30, 2021    For the Nine Months
Ended September 30, 2020
Income
   $ 3,529,394    $ 3,933,245
Net expenses
   (1,603,762 )    (1,647,447 )
Net realized gain/(loss)
   (4,047,315 )    (27,602,776 )
Net unrealized appreciation (depreciation)
   7,696,712    (1,752,369 )
Net increase from amounts committed by affiliates
   —      —




Total
   $ 5,575,029    $ (23,564,609 )

For the three months ended September 30, 2021, and September 30, 2020, the net increase/(decrease) in net assets resulting from operations was $(18,453) or $(0.00) per share, and $2,652,096 or $0.25 per share, respectively.


	For the Three Months Ended March 31, 2022			For the Three Months Ended March 31, 2021
Income	$	1,014,610		$	1,107,478
Net expenses		(523,488	)		(562,925	)
Net realized gain/(loss)		167,104			(91,660	)
Net unrealized appreciation (depreciation)		486,791			1,821,164
Net increase from amounts committed by affiliates		—			—

Total	$	1,145,017		$	2,274,057

   For the Three Months
Ended September 30, 2021    For the Three Months
Ended September 30, 2020
Income
   $ 1,374,141    $ 1,119,639
Net expenses
   (527,218 )    (425,506 )
Net realized gain/(loss)
   (4,198,825 )    (2,737,698 )
Net unrealized appreciation (depreciation)
   3,333,449    4,695,661
Net increase from amounts committed by affiliates
   —      —




Total
   $ (18,453 )    $ 2,652,096

Financial Condition, Liquidity and Capital Resources

As of ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020,~~2021, we had cash and cash equivalents of ~~$2,159,475~~$1,279,391 and ~~$729,467,~~$2,811,171, respectively. As of ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020, $2,033,024~~2021, $1,223,616 and ~~$525,975~~$2,704,193 was held in the State Street U.S. Government Money Market Fund, and ~~$126,451~~$55,775 and ~~$203,492~~$106,978 was held in a custodial account with State Street Bank and Trust Company, respectively. Cash and cash equivalents are available to fund new investments, pay operating expenses and pay distributions.

In aggregate as of ~~September 30, 2021,~~March 31, 2022, the Adviser controls 2,549,002 total shares of common stock of the Company, including reinvestment of dividends, for a net amount of approximately ~~$16.3~~$16.2 million.

The sales commissions and dealer manager fees related to the sale of our common stock were $0 and $0 for the ~~nine~~three months ended ~~September 30,~~March 31, 2022, and March 31, 2021, ~~and September 30, 2020,~~ respectively, and were offset against capital in excess of par value on the financial statements.

We expect to generate cash flows primarily from fees, interest and dividends earned from our investments, as well as principal repayments and proceeds from sales of our investments.

Prior to investing in securities of portfolio companies, we invest the net proceeds from the issuance of shares of common stock under our distribution reinvestment plan and from sales and paydowns of existing investments primarily in cash, cash equivalents, U.S. government securities, repurchase agreements, high-quality debt instruments maturing in one year or less from the time of investment, consistent with our BDC election and our election to be treated as a RIC. Additionally, we may invest in higher yielding, liquid credit investments such as bank loans and corporate notes and bonds, which are considered “junk” as they are rated below investment grade, to the extent that at time of purchase 70% of our portfolio is in qualified investments as required by rules and regulations under the 1940 Act.

As of September 30, 2021 and September 30, 2020, $0 and $0, respectively, were outstanding under the Financing Arrangement, which was paid down and closed on April 15, 2020. For the three and nine months ended September 30, 2021, and September 30, 2020, the components of total interest expense were as follows:

   For the Three Months
Ended September 30, 2021    For the Nine Months
Ended September 30, 2021
Direct interest expense
   $ —      $ —
Commitment fees
   —      —
Amortization of financing costs
   —      —




Total
   $ —      $ —




   For the Three Months
Ended September 30, 2020    For the Nine Months
Ended September 30, 2020
Direct interest expense
   $ —      $ 176,911
Commitment fees
   —      (204 )
Amortization of financing costs
   —      —




Total
   $ —      $ 176,707

On June 13, 2017, the Company, entered into the TRS with BNP Paribas over one or more loans, with a maximum aggregate notional amount of the portfolio debt securities subject to the TRS of $40 million. On April 2, 2018, the Company amended and restated the TRS Agreement with BNP Paribas to increase the maximum aggregate notional amount of the portfolio debt securities subject to the TRS to $60 million.

~~On June 10, 2020, the TRS expired. See Note 7 to the financial statements included herein for additional information on the TRS.~~

While we are authorized to issue preferred stock, we do not currently anticipate issuing any.

Contractual Obligations and Off-Balance Sheet Arrangements

We may become a party to financial instruments with off-balance sheet risk in the normal course of our business to meet the financial needs of our portfolio companies. These instruments may include commitments to extend credit and involve, to varying degrees, elements of liquidity and credit risk in excess of the amount recognized in the balance sheet. As of ~~September 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, we had no outstanding commitments to fund investments.

We have certain contracts under which we have material future commitments. We have entered into the Investment Advisory Agreement with the Adviser in accordance with the 1940 Act. Under the Investment Advisory Agreement, the Adviser provides us with investment advisory and management services. For these services, we pay (1) a management fee equal to a percentage of the average value of our gross assets and (2) an incentive fee based on our performance.

The incentive fee consists of two parts. The first part, which is calculated and payable quarterly in arrears, equals Pre-Incentive Fee Net Investment Income for the immediately preceding calendar quarter and is subject to a hurdle rate, expressed as a rate of return on our net assets, equal to 1.875% per quarter. As a result, the Adviser will not earn this incentive fee for any quarter until our pre-incentive fee net investment income for such quarter exceeds the hurdle rate of 1.875%. Once our pre-incentive fee net investment income in any quarter exceeds the hurdle rate, the Adviser will be entitled to a “catch-up” fee equal to the amount of the pre-incentive

fee net investment income in excess of the hurdle rate, until our pre-incentive fee net investment income for such quarter equals 2.34375% of the Company’s net assets at the end of such quarter. This “catch-up” feature allows the Adviser to recoup the fees foregone as a result of the existence of the hurdle rate. Thereafter, the Adviser will receive 20.0% of our pre-incentive fee net investment income. For purposes of calculating this part of the incentive fee, “Pre-Incentive Fee Net Investment Income” means interest income, distribution income and any other income (including any other fees, other than fees for providing managerial assistance, such as commitment, origination, structuring, diligence and consulting fees or other fees that we receive from portfolio companies) accrued during the calendar quarter, minus our operating expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement and any interest expense and any dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-Incentive Fee Net Investment Income includes, in the case of investments with a deferred interest feature (such as original issue discount, debt instruments with PIK interest and zero-coupon securities), accrued income that we have not yet received in cash. Pre-Incentive Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation.

The second part of the incentive fee, which is referred to as the incentive fee on capital gains, is determined and payable in arrears as of the end of each calendar year (or upon termination of the Investment Advisory Agreement). This fee equals 20.0% of our incentive fee capital gains, which will equal our realized capital gains on a cumulative basis from formation, calculated as of the end of the applicable period, computed net of all realized capital losses (proceeds less amortized cost) and unrealized capital depreciation on a cumulative basis, less the aggregate amount of any previously paid capital gains incentive fees. We will accrue for the capital gains incentive fee, which, if earned, will be paid annually. We will accrue for the capital gains incentive fee based on net realized and unrealized gains; however, under the terms of the Investment Advisory Agreement, the fee payable to the Adviser will be based on realized gains and no such fee will be payable with respect to unrealized gains unless and until such gains are actually realized. For the ~~nine~~three months ended ~~September 30,~~March 31, 2022, and March 31, 2021, ~~and September 30, 2020,~~ the Company incurred $0 and $0 of incentive fees on capital gains, respectively. Effective December 20, 2017, the Adviser ended its voluntary waiver of incentive fees. No such fees have been paid with respect to realized gains as of ~~September 30, 2021.~~March 31, 2022.

Under the Administration Agreement, the Adviser furnishes us with office facilities and equipment, provides us clerical, bookkeeping and record keeping services at such facilities and provides us with other administrative services necessary to conduct our day-to-day operations. We will reimburse the Adviser for the allocable portion (subject to the review and approval of the Board) of overhead and other expenses incurred by it in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and our allocable portion of the cost of our chief financial officer and chief compliance officer and their respective staffs, to the extent that such expenses do not exceed an annual rate of 0.4% of our gross assets. The Adviser also provides on our behalf significant managerial assistance to those portfolio companies to which we are required to offer to provide such assistance and any expenses payable to the Adviser for such managerial assistance are not subject to the cap on reimbursement.

Our organization and offering costs together are limited to 1% of total gross proceeds raised and are not due and payable to the Adviser to the extent they exceed that amount. The cumulative aggregate amount of organization and offering costs exceeds 1% of total proceeds raised. Subsequent to the termination of the Offering, the Adviser forfeited the right to reimbursement of the remaining $4,305,091 of these costs.

If any of the contractual obligations discussed above is terminated, our costs under any new agreements that we enter into may increase. In addition, we would likely incur significant time and expense in locating alternative parties to provide the services we receive under our Investment Advisory Agreement and our Administration Agreement. Any new investment advisory agreement would also be subject to approval by our stockholders.

If for any taxable year we were not a “publicly offered” RIC within the meaning of Code Section 67(c)(2)(B), certain of our direct and indirect expenses, including the management fee, the incentive fee and certain other advisory expenses, would be subject to special “pass-through” rules. Such rules would treat these expenses as additional dividends to certain of our direct or indirect stockholders (generally including individuals and entities that compute their taxable income in the same manner as an individual) and as deductible by those stockholders, subject to the 2% “floor” on miscellaneous itemized deductions and other significant limitations on itemized deductions set forth in the Code.

Distributions

In order to qualify for the special tax treatment accorded RICs and their shareholders, we are required under the Code, among other things, to distribute at least 90% of our net ordinary income and net short-term capital gains in excess of net long-term capital losses, or “investment company taxable income,” to our stockholders on an annual basis. We intend to authorize and declare quarterly distributions to be paid quarterly to our stockholders as determined by the Board. In addition, we also intend to distribute any realized net capital gains (i.e., realized net long-term capital gains in excess of realized net short-term capital losses) at least annually.

We may not be able to achieve operating results that will allow us to make distributions at a specific level or to increase the amount of our distributions from time to time. In addition, we may be limited in our ability to make distributions due to the asset coverage requirements applicable to us as a BDC under the 1940 Act. If we do not distribute a certain percentage of our income annually, we will suffer adverse U.S. federal income tax consequences, including possible failure to qualify for the special tax treatment accorded RICs and their shareholders. We cannot assure stockholders that they will receive any distributions.

To the extent our taxable earnings fall below the total amount of our distributions for a taxable year, a portion of those distributions may be deemed a return of capital to our stockholders for U.S. federal income tax purposes. Thus, the source of a distribution to our stockholders may be the original capital invested by the stockholder rather than our income or gains. Stockholders should read any written disclosure accompanying a distribution payment carefully and should not assume that the source of any distribution is our ordinary income or gains. Required distributions are driven by tax laws and thus tax accounting applies, not GAAP.

Therefore, it is possible that we pay more in required distributions than we earn for book purposes. For the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022, and March 31, 2021, ~~and September 30, 2020,~~ the Company did not distribute in excess of net investment income.

We have adopted an “opt in” distribution reinvestment plan for our stockholders. As a result, if we declare a cash distribution, our stockholders will receive distributions in cash unless they specifically “opt in” to the distribution reinvestment plan so as to have their cash distributions reinvested in additional shares of our common stock. However, certain state authorities or regulators may impose restrictions from time to time that may prevent or limit a stockholder’s ability to participate in our distribution reinvestment plan. Although distributions paid in the form of additional shares of our common stock will generally be subject to U.S. federal, state and local taxes in the same manner as cash distributions, stockholders participating in our dividend reinvestment plan will not receive any corresponding cash distributions with which to pay any such applicable taxes.

On June 24, 2020, the Board of Directors approved a change in its dividend and capital gains distribution schedule from monthly distributions to quarterly distributions, effective immediately. The first quarterly distribution was paid on October 12, 2020, to shareholders of record as of September 30, 2020. For the ~~nine~~three months ended ~~September 30, 2021,~~March 31, 2022, the Company made the following distributions:

Payable
Date
   Dividend/
Share⁽¹⁾    Total
Dividend⁽¹⁾    Dividends
Reinvested
9/30/2021
   $ 0.090    $ 903,359    $ —
6/30/2021
   0.090    909,619    322,287
3/31/2021
   0.090    924,140    331,405
1/2/2021⁽²⁾
   —      —      345,331






Total
   $ 0.270    $ 2,737,118    $ 999,023


Payable Date	Dividend/ Share ⁽¹⁾		Total Dividend ⁽¹⁾		Dividends Reinvested
3/31/2022	$	0.090	$	892,680	$	—
1/2/2022⁽²⁾		—		—		306,152

Total	$	0.090	$	892,680	$	306,152

¹	For the current period, ~~a portion of the September 30, 2021 and June 30, 2021~~there were no dividends ~~were~~ classified as a return of capital. ~~These returns~~

²	The December 2021 Dividend was reinvested in January 2022, see total December 2021 Dividend in table below.

For the year ended December 31, 2021, the Company made the following distributions:


Payable Date	Dividend/ Share ⁽¹⁾		Total Dividend ⁽¹⁾		Dividends Reinvested
12/31/2021⁽³⁾	$	0.090	$	896,061	$	—
9/30/2021		0.090		903,359		320,218
6/30/2021		0.090		909,619		322,287
3/31/2021		0.090		924,140		331,405
1/2/2021⁽²⁾		—		—		345,331

Total	$	0.360	$	3,633,179	$	1,319,241

¹	For the current period, there were no dividends classified as a return of ~~capital amounted to approximately 6.25% and 15.58% for the September 30, 2021 and June 30, 2021 dividends, respectively.~~capital.

²	The December 2020 Dividend was reinvested in January 2021, see total December 2020 Dividend in table below.

For the year ended December 31, 2020, the Company made the following distributions:

Payable
Date
   Dividend/
Share⁽¹⁾    Total
Dividend ⁽¹⁾    Dividends
Reinvested⁽²⁾⁽³⁾
12/31/2020⁽³⁾
   $ 0.090    $ 942,766    $ —
9/30/2020
   0.090    944,487    347,961
4/27/2020
   0.060    633,540    241,202
3/27/2020
   0.060    629,128    237,068
2/27/2020
   0.060    631,127    245,478
1/30/2020
   0.060    628,352    396,837
1/2/2020⁽²⁾
   —      —      396,214






Total
   $ 0.420    $ 4,409,400    $ 1,864,760

¹	~~For the current period, there were no dividends classified as a return of capital.~~

²	~~The December 2019 Dividend was reinvested in January 2020, see total December 2019 Dividend in table below.~~

³	~~The December 2020 Dividend was reinvested in January 2021.~~

~~For the year ended December 31, 2019, the Company made the following distributions:~~

Payable
Date
   Dividend/
Share⁽¹⁾    Total
Dividend⁽¹⁾    Dividends
Reinvested⁽²⁾
1/02/2020
   $ 0.060    $ 625,526    $ —
11/28/2019
   0.060    630,505    398,908
10/30/2019
   0.060    627,684    397,044
10/02/2019
   0.060    632,534    397,215
8/28/2019
   0.060    628,890    398,232
7/31/2019
   0.060    627,743    395,900
6/26/2019
   0.060    624,201    396,249
5/30/2019
   0.060    625,758    398,933
5/01/2019
   0.060    623,117    396,582
3/27/2019
   0.060    620,420    392,542
2/27/2019
   0.060    625,257    397,969
1/30/2019
   0.060    622,648    397,645
1/03/2019
   —      —      456,444






Total
   $ 0.720    $ 7,514,283    $ 4,823,663


Payable Date	Dividend/ Share ⁽¹⁾		Total Dividend ⁽¹⁾		Dividends Reinvested⁽²⁾
12/31/2020⁽²⁾	$	0.090	$	942,766	$	—
9/30/2020		0.090		944,487		347,961
4/27/2020		0.060		633,540		241,202
3/27/2020		0.060		629,128		237,068
2/27/2020		0.060		631,127		245,478
1/30/2020		0.060		628,352		396,837
1/2/2020⁽²⁾		—		—		396,214

Total	$	0.420	$	4,409,400	$	1,864,760

¹	For the current period, there were no dividends classified as a return of capital.

²	The December ~~2019~~2020 Dividend ~~will be~~was reinvested in January ~~2020.~~2021.

Related Party Transactions

We have entered into a number of business relationships with affiliated or related parties, including the following:

We entered into the Investment Advisory Agreement with the Adviser. James Dondero, our president, controls the Adviser by virtue of his control of its general partner, NexPoint Advisors GP, LLC.

Pursuant to an expense limitation agreement, the Adviser has agreed to waive fees or, if necessary, reimburse us to limit certain expenses to 1.0% of the quarter-end value of our gross assets.

The Adviser provides us with the office facilities and administrative services necessary to conduct our day-to-day operations pursuant to the Administration Agreement.

The dealer manager, NexPoint Securities, Inc., is an affiliate of the Adviser.

In aggregate as of ~~September 30, 2021,~~March 31, 2022, the Adviser controls 2,549,002 total shares of the Company, including reinvestment of dividends, for a net amount of approximately ~~$16.3~~$16.2 million.

Cumulatively since inception, the Adviser has paid $2,275,000 to voluntarily reimburse the Company for certain unrealized losses on investments. Had these payments not been made, the NAV as of ~~September 30, 2021~~March 31, 2022, would have been lower. These payments are not recoupable by the Adviser.

The Adviser and its affiliates also sponsor, or manage, and may in the future sponsor or manage, other investment funds, accounts or investment vehicles (together referred to as “accounts”) that have investment mandates that are similar, in whole and in part, with ours. The Adviser and its affiliates may determine that an investment is appropriate for us and for one or more of those other accounts. In such event, depending on the availability of such investment and other appropriate factors, and pursuant to the Adviser’s allocation policy and co-investment relief, the Adviser or its affiliates may determine that we should invest side-by-side with one or more other accounts. We do not intend to make any investments if they are not permitted by applicable law and interpretive positions of the SEC and its staff, or if they are inconsistent with the Adviser’s allocation procedures and co-investment relief.

In addition, we and the Adviser have each adopted a formal code of ethics that governs the conduct of our and the Adviser’s officers, directors and employees. Our officers and directors also remain subject to the duties imposed by both the 1940 Act and the Delaware General Corporations Law.

Critical Accounting Policies

The preparation of the financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Changes in the economic environment, financial markets and any other parameters used in determining such estimates could cause actual results to differ. We have identified the following as critical accounting policies.

Fair Value of Financial Instruments

We will value our investments in accordance with ASC Topic 820, Fair Value Measurements and Disclosure,, or ASC Topic 820. ASC Topic 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about assets and liabilities measured at fair value. ASC Topic 820’s definition of fair value focuses on exit price in the principal, or most advantageous, market and prioritizes the use of market-based inputs over entity-specific inputs within a measurement of fair value.

The portfolio will often include debt investments and equity investments that are fair valued. The portion of our portfolio that receives values from independent third parties are valued at their mid quotations obtained from unaffiliated market makers, other financial institutions that trade in similar investments or based on prices provided by independent third-party pricing services. For investments where there are no available bid quotations, fair value is derived using proprietary models that consider the analyses of independent valuation agents as well as credit risk, liquidity, market credit spreads, and other applicable factors for similar transactions.

Due to the nature of our strategy, our portfolio will include relatively illiquid investments that are privately held. Valuations of privately held investments are inherently uncertain, may fluctuate over short periods of time and may be based on estimates. The determination of fair value may differ materially from the values that would have been used if a ready market for these investments existed. Our net asset value could be materially affected if the determinations regarding the fair value of our investments were materially higher or lower than the values that we ultimately realize upon the disposal of such investments.

The Board, or its designee, is responsible for determining in good faith the fair value of the portfolio investments that are not publicly traded, whose market prices are not readily available on a quarterly basis or any other situation where portfolio investments require a fair value determination.

The valuation process is conducted at the end of each fiscal quarter, with a portion of our valuations of portfolio companies without market quotations subject to review by the independent valuation firms each quarter. When an external event with respect to one of our portfolio companies, such as a purchase transaction, public offering or subsequent equity sale occurs, we expect to use the pricing indicated by such external event to corroborate our valuation.

With respect to investments for which market quotations are not readily available, the Board undertakes a multi-step valuation process each quarter, as described below:

Preliminary valuation conclusions are then documented and discussed with a committee comprised of certain senior management employees of the Adviser (the “Valuation Committee”).

The Audit and Qualified Legal Compliance Committee of the Board, in assistance of Board valuation oversight, reviews portfolio valuation, including oversight of valuations determined by the Adviser and the Valuation Committee pursuant to the policies and procedures approved by the Board.

Based on this information, the Board discusses valuations and determines the fair value of each investment in the portfolio in good faith pursuant to board-approved policies and procedures.

As of ~~September 30,~~March 31, 2022, the Company held the following investments for which a sufficient level of current, reliable market quotations were not available:


Instrument	Type	Fair Value
Grayson Investor Corp.	Asset-Backed Securities	$	312,000
PAMCO CLO 1997-1A B	Asset-Backed Securities		87,848
American Banknote Corp.	Common Stocks		1,605,300
IQHQ, Inc.	Common Stocks		1,964,000
Terrestar Corp.	Common Stocks		4,611,901
Wayne Services Legacy Inc.	Common Stocks		5,172
SFR WLIF III, LLC	LLC Interests		1,550,641
US GAMING LLC	LLC Interests		2,981,638
Sapience Therapeutics, Inc.	Preferred Stocks		8,080,000
CCS Medical, Inc.	Senior Secured Loans		3,000,000
Terrestar Corp.	Senior Secured Loans		750,238
Terrestar Corp.	Senior Secured Loans		177,613
Terrestar Corp.	Senior Secured Loans		31,732
Terrestar Corp.	Senior Secured Loans		29,606

As of December 31, 2021, the Company held the following investments for which a sufficient level of current, reliable market quotations were not available:

Instrument

Type

Fair Value

Type

Fair Value

Grayson Investor Corp.

Asset-Backed Securities

352,500

Grayson Investor Corp

Asset-Backed Securities

304,000

PAMCO CLO 1997-1A B

Asset-Backed Securities

89,759

Asset-Backed Securities

101,040

American Banknote Corp.

Common Stocks

1,717,500

Common Stocks

2,208,750

MPM Holdings, Inc.

Common Stocks

42,500

IQHQ, Inc.

Common Stocks

1,661,000

Common Stocks

1,823,000

Terrestar Corp.

Common Stocks

4,740,040

TerreStar Corp.

Common Stocks

4,706,357

Wayne Services Legacy Inc.

Common Stocks

17,196

Common Stocks

5,172

SFR WLIF III, LLC

LLC Interests

1,540,685

SFR WLIF II, LLC

LLC Interests

3,234,434

5853


Instrument	Type	Fair Value
SFR WLIF III, LLC	LLC Interests		1,563,916
SFR WLIF II, LLC	LLC Interests		3,196,246
US GAMING LLC	LLC Interests		~~2,874,640~~2,812,212
~~Terrestar~~Sapience Therapeutics, Inc.	Senior Secured Loans		4,000,000
TerreStar Corp.	Senior Secured Loans		~~710,052~~729,979
~~Terrestar~~TerreStar Corp.	Senior Secured Loans		~~168,100~~172,817
~~Terrestar~~TerreStar Corp.	Senior Secured Loans		~~30,032~~30,875
~~Terrestar~~TerreStar Corp.	Senior Secured Loans		~~28,020~~28,807
Gemphire Therapeutics, Inc.	Warrants		—

~~As of December 31, 2020, the Company held the following investments for which a sufficient level of current, reliable market quotations were not available:~~

Instrument

Type
   Fair Value
Grayson Investor Corp
   Asset-Backed Securities    $ 286,000
PAMCO CLO 1997-1A B
   Asset-Backed Securities    77,767
American Banknote Corp.
   Common Stocks    1,125,000
IQHQ, Inc.
   Common Stocks    1,661,000
SteadyMed Ltd.
   Common Stocks    40,405
TerreStar Corp.
   Common Stocks    4,630,427
NexPoint Capital REIT, LLC
   LLC Interests    228,215
TRU KIDS
   Common Stocks    532,642
Western States Life Insurance
   Common Stocks    59,183
SFR WLIF III, LLC
   LLC Interests    1,493,629
SFR WLIF II, LLC
   LLC Interests    2,742,974
US GAMING LLC
   LLC Interests    2,070,427
TerreStar Corp.
   Senior Secured Loans    653,280
TerreStar Corp.
   Senior Secured Loans    154,659
TerreStar Corp.
   Senior Secured Loans    27,631
TerreStar Corp.
   Senior Secured Loans    26,000
Galena Biopharma, Inc.
   Warrants    1
Gemphire Therapeutics, Inc.
   Warrants    —
SCYNEXIS, Inc.
   Warrants    —

Prior to its termination, the Company valued the TRS in accordance with the TRS Agreement. Pursuant to the TRS Agreement, the value of the TRS was based on the increase or decrease in the value of the loans underlying the TRS, together with accrued interest income, interest expense and certain other expenses incurred under the TRS. The loans underlying the TRS were valued based on indicative bid prices provided by an independent third-party pricing service. Bid prices reflected the highest price that market participants may be willing to pay. These valuations are sent to the Company for review and testing.

The Valuation Committee and the Board reviewed and approved the value of the TRS, as well as the value of the loans underlying the TRS, on a quarterly basis. To the extent the Valuation Committee or the Board had any questions or concerns regarding the valuation of the loans underlying the TRS, such valuation was discussed or challenged pursuant to the terms of the TRS Agreement. For additional information on the TRS, see Note 7 to the financial statements included herein. The TRS expired on June 10, 2020.

Organization Costs

Organization costs include the cost of incorporation, such as the cost of legal services and other fees pertaining to our organization. Organization costs, together with offering costs, are limited to 1% of total gross proceeds raised in the offering and are not due and payable to the Adviser to the extent they exceed that amount. For the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022, and March 31, 2021, ~~and September 30, 2020,~~ the Adviser did not incur or pay any organization costs on our behalf. For the period from our inception to ~~September 30, 2021,~~March 31, 2022, the Adviser incurred and paid organization costs of $33,392 on our behalf.

Offering Costs

Our offering costs include legal fees, promotional costs and other costs pertaining to the public offering of our shares of common stock and are capitalized and amortized to expense over one year. For the three ~~and nine~~ months ended ~~September 30,~~March 31, 2022, the Adviser incurred offering costs of $0, on our behalf. For the three months ended March 31, 2021, the Adviser incurred offering costs of $0, ~~and $0, respectively,~~ on our behalf. For the three ~~and~~ months ended ~~September 30, 2020,~~March 31, 2022, the ~~Adviser incurred~~Company capitalized $0 of offering ~~costs of $0 and $0, respectively, on our behalf.~~costs. For the three ~~and nine~~ months ended ~~September 30,~~March 31, 2021, the Company capitalized $0 ~~and $0~~ of offering ~~costs, respectively. For the three and nine months ended September 30, 2020, the Company capitalized $0 and $0 of offering costs, respectively.~~costs. Of the capitalized offering costs, ~~$0 and~~ $0 were amortized to expense during the three ~~and nine~~ months ended ~~September 30, 2021, respectively.~~March 31, 2021. Of the capitalized offering costs, ~~$0 and~~ $0 were amortized to expense during the three ~~and nine~~ months ended ~~September 30, 2020.~~March 31, 2021. As of ~~September 30,~~March 31, 2022, and March 31, 2021, ~~and September 30, 2020,~~ $0 and $0 remained on the Statements of Assets and Liabilities, respectively.

Organization costs and offering costs are limited to 1% of total gross proceeds raised in this offering and are not due and payable to the Adviser to the extent they exceed that amount. As of ~~September 30, 2021,~~March 31, 2022, the cumulative aggregate amount of $5,327,574 of organization and offering costs exceeds 1% of total proceeds raised. Subsequent to the termination of the Offering, the Adviser forfeited the right to reimbursement of the remaining $4,305,091 of these costs.

Investment Transactions and Related Investment Income and Expense

We record our investment transactions on a trade date basis, which is the date when we have determined that all material terms have been defined for the transactions. These transactions could possibly settle on a subsequent date depending on the transaction type. All related revenue and expenses attributable to these transactions are reflected on the Statements of Operations commencing on the trade date unless otherwise specified by the transaction documents. Realized gains and losses on investment transactions are recorded on the specific identification method. We accrue interest income if we expect that ultimately we will be able to collect it. Generally, when an interest payment default occurs on a loan in our portfolio, or if our management otherwise believes that the issuer of the loan will not be able to service the loan and other obligations, we place the loan on non-accrual status and will cease recognizing interest income on that loan until all principal and interest is current through payment or until a restructuring occurs, such that the interest income is deemed to be collectible. However, we remain contractually entitled to this interest. We may make exceptions to this policy if the loan has sufficient collateral value and is in the process of collection. Accrued interest is written off when it becomes probable that such interest will not be collected, and the amount of uncollectible interest can be reasonably estimated. We also accrue for delayed compensation, which is a pricing adjustment payable by the parties to a secondary loan trade that closes late, intended to assure that neither party derives an economic advantage from the delay. Delayed compensation begins calculating at the loan’s specific coupon rate if a trade hasn’t settled within 7 business days of trading. Original issue discounts, market discounts or premiums are accreted or amortized using the effective interest method as interest income and will be accreted or amortized over the maturity period of the investments. We will record prepayment premiums on loans and debt securities as interest income. Dividend income, if any, will be recognized on an accrual basis to the extent that we expect to collect such amount.

We may have investments in our portfolio that contain a PIK interest provision. Any PIK interest will be added to the principal balance of such investments and is recorded as income, if the portfolio company valuation indicates that such PIK interest is

collectible. In order to qualify for the special tax treatment accorded RICs and their shareholders, substantially all of our income (including PIK interest) must be distributed to stockholders in the form of dividends, even if we have not collected any cash.

Interest expense is recorded on an accrual basis. Certain expenses related to legal and tax consultation, due diligence, rating fees, valuation expenses and independent collateral appraisals may arise when we make certain investments.

Loan Origination, Facility, Commitment and Amendment Fees

We may receive fees in addition to interest income from loans during the life of the investment. We may receive origination fees upon the origination of an investment. These origination fees are initially deferred and deducted from the cost basis of the investment and subsequently accreted into income over the term of the loan. We may receive facility, commitment and amendment fees, which are paid to us on an ongoing basis. Facility fees, sometimes referred to as asset management fees, are accrued as a percentage periodic fee on the base amount (either the funded facility amount or the committed principal amount). Commitment fees are based upon the undrawn portion committed by us and are recorded on an accrual basis. Amendment fees are paid in connection with loan amendments and waivers and are accounted for upon completion of the amendments or waivers, generally when such fees are receivable. Any such fees are included in other income on the Statements of Operations.

Net Realized Gains or Losses and Net Change in Unrealized Appreciation or Depreciation

We measure net realized gains or losses by the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment, without regard to unrealized appreciation or depreciation previously recognized, but considering unamortized upfront fees and prepayment penalties. Net change in unrealized appreciation or depreciation will reflect the change in portfolio investment values during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation, when gains or losses are realized.

U.S. Federal Income Taxes

We have elected to be treated as a RIC under Subchapter M of the Code and intend each year to qualify and be eligible to be treated as such. As a RIC, we generally will not have to pay corporate-level federal income taxes on any investment company taxable income or net capital gains that we distribute as dividends to our stockholders. In order to qualify for the special tax treatment accorded RICs and their shareholders, we must meet certain gross income, diversification, and distribution requirements.

Recent Accounting Pronouncements

Please refer to Note 2 to the financial statements included herein for discussion of recent accounting pronouncements.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

We are subject to financial market risks, most significantly changes in interest rates. As of ~~September 30, 2021, 78%~~March 31, 2022, 81% (based on fair value) of the investments in our portfolio had floating interest rates. These investments are usually based on a floating LIBOR and typically have interest rate reset provisions that adjust applicable interest rates under such loans to current market rates on a monthly or quarterly basis.

~~Pursuant to the terms of the TRS which expired on June 10, 2020, we paid fees to BNP Paribas a rate equal to~~ ~~one-month~~ LIBOR plus 2.00% per annum on the utilized notional amount of the loans subject to the TRS in exchange for the right to receive the economic benefit of a pool of loans having a maximum notional market value amount of $60,000,000. Pursuant to the terms of the Financing Arrangement, which was paid down and closed on April 15, 2020, we paid fees to the BNPP entities at floating rate based on the asset type, but generally ~~one-month~~ ~~LIBOR plus 1.30% per annum on the amount borrowed.~~

To the extent that any present or future credit facilities or other financing arrangements that we or any of our subsidiaries enter into are based on a floating interest rate, we will be subject to risks relating to changes in market interest rates. In periods of rising interest rates when we or our subsidiaries have such debt outstanding, or financing arrangements in effect, our interest expense would increase, which could reduce our net investment income, especially to the extent we hold fixed rate investments.

A rise in the general level of interest rates can be expected to lead to higher interest rates applicable to our debt investments, especially to the extent that we predominantly hold variable-rate investments, and to declines in the value of any ~~fixed- rate~~fixed-rate investments we hold. To the extent that a majority of our investments may be in variable-rate investments, an increase in interest rates could make it easier for us to meet or exceed the hurdle rate for the income incentive fee payable to the Adviser and may result in a substantial increase in our net investment income, and also to the amount of incentive fees payable to our Adviser with respect to our increasing pre-incentive fee net investment income.

In July 2017, the Financial Conduct Authority (the authority that regulates LIBOR) announced it intends to stop compelling banks to submit rates for the calculation of LIBOR after 2021. The Alternative Reference Rates Committee (“ARRC”) has proposed the Secured Overnight Financing Rate (“SOFR”) as the recommended alternative to USD-LIBOR for use in derivatives and other financial contracts that are currently indexed to USD-LIBOR. ARRC has proposed a paced market transition plan to SOFR from

USD-LIBOR and organizations are currently working on industry wide and company specific transition plans as it relates to derivatives and cash markets exposed to USD-LIBOR. We have material contracts that are indexed to USD-LIBOR and are monitoring this activity and evaluating the related risks.

In connection with the COVID-19 pandemic, the U.S. Federal Reserve and other central banks have reduced certain interest rates and LIBOR has decreased. A prolonged reduction in interest rates will reduce our gross investment income and could result in a decrease in our net investment income if such decreases in LIBOR are not offset by a corresponding increase in the spread over LIBOR that we earn on any portfolio investments, a decrease in in our operating expenses, including with respect to our income incentive fee, or a decrease in the interest rate of our floating interest rate liabilities tied to LIBOR.

Assuming that the Statement of Assets and Liabilities as of ~~September 30, 2021~~March 31, 2022 were to remain constant and that we took no actions to alter our existing interest rate sensitivity, the following table shows the annualized impact of hypothetical base rate changes in interest rates.

Change in interest rates    Increase (decrease) in
interest income    (Increase) decrease in
interest expense    Increase (decrease)
in NII
Down 25 basis points
   $ 3,377    $ —      $ 3,377
Up 50 basis points
   145,827    —      145,827
Up 100 basis points
   291,655    —      291,655
Up 200 basis points
   583,310    —      583,310
Up 300 basis points
   874,965    —      874,965


Change in interest rates	Increase (decrease) in interest income		(Increase) decrease in interest expense		Increase (decrease) in NII
Down 25 basis points	$	—	$	—	$	—
Up 50 basis points		94,539		—		94,539
Up 100 basis points		189,078		—		189,078
Up 200 basis points		378,155		—		378,155
Up 300 basis points		567,233		—		567,233

Although we believe that this analysis is indicative of our existing sensitivity to interest rate changes, it does not adjust for changes in the credit market, credit quality, the size and composition of the assets in our portfolio and other business developments, including borrowing under future credit facilities or other borrowing. Accordingly, we can offer no assurances that actual results would not differ materially from the analysis above.

We may in the future hedge against interest rate fluctuations by using standard hedging instruments such as interest rate swaps, futures, options and forward contracts to the limited extent permitted under the 1940 Act and applicable commodities laws. While hedging activities may insulate us against adverse changes in interest rates, they may also limit our ability to participate in the benefits of lower interest rates with respect to the investments in our portfolio with fixed interest rates.

6256

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in the Company’s filings under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Investment Company Act of 1940, as amended, is recorded, processed, summarized and reported within the periods specified in the rules and forms of the Securities and Exchange Commission. Such information is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company’s management, including the principal executive officer and principal financial officer, recognizes that any set of controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. As of the period covered by this report, we, including our president and chief financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Based upon that evaluation, our president and chief financial officer concluded that our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There have been no material changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

6357

Part II – Other Information

Item 1:

Legal Proceedings.

Although we may, from time to time, be involved in litigation arising out of our operations in the normal course of business or otherwise, we are currently not a party to any pending material legal proceedings.

Item 1A:

Risk Factors.

None.

Item 2:

Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3:

Defaults Upon Senior Securities.

None.

Item 4:

Mine Safety Disclosures.

None.

Item 5:

Other Information.

~~None.~~None

6458

Item 6:

Exhibits


Number		Description

3.1		Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit (a)(3) to ~~Post-Effective~~Post- Effective Amendment No. 1 to the Company’s Registration Statement on Form N-2 (File No. 333-196096) filed on December 12, 2014)

3.2		Amended and Restated Bylaws (Incorporated by reference to Exhibit (b)(3) to Post-Effective Amendment No. 1 to the Company’s Registration Statement on Form N-2 (File No. 333-196096) filed on December 12, 2014)

4.1		Forms of Subscription Agreement (Incorporated by reference to the Prospectus Appendix A. Appendix B and Appendix C filed with Post-Effective Amendment No. 7 to the Company’s Registration Statement on Form N-2 (File No. 333-196096) filed on May 11, 2017)

4.2		Distribution Reinvestment Plan (Incorporated by reference to Exhibit (e) to Post-Effective Amendment No. 1 to the Company’s Registration Statement on Form N-2 (File No. 333-196096) filed on December 12, 2014)

10.1		Amended and Restated Investment Advisory Agreement (Incorporated by reference to Exhibit (g)(1) to Post-Effective Amendment No. 8 to the Company’s Registration Statement on Form N-2 (File No. 333-196096) filed on September 30, 2017)

10.2		Sub-Administration and Accounting Agreement (Incorporated by reference to Company’s Registration Statement on Form N-2 (File No. 333-216277) filed on February 27, 2017)

10.3		Amended and Restated Administration Agreement (Incorporated by reference to Exhibit (k)(2) to Post-Effective Amendment No. 8 to the Company’s Registration Statement on Form N-2 (File No. 333-196096) filed on September 30, 2017)

10.4		Dealer Manager Agreement (Incorporated by reference to Post-Effective Amendment No. 4 to the Company’s Registration Statement on Form N-2 (File No. 333-196096) filed on March 2, 2016)

10.5		Form of Participating Broker-Dealer Agreement (Included as Exhibit A to the Dealer Manager Agreement)

10.6		Custodian Agreement (Incorporated by reference to Post-Effective Amendment No. 4 to the Company’s Registration Statement on Form N-2 (File No. 333-196096) filed on March 2, 2016)

10.7		Form of Agency Agreement (Incorporated by reference to Pre-Effective Amendment No. 3 to the Company’s Registration Statement on Form N-2 (File No. 333-196096) filed on July 24, 2014)

10.8		Escrow Agreement (Incorporated by reference to Post-Effective Amendment No. 4 to the Company’s Registration Statement on Form N-2 (File No. 333-196096) filed on March 2, 2016)

10.9		Expense Limitation Agreement (Incorporated by reference to Post-Effective Amendment No. 4 to the Company’s Registration Statement on Form N-2 (File No. 333-196096) filed on March 2, 2016)

10.10		Control Agreement, dated and effective as of June 9, 2017, by and between NexPoint Capital, Inc. and BNP Paribas Prime Brokerage International, Ltd. and State Street Bank and Trust Company ((Incorporated by reference to Exhibit 10.10 to Registrants Quarterly Report on 10-Q ~~(File~~ (File No. 814-01074) filed on November 9, 2017)

10.11		Master Confirmation for Loan Total Return Swap Transactions, dated and effective as of June 13, 2017, by and between NexPoint Capital Inc. and BNP Paribas Prime Brokerage International, Ltd. (Incorporated by reference to Exhibit 10.11 to Registrants Quarterly Report on 10-Q (File No. 814-01074) filed on November 9, 2017)

10.12		Committed Facility Agreement, dated and effective as of October 19, 2017, by and between NexPoint Capital, Inc. and BNP Paribas Prime Brokerage International, Ltd. (Incorporated by reference to Exhibit 10.1 to Registrants Current Report on 8-K (File No. 814-01074) filed on October 19, 2017)


Number		Description

10.13		U.S. PB Agreement, dated and effective as of October 19, 2017, by and between NexPoint Capital, Inc. and BNP Paribas Prime Brokerage, Inc. (Incorporated by reference to Exhibit 10.2 to Registrants Current Report on 8-K (File No. 814-01074) filed on October 19, 2017)


~~Number~~		~~Description~~

10.14		International PB Agreement, dated and effective as of October 19, 2017, by and between NexPoint Capital, Inc., BNP Paribas Prime Brokerage International, Ltd., and BNP Paribas acting through its New York branch (Incorporated by reference to Exhibit 10.3 to Registrants Current Report on 8-K (File No. ~~814-01074)~~ 814- 01074) filed on October 19, 2017)

10.15		U.S. Triparty Agreement, dated and effective as of October 19, 2017, by and between NexPoint Capital, Inc., BNP Paribas Prime Brokerage, Inc. and Street Bank and Trust Company (Incorporated by reference to Exhibit 10.4 to Registrants Current Report on 8-K (File No. 814-01074) filed on October 19, 2017)

10.16		International Triparty Agreement, dated and effective as of October 19, 2017, by and between NexPoint Capital, Inc., BNP Paribas Prime Brokerage International, Ltd., and State Street Bank and Trust Company, as custodian (Incorporated by reference to Exhibit 10.5 to Registrants Current Report on 8-K (File No. ~~814-01074)~~ 814- 01074) filed on October 23, 2017)

10.17		Amended and Restated Master Confirmation for Loan Total Return Swap Transactions, dated and effective as of April 2, 2018, by and between NexPoint Capital, Inc. and BNP Paribas (Incorporated by reference to Exhibit 10.1 to Registrants Current Report on 8-K (File No. 814-01074) filed on April 2, 2018)

31.1*		Certifications by President pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

31.2*		Certifications by Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

32.1*		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

* Filed herewith

6660

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.


	NEXPOINT CAPITAL, INC.

Date: ~~November 12, 2021~~May 16, 2022	By:	~~/s/~~ /s/ James Dondero
	Name:	James Dondero
	Title:	President and Principal Executive Officer

Date: ~~November 12, 2021~~May 16, 2022	By:	~~/s/~~ /s/ Frank Waterhouse
	Name:	Frank Waterhouse
	Title:	Treasurer, Principal Accounting Officer and Principal Financial Officer

6761


Financials – 2.7%
American Banknote Corp. ^{(9) (10) (15)}				750,000	$	2,062,500	$	1,717,500

Healthcare – 0.7%
Amryt Pharma, PLC ^{(7) (15) (16)}				40,000		500,000		483,600

Real Estate – 12.2%
IQHQ, Inc. ^{(9) (10)}				100,000		1,500,000		1,661,000
NexPoint Real Estate Finance, Inc. ⁽¹⁷⁾				315,631		6,691,375		6,148,490

								7,809,490

Real Estate Investment Trust (REIT) – 2.2%
NexPoint Residential Trust, Inc. ^{(7) (17)}				23,068		731,363		1,427,448

Service – 0.0%
Wayne Services Legacy Inc. ^{(9) (10) (15)}				237		253,404		17,196

Telecommunication Services – 7.4%
TerreStar Corp. ^{(9) (10) (15)}				14,035		1,599,990		4,740,040


Total Common Stocks								17,155,028


LLC Interests – 11.9%
Consumer Products – 4.5%
US GAMING LLC ^{(9) (10) (15)}				2,000		2,000,000		2,874,640

Real Estate – 7.4%
SFR WLIF II, LLC ^{(9) (10) (17)}				3,348,888		3,348,888		3,234,434
SFR WLIF III, LLC ^{(9) (10) (17)}				1,651,112		1,651,112		1,540,685

								4,775,119


Total LLC Interests								7,649,759


	Preferred Dividend Rate

Preferred Stocks – 2.8%
Financials – 2.8%
777 PARTNERS LLC		10.000%		750		750,000		750,000
United Fidelity Bank FSB		7.000%		1,000		1,000,000		1,000,000

								1,750,000


Total Preferred Stocks								1,750,000


Warrants – 0.2%
Energy – 0.1%
QUARTERNORTH TRANCHE 1 ⁽¹⁵⁾			8/27/2029	3,051		—		30,510
QUARTERNORTH TRANCHE 2 ⁽¹⁵⁾			8/27/2029	5,876		—		35,256

							65,766

Healthcare – 0.0%
Gemphire Therapeutics, Inc. ^{(9) (10) (15)}			3/15/2022	4,752		—		—

Media/Telecommunications – 0.1%
iHeartMedia, Inc. ^{(7) (15)}			5/1/2039	2,875		52,988		71,861


Total Warrants								137,627

Total Investments – 98.1%					$	57,087,087	$	62,987,154

Cash Equivalents – 3.2%⁽¹⁹⁾							$	2,033,024
Other Assets & Liabilities, net – (1.2%)							$	(801,926	)

Net Assets – 100.0%							$	64,218,252


					Shares
Common Stocks – 15.0%
Chemicals – 0.1%
MPM Holdings, Inc. ⁽¹⁶⁾						8,500		17,000		42,500

Financials – 1.8%
American Banknote Corp. ⁽¹⁰⁾^{(11) (16)}						750,000		2,062,500		1,125,000


Healthcare – 0.9%
Amryt Pharma, PLC ⁽⁸⁾^{(16) (17)}						40,000		500,000		566,400

SteadyMed Ltd. ⁽⁸⁾^{(10) (11) (16)}						54,749		14,508		40,405

										606,805

Real Estate – 2.6%
IQHQ, Inc. ⁽¹⁰⁾⁽¹¹⁾						100,000		1,500,000		1,661,000

Real Estate Investment Trust (REIT) – 1.5%
NexPoint Residential Trust, Inc. ⁽⁸⁾⁽¹⁸⁾						22,640		708,025		957,898

Retail – 0.8%
Tru Kids, Inc. ⁽¹⁰⁾^{(11) (16)}						237		1,119,168		532,642

Service – 0.1%
Wayne Services Legacy Inc. ⁽¹⁰⁾^{(11) (16)}						237		253,404		59,183

Telecommunication Services – 7.2%
TerreStar Corp. ⁽¹⁰⁾^{(11) (16)}						14,035		1,599,990		4,630,427


Total Common Stocks										9,615,455


LLC Interests – 10.2%
Consumer Products – 3.2%
US GAMING LLC ⁽¹⁰⁾^{(11) (16)}						2,000		2,000,000		2,070,427

Real Estate – 6.6%
SFR WLIF III, LLC ⁽¹⁰⁾^{(11) (18)}						1,651,112		1,651,112		1,493,629

SFR WLIF II, LLC ⁽¹⁰⁾^{(11) (18)}						3,348,888		3,348,888		2,742,974

										4,236,603

Real Estate Investment Trust (REIT) – 0.4%
NexPoint Capital REIT, LLC ⁽¹⁰⁾^{(11) (18) (19)}						100		—		228,215


Total LLC Interests										6,535,245


Partnership Units – 8.1%
Real Estate – 8.1%
NexPoint Real Estate Finance Operating Partnership, LP ⁽¹⁸⁾						315,631		6,312,618		5,214,223


Total Partnership Units										5,214,223

	Preferred Dividend Rate
Preferred Stocks – 0.0%
Real Estate Investment Trust (REIT) – 0.0%
RAIT Financial Trust ⁽²⁰⁾		8.875	%			148,057		3,051,714		—


Total Preferred Stocks


Warrants – 0.1%
Healthcare – 0.0%
Galena Biopharma, Inc. ⁽¹⁰⁾^{(11) (16)}				1/12/2021		1,500,054		—		1
Gemphire Therapeutics, Inc. ⁽¹⁰⁾^{(11) (16)}				3/15/2022		4,752		—		—
SCYNEXIS, Inc. ⁽¹⁰⁾^{(11) (16)}				6/21/2021		19,500		—		—

										1

Media/Telecommunications – 0.1%
iHeartMedia, Inc. ⁽⁸⁾⁽¹⁶⁾				5/1/2039		2,875		52,988		33,901


Total Warrants										33,902


Total Investments – 100.7%							$	66,465,260	$	64,668,615

Cash Equivalents – 0.8%⁽²¹⁾									$	525,975
Other Assets & Liabilities, net – (1.5%)									$	(1,004,118	)

Net Assets – 100.0%									$	64,190,472


Investments:	Balance as of December 31, 2019			Transfers into Level 3		Transfer out of Level 3		Net amortization (accretion) of premium/ (discount)		Net realized gains/ (losses)			Net change in unrealized gains/ (losses)			Purchases/ PIK		(Sales and redemptions)			Balance as of September 30, 2020		Change in unrealized gain/(loss) on Level 3 securities still held at period end

Assets
Senior Secured Loans
Telecommunication Services	$	721,602		$	—	$	—	$	—	$	—		$	633		$	89,713	$	—		$	811,948	$	633
Unsecured Loans
Materials		3,713,191			—		—		124,719		(2,746,641	)		482,389			313,727		(1,887,385	)		—		—
Asset-Backed Securities
Financials		139,629			333,764		—		—		—			(191,083	)		—		—			282,310		(191,083	)
Common Stocks
Financials		2,467,500			—		—		—		—			(735,000	)		—		—			1,732,500		(735,000	)
Healthcare		40,405			—		—		—		—			—			—		—			40,405		—
Materials		20,898			—		—		—		—			(20,898	)		—		—			—		(20,898	)
Real Estate		—			1,500,000		—		—		—			161,000			—		—			1,661,000		161,000
Telecommunication Services		3,890,081			—		—		—		—			814,872			—		—			4,704,953		814,872
LLC Interests
Consumer Products		2,000,000			—		—		—		—			—			—		—			2,000,000		—
Real Estate		4,932,657			—		—		—		—			(1,003,967	)		—		—			3,928,690		(1,003,967	)
Real Estate Investment Trusts (REITs)		2,425,989			—		—		—		—			10,689			—		(2,189,561	)		247,117		10,689
Warrants
Healthcare		—			29,837		—		—		—			(29,577	)		—		—			260		(29,577	)
Materials		647			—		—		—		—			(647	)		—		—			—		(647	)

Total	$	20,352,599		$	1,863,601	$	—	$	124,719	$	(2,746,641	)	$	(511,589	)	$	403,440	$	(4,076,946	)	$	15,409,183	$	(993,978	)

Liabilities
Total Return Swaps⁽¹⁾	$	(2,745,042	)	$	—	$	—	$	—	$	(6,929,996	)	$	2,745,042		$	7,425,035	$	(495,039	)	$	—	$	—


	For the Three Months Ended September 30,					For the Nine Months Ended September 30,

	2021			2020		2021		2020

Net increase (decrease) in net assets from operations	$	(18,453	)	$	2,652,096	$	5,575,029	$	(23,564,609	)
Weighted average common shares outstanding		10,141,588			10,528,658		10,316,029		10,520,781
Earnings (loss) per common share-basic and diluted	$	—		$	0.25	$	0.54	$	(2.24	)


	Three months ended September 30, 2020		Nine months ended September 30, 2020
Direct interest expense	$	—	$	176,911
Commitment fees		—		(204	)
Amortization of financing costs		—		—

Total interest expense	$	—	$	176,707

Average daily amount outstanding		—		22,670,341	⁽¹⁾
Weighted average interest rate		—		2.67	%⁽¹⁾


Payable Date	Dividend/ Share⁽¹⁾		Total Dividend⁽¹⁾		Dividends Reinvested
9/30/2021	$	0.090	$	903,359	$	—
6/30/2021		0.090		909,619		322,287
3/31/2021		0.090		924,140		331,405
1/2/2021⁽²⁾		—		—		345,331

Total	$	0.270	$	2,737,118	$	999,023

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

Yes ☐ No ☒